



HU000027057T2

(19) **HU****MAGYARORSZÁG**
Szellemi Tulajdon Nemzeti Hivatala(11) Lajstromszám: **E 027 057**(13) **T2****EURÓPAI SZABADALOM**
SZÖVEGÉNEK FORDÍTÁSA

- (21) Magyar ügyszám: **E 12 191628**
(22) A bejelentés napja: **2008. 07. 25.**
- (96) Az európai bejelentés bejelentési száma:
EP 20080191628
- (97) Az európai bejelentés közzétételi adatai:
EP 2562184 A1 **2013. 02. 27.**
- (97) Az európai szabadalom megadásának meghirdetési adatai:
EP 2562184 B1 **2015. 10. 07.**
- (51) Int. Cl.: **C07K 14/47** (2006.01)
A61K 39/00 (2006.01)
C07K 144/95 (2006.01)

(30) Elsőbbségi adatok: 07014797 2007. 07. 27. EP 953161 P 2007. 07. 31. US			(73) Jogosult(ak): Immatics Biotechnologies GmbH, 72076 Tübingen (DE)
(72) Feltaláló(k): SINGH, Harpreet, 81679 München (DE) Schoor, Oliver, 72070 Tübingen (DE) Trautwein, Claudia, 42489 Wülfrath (DE) HILF, Norbert, 72138 Kirchentellinsfurt (DE) WEINSCHENK, Toni, 73773 Aichwald (DE) Walter, Steffen, 72764 Reutlingen (DE) LEWANDROWSKI, Peter, 72070 Tübingen-Hirschau (DE)			(74) Képviselő: Danubia Szabadalmi és Jogi Iroda Kft., Budapest

(54) **Újszerű immunogén epitóp immunterápiához**

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.



(11) **EP 2 562 184 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
07.10.2015 Bulletin 2015/41

(51) Int Cl.:
C07K 14/47 ^(2006.01) **A61K 39/00** ^(2006.01)
C07K 14/495 ^(2006.01)

(21) Application number: **12191628.2**

(22) Date of filing: **25.07.2008**

(54) **Novel immunogenic epitopes for immunotherapy**

Neuartige immunogenetische Epitope zur Immuntherapie

Nouveaux épitopes immunogènes pour l'immunothérapie

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT
RO SE SI SK TR**
Designated Extension States:
AL BA MK RS

(30) Priority: **27.07.2007 EP 07014797**
31.07.2007 US 953161 P

(43) Date of publication of application:
27.02.2013 Bulletin 2013/09

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
08785106.9 / 2 183 278

(73) Proprietor: **immatics biotechnologies GmbH**
72076 Tübingen (DE)

(72) Inventors:
• **Singh, Harpreet**
81679 München (DE)
• **Schoor, Oliver**
72070 Tübingen (DE)
• **Trautwein, Claudia**
42489 Wülfrath (DE)
• **Hilf, Norbert**
72138 Kirchentellinsfurt (DE)
• **Weinschenk, Toni**
73773 Aichwald (DE)

• **Walter, Steffen**
72764 Reutlingen (DE)
• **Lewandrowski, Peter**
72070 Tübingen-Hirschau (DE)

(74) Representative: **Krauss, Jan**
Boehmert & Boehmert
Anwaltspartnerschaft mbB
Patentanwälte Rechtsanwälte
Pettenkoferstrasse 20-22
80336 München (DE)

(56) References cited:
WO-A-2005/116051 WO-A1-01/72331

• **Kenneth Murphy ET AL: "Janeway's
Immunobiology" In: "Janeway's
Immunobiology", 2 January 2008 (2008-01-02),
Taylor & Francis, XP55049307, ISBN:
978-0-81-534123-9 pages 129-132, * the whole
document ***
• **GILLES GUICHARD ET AL: "Efficient Binding of
Reduced Peptide Bond Pseudopeptides to Major
Histocompatibility Complex Class I Molecule",
JOURNAL OF BIOLOGICAL CHEMISTRY,
AMERICAN SOCIETY FOR BIOCHEMISTRY AND
MOLECULAR BIOLOGY, US, vol. 270, no. 44, 3
November 1995 (1995-11-03), pages 26057-26059,
XP008153807, ISSN: 0021-9258, DOI:
10.1074/JBC.270.44.26057 [retrieved on
1995-11-03]**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

[0001] The present invention relates to a novel amino acid sequence of a peptide derived from tumour associated antigens that is able to bind to MHC complexes of class I, and elicit an immune response.

Background of the invention

[0002] Stimulation of an immune response is dependent upon the presence of antigens recognised as foreign by the host immune system. The discovery of the existence of tumour associated antigens has now raised the possibility of using a host's immune system to intervene in tumour growth. Various mechanisms of harnessing both the humoral and cellular arms of the immune system are currently being explored for cancer immunotherapy.

[0003] Certain elements of the cellular immune response are capable of specifically recognising and destroying tumour cells. The isolation of cytotoxic T-cells (CTL) from tumour-infiltrating cell populations or from peripheral blood suggests that these cells play an important role in natural immune defences against cancer (Cheever et al., *Annals N.Y. Acad. Sci.* 1993 690:101-112; Zeh HJ, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC; *J Immunol.* 1999, 162(2):989-94; High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumour efficacy.). CD8-positive T-cells (TCD8⁺) in particular, which recognise Class I molecules of the major histocompatibility complex (MHC)-bearing peptides of usually 8 to 10 amino acid residues derived from proteins or defect ribosomal products (DRIPS) (Schubert U, Ant6n LC, Gibbs J, Norbury CC, Yewdell JW, Bennink JR.; Rapid degradation of a large fraction of newly synthesized proteins by proteasomes; *Nature* 2000; 404(6779):770-774) located in the cytosol, play an important role in this response. The MHC-molecules of the human are also designated as human leukocyte-antigens (HLA).

[0004] There are two classes of MHC-molecules: MHC class I molecules that can be found on most cells having a nucleus which present peptides that result from proteolytic cleavage of endogenous proteins, DRIPS, and larger peptides. MHC class II molecules can be found predominantly on professional antigen presenting cells (APCs), and present peptides of exogenous proteins that are taken up by APCs during the course of endocytosis, and are subsequently processed (Cresswell P. *Annu. Rev. Immunol.* 1994; 12:259-93). Complexes of peptide and MHC class I molecules are recognised by CD8-positive cytotoxic T-lymphocytes bearing the appropriate TCR, complexes of peptide and MHC class II molecules are recognised by CD4-positive-helper-T-cells bearing the appropriate TCR. It is well known that the TCR, the peptide and the MHC are thereby abundant in a stoichiometric amount of 1:1:1.

[0005] CD4-positive helper T-cells play an important role in orchestrating the effector functions of anti-tumour T-cell responses and for this reason the identification of CD4-positive T-cell epitopes derived from tumour associated antigens (TAA) may be of great importance for the development of pharmaceutical products for triggering anti-tumour immune responses (Kobayashi, H., R. Omiya, M. Ruiz, E. Huarte, P. Sarobe, J. J. Lasarte, M. Herraiz, B. Sangro, J. Prieto, F. Borrás-Cuesta, and E. Celis. 2002. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. *Clin. Cancer Res.* 8:3219-3225., Gnjatich, S., D. Atanackovic, E. Jäger, M. Matsuo, A. Selvakumar, N.K. Altorki, R.G. Maki, B. Dupont, G. Ritter, Y.T. Chen, A. Knuth, and L.J. Old. 2003. Survey of naturally occurring CD4+ T-cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses. *Proc. Natl. Acad. Sci. U.S.A.* 100(15):8862-7) CD4+ T cells can lead to locally increased levels of IFN γ (Qin Z, Schwartzkopff J, Pradera F, Kammer-toens T, Seliger B, Pircher H, Blankenstein T; A critical requirement of interferon gamma-mediated angiostasis for tumour rejection by CD8+ T cells; *Cancer Res.* 2003 J; 63(14):4095-4100).

[0006] In the absence of inflammation, expression of MHC class II molecules is mainly restricted to cells of the immune system, especially professional antigen-presenting cells (APC), e.g., monocytes, monocyte-derived cells, macrophages, dendritic cells. In tumour patients, cells of the tumour have surprisingly been found to express MHC class II molecules (Dengjel J, Nastke MD, Gouttefangeas C, Gitsioudis G, Schoor O, Altenberend F, Müller M, Krämer B, Missiou A, Sauter M, Hennenlotter J, Wernet D, Stenzl A, Rammensee HG, Klingel K, Stevanović S.; Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas; *Clin Cancer Res.* 2006; 12:4163-4170).

[0007] It was shown in mammalian animal models, e.g., mice, that even in the absence of CTL effector cells (i.e., CD8-positive T lymphocytes), CD4-positive T-cells are sufficient for inhibiting visualization of tumours via inhibition of angiogenesis by secretion of interferon gamma (IFN γ) (Qin, Z. and T. Blankenstein. 2000. CD4+ T-cell-mediated tumour rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. *Immunity.* 12:677-686). Additionally, it was shown that CD4-positive T-cells recognizing peptides from tumour-associated antigens presented by HLA class II molecules can counteract tumour progression via the induction of antibody (Ab) responses (Kennedy, R.C., M.H. Shearer, A.M. Watts, and R.K. Bright, 2003. CD4+ T lymphocytes play a critical role in antibody production and tumour immunity against simian virus 40 large tumour antigen. *Cancer Res.* 63:1040-1045). In contrast to tumour-associated peptides binding to HLA class I molecules, only a small number of class II ligands of TAA have been described so far (www.cancerimmunity.org, www.syfpeithi.de).

[0008] Since the constitutive expression of HLA class II molecules is usually limited to cells of the immune system (Mach, B., V. Steimle, E. Martinez-Soria, and W. Reith. 1996. Regulation of MHC class II genes: lessons from a disease.

Annu. Rev. Immunol. 14:301-331), the possibility of isolating class II peptides directly from primary tumours was not considered possible. However, Dengjel et al. were recently successful in identifying a number of MHC Class II epitopes directly from tumours (EP 04 023 546.7, EP 05 019 254.1; Dengjel J, Nastke MD, Gouttefangeas C, Gitsioudis G, Schoor O, Altenberend F, Müller M, Krämer B, Missiou A, Sauter M, Hennenlotter J, Wernet D, Stenzl A, Rammensee HG, Klingel K, Stevanović S.; Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas; Clin Cancer Res. 2006; 12:4163-4170).

[0009] For a peptide to trigger (elicit) a cellular immune response, it must bind to an MHC-molecule. This process is dependent on the allele of the MHC-molecule and specific polymorphisms of the amino acid sequence of the peptide. MHC-class-I-binding peptides are usually 8-10 amino acid residues in length and usually contain two conserved residues ("anchors") in their sequence that interact with the corresponding binding groove of the MHC-molecule. In this way each MHC allele has a "binding motif" determining which peptides can bind specifically to the binding groove (Rammensee H. G., Bachmann J. and Stevanovic, S; MHC Ligands and Peptide Motifs, Chapman & Hall 1998).

[0010] In the MHC class I dependent immune reaction, peptides not only have to be able to bind to certain MHC class I molecules expressed by tumour cells, they also have to be recognized by T-cells bearing specific T-cell receptors (TCR).

[0011] The antigens that are recognised by the tumour specific cytotoxic T- lymphocytes, that is, their epitopes, can be molecules derived from all protein classes, such as enzymes, receptors, transcription factors, etc. which are up-regulated in cells of the respective tumour. Furthermore, tumour associated antigens, for example, can also be unique to tumour cells, for example as products of mutated genes or from alternative open reading frames (ORFs), or from protein splicing (Vigneron N, Stroobant V, Chapiro J, Ooms A, Degiovanni G, Morel S, van der Bruggen P, Boon T, Van den Eynde BJ. An antigenic peptide produced by peptide splicing in the proteasome, Science 2004 Apr 23; 304 (5670):587-90.). Another important class of tumour associated antigens are tissue-specific antigens, such as CT ("cancer testis")-antigens that are expressed in different kinds of tumours and in healthy tissue of the testis.

[0012] Various tumour associated antigens have been identified. Further, much research effort has been spent to identify additional tumour associated antigens. Some groups of tumour associated antigens, also referred to in the art as tumour specific antigens, are tissue specific. Examples include, but are not limited to, tyrosinase for melanoma, PSA and PSMA for prostate cancer and chromosomal cross-overs such as bcr/abl in lymphomas. However, many tumour associated antigens identified occur in multiple tumour types, and some, such as oncogenic proteins and/or tumour suppressor genes (tumour suppressor genes are, for example reviewed for renal cancer in Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol. 2003 Dec; 170(6 Pt 1):2163-72) which actually cause the transformation event, occur in nearly all tumour types. For example, normal cellular proteins that control cell growth and differentiation, such as p53 (which is an example for a tumour suppressor gene), ras, c-met, myc, pRB, VHL, and HER-2/neu, can accumulate mutations resulting in up-regulation of expression of these gene products thereby making them oncogenic (McCartey et al. Cancer Research 1998 15:58 2601-5; Disis et al. Ciba Found. Symp. 1994 187:198-211). These mutant proteins can also be a target of a tumour specific immune response in multiple types of cancer.

[0013] For proteins to be recognised by cytotoxic T-lymphocytes as tumour-specific or -associated antigens, and for them to be used in a therapy, particular prerequisites must be fulfilled. The antigen should be expressed mainly by tumour cells and not or in comparably small amounts by normal healthy tissues. It is furthermore desirable, that the respective antigen is not only present in a type of tumour, but also in high concentrations (i.e. copy numbers of the respective peptide per cell). Tumour-specific and tumour-associated antigens are often derived from proteins directly involved in transformation of a normal cell to a tumour cell due to a function e.g. in cell cycle control or apoptosis. Additionally, downstream targets of the proteins directly causative for a transformation may be upregulated und thus may be indirectly tumour-associated. Such indirectly tumour-associated antigens may also be targets of a vaccination approach (Singh-Jasuja H., Emmerich N. P., Rammensee H. G., Cancer Immunol. Immunoether. 2004 Mar; 453 (3): 187-95). In both cases it is essential to have epitopes in the amino acid sequence of the antigen, since such peptide ("immunogenic peptide") that is derived from a tumour associated antigen should lead to an in vitro or in vivo T-cell-response.

[0014] Basically, any peptide able to bind a MHC molecule may function as a T-cell epitope. A prerequisite for the induction of an in vitro or in vivo T-cell-response is the presence of a T-cell with a corresponding TCR and the absence of immunological tolerance for this particular epitope.

[0015] Therefore, TAAs are a starting point for the development of a tumour vaccine. The methods for identifying and characterizing the TAAs are based on the use of CTL that can be isolated from patients or healthy subjects, or they are based on the generation of differential transcription profiles or differential peptide expression patterns between tumours and normal tissues (Lemmel C., Weik S., Eberle U., Dengjel J., Kratt T., Becker H. D., Rammensee H. G., Stevanovic S. Nat. Biotechnol. 2004 Apr.; 22(4):450-4, T. Weinschenk, C. Gouttefangeas, M. Schirle, F. Obermayr, S. Walter, O. Schoor, R. Kurek, W. Loeser, K. H. Bichler, D. Wernet, S. Stevanovic, and H. G. Rammensee. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res. 62 (20):5818-5827, 2002.).

[0016] However, the identification of genes overexpressed in tumour tissues or human tumour cell lines, or selectively expressed in such tissues or cell lines, does not provide precise information as to the use of the antigens transcribed

from these genes in an immune therapy. This is because only an individual subpopulation of epitopes of these antigens are suitable for such an application since a T-cell with a corresponding TCR has to be present and immunological tolerance for this particular epitope needs to be absent or minimal. It is therefore important to select only those peptides from overexpressed or selectively expressed proteins that are presented in connection with MHC molecules against which a functional T-cell can be found. Such a functional T-cell is defined as a T-cell that upon stimulation with a specific antigen can be clonally expanded and is able to execute effector functions ("effector T-cell").

[0017] T-helper cells play an important role in orchestrating the effector function of CTLs in anti-tumour immunity. T-helper cell epitopes that trigger a T-helper cell response of the T_H1 type support effector functions of CD8-positive killer T-cells, which include cytotoxic functions directed against tumour cells displaying tumour-associated peptide/MHC complexes on their cell surfaces. In this way tumour-associated T-helper cell epitopes, alone or in combination with other tumour-associated peptides, can serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses.

[0018] Since both types of response, CD8 and CD4 dependent, contribute jointly and synergistically to the anti-tumour effect, the identification and characterization of tumour-associated antigens recognised by either CD8+ CTLs (ligand: MHC class I molecule + peptide epitope) or by CD4-positive CTLs (ligand: MHC class II molecule + peptide epitope) is important in the development of tumour vaccines. It is therefore an object of the present invention, to provide novel amino acid sequences for peptides that are able to bind to MHC complexes of either class.

[0019] WO 2005/116051 discloses peptides binding to MHC class I.

Brief description of the drawings

[0020]

Fig. 1 shows the ESI-liquid chromatography mass spectra identifying tumour associated peptide (TUMAP) PCN-002 from colon carcinoma sample CCA707 (Fig. 1a), TOP-002 from glioblastoma sample GB1006 (Fig. 1b), PTP-001 from glioblastoma sample GB1006 (Fig. 1c), GAL-001 from renal cell carcinoma sample RCC190 (Fig. 1d), CHI-001 from glioblastoma sample GB1002 (Fig. 1e), JAK-001 from glioblastoma sample GB1002 (Fig. 1f), AKR-001 from non-small lung cell cancer NSCLC-Pool 2 (Fig. 1g), and FNI-001 from pancreatic carcinoma sample PC330 (Fig. 1h) that were presented in a MHC class I restricted manner.

Fig. 2 shows the ESI-liquid chromatography mass spectra identifying tumour associated peptide (TUMAP) CEA-009 from gastric carcinoma GC-Pool 2 (Fig. 2a), TGFBI-006 from gastric carcinoma GC-Pool 1 (Fig. 2b), TGFBI-007 from glioblastoma sample GB6002 (Fig. 2c), TGFBI-008 from glioblastoma sample GB1004 (Fig. 2d), TGFBI-009 from non-small lung cell cancer NSCLC-Pool 1 (Fig. 2e), and TGFBI-010 from glioblastoma sample GB6002 (Fig. 2f) that were presented in a MHC class II restricted manner.

Fig. 3 depicts the expression profiles of two genes encoding glioblastoma associated peptides PTP-001 (Fig. 3a) and CHI-001 (Fig. 3b). Expression of the genes is absent or very low in normal tissues while increased up to more than 250-fold in glioblastoma samples (GB1006T to GB1011T; NCH359T and NCH361T).

Fig. 4 depicts binding affinities of selected peptides to HLA-A*0201 as measured by Epi ELISA according to Sylvester-Hvid, C, Kristensen, N, Blicher, T, Ferre, H, Lauemoller, SL, Wolf, XA, Lamberth, K, Nissen, MH, Pedersen, LO, and Buus, S; 2002, Establishment of a quantitative ELISA capable of determining peptide - MHC class I interaction, Tissue Antigens, 59, 251-258. The analysis was limited to peptides known to be MHC class I binding peptides. Affinities of HLA-DR binding peptides cannot be measured with this assay.

Figure 5 depicts the Tetramer analysis of microsphere driven proliferation of ODC-001 and NOX-001 specific CD8+ lymphocytes from peripheral blood.

1×10^6 CD8+ enriched PBMCs per well of the healthy HLA-A*0201+ donor HD100 was stimulated weekly with microspheres coupled to anti-CD28 plus high density tumor antigen A*0201/ODC-001 (upper panel) or anti-CD28 plus high density tumor antigen A*0201/NOX-001 (lower panel). After three stimulations in vitro, all cells were stained with antibody CD8 FITC plus tetramers A*0201/NOX-001 PE and A*0201/ODC-001 APC. Cells are gated on the lymphocyte population or CD8+ lymphocytes (right panel) and numbers represent percentage of tetramer+ within CD8+ lymphocytes.

Figure 6 depicts the in vitro immunogenicity of TGFBI-004 as detected by IFN γ ELISPOT after five stimulation cycles. Cells were primed and restimulated repeatedly with TGFBI-004 and then incubated with relevant TGFBI-004 (Well 1, 2, 3 and 4) and irrelevant (Neg. control) peptide, respectively. The analysis after IFN γ ELISPOT was performed

on an ELISPOT Reader (CTL, Cleveland, USA). PHA-Ionomycin served as positive control. Numbers indicate the count of positive spots.

Figure 7 depicts the in vitro immunogenicity of TGFBI-004 as detected by ICS after five stimulation cycles.

Cells were primed with TGFBI-004-loaded autologous DCs and restimulated repeatedly with autologous PBMCs plus TGFBI-004. For the read-out cells were incubated with relevant TGFBI-004 (Well 1, 2, 3 and 4) and irrelevant (Neg. Control) peptide, respectively. Additionally to the intracellular IFN γ staining, cells were also stained with CD4-FITC and CD8-PerCP antibodies. The analysis was performed on a four-color FACSCalibur cytometer (BD Biosciences, Germany).

Figure 8 depicts the ELISPOT analysis of IFN γ production by T-cell lines upon in vitro restimulation with the NOX-001 peptide. A. T-Cell line 7+ from donor HBC-154 (sorted CD8+ NOX-001 tetramer+); B. T-Cell line 7- from donor HBC-154 (sorted CD8+ NOX-001 tetramer-).

Sorted CD8+ NOX-001 tetramer+ (A.) and CD8+ NOX-001 tetramer- (B.) cells were analysed by IFN γ ELISPOT after restimulation with irrelevant (MLA-001) (upper wells) and relevant (NOX-001) (lower wells) peptide (10 μ g/ml). Numbers indicate the count of positive spots.

Figure 9 shows affinities of peptides contained in the present invention to HLA-A*0201. Dissociation constants (K_D) of P116 HLA class I peptides and the viral marker peptide HBV-001 were measured by an ELISA-based assay (see Examples).

Detailed description of the invention

[0021] In a first aspect the invention provides a peptide consisting of the sequence ALFVRLALLA according to SEQ ID No. 8 which induces T cells cross-reacting with said peptide.

[0022] In the present invention, the term "homologous" refers to the degree of identity between sequences of two amino acid sequences, i.e. peptide or polypeptide sequences. The aforementioned "homology" is determined by comparing two sequences aligned under optimal conditions over the sequences to be compared. The sequences to be compared herein may have an addition or deletion (for example, gap and the like) in the optimum alignment of the two sequences. Such a sequence homology can be calculated by creating an alignment using, for example, the ClustalW algorithm (Nucleic Acid Res., 22(22): 4673-4680 (1994). Commonly available sequence analysis software, more specifically, Vector NTI, GENETYX or analysis tools provided by public databases, such as e.g. <http://dragon.bio.purdue.edu/bioinfolinks/> may also be used.

[0023] A person skilled in the art will be able to assess whether T-cells induced by a variant of a specific peptide will be able to cross-react with the peptide itself by (Fong, L, Hou, Y, Rivas, A, Benike, C, Yuen, A, Fisher, GA, Davis, MM, and Engleman, EG; 2001, Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy, Proc. Natl. Acad. Sci. U.S.A, 98, 8809-8814); (Zaremba, S, Barzaga, E, Zhu, M, Soares, N, Tsang, KY, and Schlom, J; Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen, Cancer Res., 1997, 57, 4570-4577; Colombetti, S, Fagerberg, T, Baumgartner, P, Chapatte, L, Speiser, DE, Rufer, N, Michielin, O, and Levy, F.; Impact of orthologous melan-A peptide immunizations on the anti-self melan-A/HLA-A2 T cell cross-reactivity, J Immunol., 2006, 176, 6560-6567; Appay, V, Speiser, DE, Rufer, N, Reynard, S, Barbey, C, Cerottini, JC, Leyvraz, S, Pinilla, C, and Romero, P; Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide, Eur.J Immunol., 2006, 36, 1805-1814).

[0024] Table 1 shows the peptides, their respective SEQ ID NO as well as information on the parent proteins.

Table 1: Peptides

SEQ ID NO	Peptide Code	Sequence	HLA Alleles	Gene(s)
1	C20-001	ALSNLEVTL	A*02	C20orf42
2	NOX-001	ILAPVILYI	A*02	NOX1
3	PCN-001	KLMDLDVEQL	A*02	PCNA
4	PCN-002	SMSADVPLV	A*02	PCNA
5	TOP-001	KIFDEILVNA	A*02	TOP2A, TOP2B
6	TOP-002	AAFVEELDKV	A*02	TOP2B
7	CEA-009	VLLLVHNLQPQLFG	class II	CEACAM5

EP 2 562 184 B1

(continued)

SEQ ID NO	Peptide Code	Sequence	HLA Alleles	Gene(s)
8	TGFBI-001	ALFVRLALLA	A*02,A*02/B*13?	TGFBI
9	TGFBI-006	GDKLEVSLKNNVVS	class II	TGFBI
10	TGFBI-007	GKKLRVFVYRNSLCIENS	class II	TGFBI
11	TGFBI-008	LKNNVSVNKEPVAEPD	class II	TGFBI
		KNNWSVNKEPVAEPD	class II	TGFBI
		KNNVSVNKEPVA	class II	TGFBI
		LKNNWSVNKEPVA	class II	TGFBI
12	TGFBI-009	NGVIHYIDELLIPDS	class II	TGFBI
		GVIHYIDELLIPDSA	class II	TGFBI
13	TGFBI-010	LNRLGDPEALRDL	class II	TGFBI
14	TGFBI-004	TPPIDAHTRNLLRNH	class II	TGFBI
15	PTP-001	ALTTLMHQL	A*02	PTPRZ1
16	GAL-001	SLDPSSPQV	A*02	GAL3ST1
17	CHI-001	SLWAGVWL	A*02	CHI3L2
18	JAK-001	KLTDIQIEL	A*02	JAKMIP2
19	AKR-001	YLIHFPVSV	A*02	AKR1C1, AKR1C2
20	FN1-001	IVDDITYNV	A*02	FN1
21	EGFR-002	GAVRFSNNPALCNVES	class II	EGFR
		AVRFSNNPALCNVES	class II	EGFR
		AVRFSNNPALCNVE	class II	EGFR
22	EGFR-005	NPTTYQMDVNPEGKYS	class II	EGFR
23	EGFR-006	FKKIKVLGSGAFG	class II	EGFR
24	CHI3L1-001	TTLIKEMKAEFIKEAQPG	class II	CHI3L1
		TLIKEMKAEFIKEAQPG	class II	CHI3L1
		TTLIKEMKAEFIKEA	class II	CHI3L1
		TLIKEMKAEFIKEA	class II	CHI3L1
		IKEMKAEFIKEAQPG	class II	CHI3L1
		TTLIKEMKAEFIKE	class II	CHI3L1
25	CHI3L1-007	VKSKVQYLKDRQLAG	class II	CHI3L1
26	CHI3L1-008	SRRTFIKSVPPFLRT	class II	CHI3L1
27	DCA-001	KLGDGFLATVV	A*02	DCAMKL2
28	KCN-001	SLFDQVVKV	A*02	KCNJ10
29	GPM-001	ALLSEVIQL	A*02	GPM6B

Chromosome 20 open reading frame 42

[0025] C20orf42 is a focal adhesion protein involved in attachment of the actin cytoskeleton to the plasma membrane and in integrin-mediated cellular processes. Deficiency of C20orf42 as a result of loss-of-function mutations causes Kindler syndrome, an autosomal recessive genodermatosis characterized by skin blistering, progressive skin atrophy, photosensitivity and, occasionally, carcinogenesis (Herz, C, Aumailley, M, Schulte, C, Schlotzer-Schrehardt, U, Bruckner-

Tuderman, L, and Has, C; Kindlin-1 is a phosphoprotein involved in regulation of polarity, proliferation, and motility of epidermal keratinocytes, *J Biol Chem.*, 2006, 281, 36082-36090). Recently, a severe gastrointestinal tract involvement with hemorrhagic colitis has been reported in a patient with a loss-of-function mutation (Sadler, E, Klaussegger, A, Muss, W, Deinsberger, U, Pohla-Gubo, G, Laimer, M, Lanschuetzer, C, Bauer, JW, and Hintner, H; Novel KIND1 gene mutation in Kindler syndrome with severe gastrointestinal tract involvement, *Arch. Dermatol.*, 2006, 142, 1619-1624).

[0026] In the context of cancer, C20orf42 has been described within studies investigating gene expression in cancer-relevant settings. It was found to be overexpressed in 70% of colon carcinomas and 60% of lung carcinomas tested ($n = 10$). Normal tissue expression by Northern Blot was restricted to neuromuscular tissues (Weinstein, EJ, Bourner, M, Head, R, Zakeri, H, Bauer, C, and Mazzarella, R; URP1: a member of a novel family of PH and FERM domain-containing membrane-associated proteins is significantly over-expressed in lung and colon carcinomas, *Biochim. Biophys. Acta*, 2003, 1637, 207-216). Furthermore, C20orf42 has been identified as a gene involved in TGF- β -mediated cell migration and tumour invasion (Kloeker, S, Major, MB, Calderwood, DA, Ginsberg, MH, Jones, DA, and Beckerle, MC; The Kindler syndrome protein is regulated by transforming growth factor-beta and involved in integrin-mediated adhesion, *J. Biol. Chem.*, 2004, 279, 6824-6833).

NADPH oxidase homolog-1 (NOX1)

[0027] NOX1, is a growth factor-responsive enzyme that catalyzes formation of the reactive oxygen species superoxide (O_2^-) and hydrogen peroxide (H_2O_2). Its expression was originally identified in colon, prostate, uterus, and proliferating vascular smooth muscle cells (Suh, Y. A. et al. 1999; Cell transformation by the superoxide-generating oxidase Mox1. *Nature* 401, 79-82). Its expression is linked to a number of biological responses including cellular proliferation, angiogenesis, and activation of cellular signalling pathways (Harper, R. W., Xu, C., Soucek, K., Setiadi, H. & Eiserich, J. P. A reappraisal of the genomic organization of human Nox1 and its splice variants. *Arch. Biochem. Biophys.* 2005, 435, 323-330).

[0028] NOX1 is highly expressed in the colon but its function in colonic physiology or pathology is still poorly understood. In normal tissues, NOX1 expression was low in the ileum, intermediate in the right colon, and high in the left colon. There was no statistical difference in NOX1 expression between samples derived from adenomas, well differentiated or poorly differentiated colon adenocarcinomas. NOX1 was highly expressed in colon epithelial cells, both within the crypts and on the luminal surface. In conclusion, NOX1 is an enzyme that is constitutively expressed in colon epithelium and is not directly associated with tumorigenesis (Szanto, I. et al. Expression of NOX1, a superoxide-generating NADPH oxidase, in colon cancer and inflammatory bowel disease. *J Pathol.* 2005, 207, 164-176).

[0029] Immunohistochemistry showed that NOX1 was constitutively expressed in surface mucous cells. Adenomas and well differentiated adenocarcinomas up-regulated NOX1 expression.

[0030] Nuclear factor (NF)-kappaB was predominantly activated in adenoma and adenocarcinoma cells expressing abundant NOX1, suggesting that NOX1 may stimulate NF-kappaB-dependent antiapoptotic pathways in colon tumours (Fukuyama, M. et al. Overexpression of a novel superoxide-producing enzyme, NADPH oxidase 1, in adenoma and well differentiated adenocarcinoma of the human colon. *Cancer Lett.* 2005, 221, 97-104).

[0031] Wnt3a/beta-Catenin signalling has been described to induce NOX1 expression (Petropoulos, H. & Skerjanc, I. S. Beta-catenin is essential and sufficient for skeletal myogenesis in P19 cells. *J Biol Chem.* 2002, 277, 15393-15399).

[0032] Recently, reactive oxygen species have been suggested to induce endothelial apoptosis that subsequently induces the expression of various adhesion molecules for tumour cells. This indicates that by tackling the production of ROS preventing tumour recurrence at distant sites might be feasible (Ten, KM, van der Wal, JB, Sluiter, W, Hofland, LJ, Jeekel, J, Sonneveld, P, and van Eijck, CH; The role of superoxide anions in the development of distant tumour recurrence, *Br.J Cancer*, 2006, 95, 1497-1503).

Proliferating Cell Nuclear Antigen (PCNA)

[0033] PCNA is found in the nucleus and is a cofactor of DNA polymerase delta. The encoded protein acts as a homotrimer and helps increase the processivity of leading strand synthesis during DNA replication. Therefore, it is expressed in all proliferating cells, especially tumour cells, and is used as a marker to detect proliferation.

DNA topoisomerase II

[0034] TOP2A and TOP2B encode isoforms of a DNA topoisomerase, an enzyme that controls and alters the topologic states of DNA during transcription. This nuclear enzyme is involved in processes such as chromosome condensation, chromatid separation, and the relief of torsional stress that occurs during DNA transcription and replication. DNA topoisomerase catalyses the transient breaking and rejoining of two strands of duplex DNA which allows the strands to pass through one another, thus altering the topology of DNA. The two isoforms of this enzyme exist as likely products of a

gene duplication event. The gene encoding the alpha form is localised to chromosome 17 and the beta gene is localized to chromosome 3. TOP2A is the target for several anticancer agents and a variety of mutations in this gene have been associated with the development of drug resistance.

[0035] The TOP2A gene is located adjacent to the HER-2 oncogene, the most frequently amplified oncogene in breast cancer, at the chromosome location 17q12-q21 and is either amplified or deleted, with equal frequency, in almost 90% of HER-2 amplified primary breast tumours (Jarvinen, TA and Liu, ET; Topoisomerase II alpha gene (TOP2A) amplification and deletion in cancer-more common than anticipated, *Cytopathology*, 2003, 14, 309-313). Furthermore, TOP2A amplifications have been reported for other cancers.

[0036] Without TOP2A DNA replication and cell division are impossible. It has therefore become the main target of many antitumour therapy regimens, even though the exact mechanism of cell killing remains elusive (Kellner, U, Sehested, M, Jensen, PB, Gieseler, F, and Rudolph, P; Culpit and victim -DNA topoisomerase II, *Lancet Oncol.*, 2002, 3, 235-243). The success of this approach is limited by the development of spontaneous resistance, and drug-induced DNA damage can increase malignancy. Recent data suggest that amplification and deletion of TOP2A may account for both sensitivity and resistance to TOP2A-inhibitor-chemotherapy, depending on the specific genetic defect at the TOP2A locus.

[0037] It is not clear whether the involvement of TOP2B in cancer is similar to TOP2A or whether there is a major difference between the two isoforms. TOP2B can at least supplement for some of the TOP2A activity (Sakaguchi, A and Kikuchi, A; Functional compatibility between isoform alpha and beta of type II DNA topoisomerase, *J Cell Sci.*, 2004, 117, 1047-1054).

Carcinoembryonic antigen-related cell adhesion molecule 5

[0038] Carcinoembryonic antigen (CEA = CEACAM5) is a 180 kDa heavily glycosylated membrane protein composed of three C2 Ig-like repeating units flanked by a N-terminal Ig V-like region and a C-terminal region, which includes glycoposphatidylinositol linkage region (Hegde, P, Qi, R, Gaspard, R, Abernathy, K, Dharap, S, Earle-Hughes, J, Gay, C, Nwokekeh, NU, Chen, T, Saeed, AI, Sharov, V, Lee, NH, Yeatman, TJ, and Quackenbush, J; Identification of tumour markers in models of human colorectal cancer using a 19,200-element complementary DNA microarray, *Cancer Res.*, 2001, 61, 7792-7797).

[0039] As an oncofetal antigen, CEA is expressed during foetal development, but also, at low levels, in the gastrointestinal epithelium of adults. However, CEA is overexpressed in a high percentage of human tumours, including 90% of gastrointestinal, colorectal and pancreatic cancer, 70% of non-small cell lung cancer cells and 50% of breast cancers (Thompson, JA, Grunert, F, and Zimmermann, W; Carcinoembryonic antigen gene family: molecular biology and clinical perspectives, *J Clin Lab Anal.*, 2005, 5, 344-366). Due to its high expression by tumour cells and its secretion to the serum, CEA has been broadly used as a tumour marker (Sikorska, H, Shuster, J, and Gold, P; Clinical applications of carcinoembryonic antigen, *Cancer Detect. Prev.*, 1988, 12, 321-355) and is the standard serum marker for colorectal cancer monitoring (Locker, GY, Hamilton, S, Harris, J, Jessup, JM, Kemeny, N, Macdonald, JS, Somerfield, MR, Hayes, DF, and Bast, RC, Jr.; ASCO 2006 update of recommendations for the use of tumour markers in gastrointestinal cancer, *J Clin Oncol*, 2006, 24, 5313-5327.).

[0040] Despite the overexpression of CEA in tumour cells, cancer patients do not normally show an immune response against this antigen (Orefice, S, Fossati, G, Pietrojusti, E, and Bonfanti, G; Delayed cutaneous hypersensitivity reaction to carcinoembryonic antigen in cancer patients, *Tumouri*, 1982, 68, 473-475). The immune system commonly becomes tolerant to CEA, because it is normally expressed at low levels in the body. However, in a series of clinical vaccine trials, the immunogenicity of CEA has been demonstrated (Sarobe, P, Huarte, E, Lasarte, JJ, and Borrás-Cuesta, F; Carcinoembryonic antigen as a target to induce anti-tumour immune responses, *Curr. Cancer Drug Targets.*, 2004, 4, 443-454), especially in colorectal carcinoma (CRC) (Mosolits, S, Ullenhag, G, and Mellstedt, H; Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results, *Ann.Oncol.*, 2005, 16, 847-862), and CEA is the tumour associated antigen (TAA) with the greatest number of vaccine platforms tested in this tumour type (von Mehren, M; Colorectal cancer vaccines: what we know and what we don't yet know, *Semin. Oncol.*, 2005, 32, 76-84).

[0041] Several cytotoxic and helper T-cell epitopes have been described for CEA (Crosti, M, Longhi, R, Consogno, G, Melloni, G, Zannini, P, and Protti, MP; Identification of novel subdominant epitopes on the carcinoembryonic antigen recognized by CD4+ T-cells of lung cancer patients, *J Immunol.*, 2006, 176, 5093-5099; Novellino, L, Castelli, C, and Parmiani, G; A listing of human tumour antigens recognized by T-cells: March 2004 update, *Cancer Immunol.Immunother.*, 2004, 54, 187-207; Ruiz, M, Kobayashi, H, Lasarte, JJ, Prieto, J, Borrás-Cuesta, F, Celis, E, and Sarobe, P; Identification and characterization of a T-helper peptide from carcinoembryonic antigen, *Clin Cancer Res.*, 2004, 10, 2860-2867), enabling a variety of peptide-based vaccination trials in CRC (Babatz, J, Rollig, C, Lobel, B, Folprecht, G, Haack, M, Gunther, H, Kohne, CH, Ehninger, G, Schmitz, M, and Bomhauser, M; Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumours after vaccination with altered peptide ligand-loaded dendritic cells, *Cancer Immunol. Immunother.*, 2006, 55, 268-276; Fong, L, Hou, Y, Rivas, A, Benike, C, Yuen, A, Fisher, GA, Davis, MM, and Engleman, EG; Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for

tumour immunotherapy, *Proc. Natl. Acad. Sci. U.S.A.*, 2001, 98, 8809-8814; Liu, KJ, Wang, CC, Chen, LT, Cheng, AL, Lin, DT, Wu, YC, Yu, WL, Hung, YM, Yang, HY, Juang, SH, and Whang-Peng, J; Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides, *Clin Cancer Res.*, 2004, 10, 2645-2651; Matsuda, K, Tsunoda, T, Tanaka, H, Umano, Y, Tanimura, H, Nukaya, I, Takesako, K, and Yamaue, H; Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide-pulsed dendritic cells, *Cancer Immunol.Immunother.*, 2004, 53, 609-616; Ueda, Y, Itoh, T, Nukaya, I, Kawashima, I, Okugawa, K, Yano, Y, Yamamoto, Y, Naitoh, K, Shimizu, K, Imura, K, Fuji, N, Fujiwara, H, Ochiai, T, Itoi, H, Sonoyama, T, Hagiwara, A, Takesako, K, and Yamagishi, H; Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas, *Int.J Oncol.*, 2004, 24, 909-917; Weihrauch, MR, Ansen, S, Jurkiewicz, E, Geisen, C, Xia, Z, Anderson, KS, Gracien, E, Schmidt, M, Wittig, B, Diehl, V, Wolf, J, Bohlen, H, and Nadler, LM; Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer, *Clin Cancer Res.*, 2005, 11, 5993-6001). These and other clinical trials to date have demonstrated safety of CEA vaccinations and evidence for the induction of immune response against this antigen (von Mehren, M; Colorectal cancer vaccines: what we know and what we don't yet know, *Semin. Oncol.*, 2005, 32, 76-84).

Transforming Growth Factor, Beta-Induced (TGFB1)

[0042] TGFB1 was first identified as a TGF-beta-inducible gene in a human lung adenocarcinoma cell line. It encodes for a secreted extracellular matrix protein, which is thought to act on cell attachment and extracellular matrix composition.

[0043] TGFB1 was shown to be among the most significantly elevated genes in colorectal cancers and it is expressed at high levels in adenomas as well. Quantitative PCR results demonstrated strong elevation in both unpurified tumours and purified tumour epithelial cells. Accordingly, in situ hybridization experiments revealed TGFB1 to be expressed in many cell types, in both the stromal and epithelial compartments (Buckhaults, P, Rago, C, St, CB, Romans, KE, Saha, S, Zhang, L, Vogelstein, B, and Kinzler, KW; Secreted and cell surface genes expressed in benign and malignant colorectal tumours, *Cancer Res.*, 2001, 61, 6996-7001).

[0044] In a meta-analysis of studies investigating gene expression in colorectal carcinoma, TGFB1 was identified as one of only nine genes described as upregulated repeatedly (4 studies for TGFB1) (Shih, W, Chetty, R, and Tsao, MS; Expression profiling by microarrays in colorectal cancer, *Oncol. Rep.*, 2005, 13, 517-524).

[0045] In human pancreatic tissues, there was a 32.4-fold increase in TGFB1 mRNA levels in pancreatic cancers in comparison to normal control tissues. In situ hybridization analysis revealed that TGFB1 mRNA was expressed mainly in the cancer cells within the pancreatic tumour mass (Schneider, D, Kleeff, J, Berberat, PO, Zhu, Z, Korc, M, Friess, H, and Buchler, MW; Induction and expression of betaig-h3 in pancreatic cancer cells, *Biochim. Biophys. Acta*, 2002, 1588, 1-6).

[0046] TGFB1 was identified as a gene promoting angiogenesis in an in vitro model. Additionally, dramatically enhanced expression of TGFB1 was detected in several tumours. Antisense oligonucleotides to TGFB1 blocked both gene expression and endothelial tube formation in vitro, suggesting that TGFB1 may play a critical role in endothelial cell-matrix interactions (Aitkenhead, M, Wang, SJ, Nakatsu, MN, Mestas, J, Heard, C, and Hughes, CC; Identification of endothelial cell genes expressed in an in vitro model of angiogenesis: induction of ESM-1, (beta)ig-h3, and NrCAM, *Microvasc. Res.*, 2002, 63, 159-171).

Protein Tyrosine Phosphatase, Receptor-Type, Zeta (PTPRZ1)

[0047] PTPRZ1 is a member of the receptor type protein tyrosine phosphatase family and encodes a single-pass type I membrane protein with two cytoplasmic tyrosine-protein phosphatase domains, an alpha-carbonic anhydrase domain and a fibronectin type-III domain. Expression of this gene is induced in gastric cancer cells (Wu, CW, Li, AF, Chi, CW, and Lin, WC; Protein tyrosine-phosphatase expression profiling in gastric cancer tissues, *Cancer Lett.*, 2006, 242, 95-103), in the remyelinating oligodendrocytes of multiple sclerosis lesions (Harroch, S, Furtado, GC, Brueck, W, Rosenbluth, J, Lafaille, J, Chao, M, Buxbaum, JD, and Schlessinger, J; A critical role for the protein tyrosine phosphatase receptor type Z in functional recovery from demyelinating lesions, *Nat. Genet.*, 2002, 32, 411-414), and in human embryonic kidney cells under hypoxic conditions (Wang, V, Davis, DA, Haque, M, Huang, LE, and Yarchoan, R; Differential gene up-regulation by hypoxia-inducible factor-1 alpha and hypoxia-inducible factor-2 alpha in HEK293T-cells, *Cancer Res.*, 2005, 65, 3299-3306).

[0048] Both the protein and transcript are overexpressed in glioblastoma cells, promoting their haptotactic migration (Lu, KV, Jong, KA, Kim, GY, Singh, J, Dia, EQ, Yoshimoto, K, Wang, MY, Cloughesy, TF, Nelson, SF, and Mischel, PS; Differential induction of glioblastoma migration and growth by two forms of pleiotrophin, *J Biol Chem.*, 2005, 280, 26953-26964).

[0049] Furthermore, PTRPZ1 is frequently amplified at the genomic DNA level in glioblastoma (Mulholland, PJ, Fiegler, H, Mazzanti, C, Gorman, P, Sasieni, P, Adams, J, Jones, TA, Babbage, JW, Vatcheva, R, Ichimura, K, East, P, Poulikas, C, Collins, VP, Carter, NP, Tomlinson, IP, and Sheer, D; Genomic profiling identifies discrete deletions associated with translocations in glioblastoma multiforme, *Cell Cycle*, 2006, 5, 783-791).

Janus Kinase and Microtubule Interacting Protein 2 (JAKMIP2)

[0050] JAKMIP2 was identified as one of many known or putative downstream targets of PAX3-FKHR which were highly overexpressed in ARMS (Paediatric rhabdomyosarcoma, alveolar subtype) (Lae, M, Ahn, E, Mercado, G, Chuai, S, Edgar, M, Pawel, B, Olshen, A, Barr, F, and Ladanyi, M; Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas, *J Pathol.*, 2007, 212, 143-151).

Fibronectin 1 (FN1)

[0051] Fibronectin is a high-molecular-weight glycoprotein containing about 5% carbohydrate that binds to receptor proteins that span the cell's membrane, called integrins. In addition to integrins, they also bind extracellular matrix components such as collagen, fibrin and heparin. There are several isoforms of fibronectin, all of which are the product of a single gene. FNs play a critical role in the maintenance of normal cell morphology, cell adhesion, migration, hemostasis, thrombosis, wound healing, differentiation and proliferation (Hynes, RO; Fibronectins, *Sci. Am.*, 1987, 254, 42-51).

[0052] The polymeric fibronectin, sFN, is formed in vitro by treating soluble fibronectin with a 76-aa peptide, III1-C (called Anastellin), which is derived from the first type III repeat in fibronectin. In vivo studies in tumour-bearing mice showed that systemic application of Anastellin or sFN suppressed tumour growth, angiogenesis and metastasis (Yi, M and Ruoslahti, E; A fibronectin fragment inhibits tumour growth, angiogenesis, and metastasis, *Proc. Natl. Acad. Sci. U.S.A.*, 2001, 98, 620-624). Anginex is a synthetic 33-amino acid peptide that was originally modelled to reproduce the beta-sheet structure of antiangiogenic proteins. It has been shown that anginex initiates fibronectin polymerization and is inactive in mice that lack plasma fibronectin (Akerman, ME, Pilch, J, Peters, D, and Ruoslahti, E; Angiostatic peptides use plasma fibronectin to home to angiogenic vasculature, *Proc. Natl. Acad. Sci. U.S.A.*, 2005, 102, 2040-2045). In a study, they examined the effects of FN on D-galactosamine (GalN)/lipopolysaccharide (LPS)-induced fulminant liver failure in mice. The results suggest that FN protected against GalN/LPS-induced liver failure by a mechanism involving inhibition of NF-kappaB activation, which caused down-regulation of TNF-alpha and involved up-regulation of IL-10, and elevation of Bcl-xL induced a blockage of apoptotic signals, by which apoptosis of hepatocytes caused by GalN/LPS was suppressed (Qiu, Z, Kwon, AH, Tsuji, K, Kamiyama, Y, Okumura, T, and Hirao, Y; Fibronectin prevents D-galactosamine/lipopolysaccharide-induced lethal hepatic failure in mice, *Shock*, 2006, 25, 80-87). Other results indicate that FN stimulates human lung carcinoma cell proliferation and diminishes apoptosis in vitro by inducing COX-2 gene expression and PGE2 biosynthesis (Han, S, Sidell, N, Roser-Page, S, and Roman, J; Fibronectin stimulates human lung carcinoma cell growth by inducing cyclooxygenase-2 (COX-2) expression, *Int. J. Cancer*, 2004, 111, 322-331).

[0053] Fibronectin (FN) has been shown to undergo alternative splicing exclusively during organogenesis and tumorigenesis. One such splice variant, extradomain-B (ED-B) FN, is normally absent in normal adult tissues and is proposed to be a marker of tumoural angiogenesis (Khan, ZA, Caurtero, J, Barbin, YP, Chan, BM, Uniyal, S, and Chakrabarti, S; ED-B fibronectin in non-small cell lung carcinoma, *Exp. Lung Res.*, 2005, 31, 701-711). Mhawech et al. showed that head and neck tumours with a positive staining for EDB had a trend to a significant lower overall survival of patients (Mhawech, P, Dulguerov, P, Assaly, M, Ares, C, and Allal, AS; EB-D fibronectin expression in squamous cell carcinoma of the head and neck, *Oral Oncol.*, 2005, 41, 82-88).

[0054] Fibronectin expression regulates angiogenesis and vasculogenesis and participates in brain tissue responses to ischemia and seizures. The gene expression of fibronectin was significantly increased ($p < 0.05$) in the SWS (Sturge-Weber syndrome) fibroblasts compared with that of fibroblasts from SWS normal skin (Comi, AM, Hunt, P, Vawter, MP, Pardo, CA, Becker, KG, and Pevsner, J; Increased fibronectin expression in sturge-weber syndrome fibroblasts and brain tissue, *Pediatr. Res.*, 2003, 53, 762-769). The fibronectin concentration was significantly higher in ovarian cancers compared with benign ovarian tumours and normal ovaries. Fibronectin concentration significantly elevated in ovarian cancer patients with recurrent disease compared with ovarian cancer patients without recurrence. The expression of tumour-derived matrixolytic enzymes and fibronectin are important in the growth of ovarian tumours (Demeter, A, Szirmai, K, Olah, J, Papp, Z, and Jeney, A; Elevated expression of matrix metalloproteinase-9, and fibronectin concentration in recurrent epithelial ovarian cancer, *Orv. Hetil.*, 2004, 145, 1617-1624). The fact that FN was one of the only two genes significantly down-regulated out of the 1,176 genes analyzed in a study stresses the hypothesis that FN may behave as an important metastasis suppressor gene in mammary cancer (Urtreger, AJ, Werbajh, SE, Verrecchia, F, Mauviel, A, Puricelli, LI, Kornbliht, AR, and Bal de Kier Joffe ED; Fibronectin is distinctly downregulated in murine mammary adenocarcinoma cells with high metastatic potential, *Oncol. Rep.*, 2006, 16, 1403-1410).

[0055] In a report, they found that three soluble fibronectin peptides (RGD, CS-1, and FN-C/H-V) induce apoptosis in

lung fibroblasts. Apoptosis occurred by disruption of adhesion (anoikis). The use of small fibronectin peptides to promote fibroblast apoptosis warrants further study as possible antifibrotic therapy (Hadden, HL and Henke, CA; Induction of lung fibroblast apoptosis by soluble fibronectin peptides, *Am.J Respir.Crit Care Med*, 2000, 162, 1553-1560). Another study has demonstrated that fibronectin (FN) stimulates human non-small cell lung carcinoma (NSCLC) cell proliferation. They show that FN increases MMP-9 protein, mRNA expression, and gelatinolytic activity in NSCLC cells (Han, S, Ritzenthaler, JD, Sitaraman, SV, and Roman, J; Fibronectin increases matrix metalloproteinase 9 expression through activation of c-Fos via extracellular-regulated kinase and phosphatidylinositol 3-kinase pathways in human lung carcinoma cells, *J Biol Chem.*, 2006, 281, 29614-29624). In one study, they investigated whether the tumour-suppressive effects of vitamin D (VD) compounds may also be mediated by mechanisms that govern cell adhesiveness. Introduction of small interfering RNA against FN resulted in down-regulation of FN expression and diminished cell adhesiveness to a collagen-type I matrix. Their findings highlight the significance of FN in modulating thyroid cancer cell adhesiveness and, at least in part, in mediating VD actions on neoplastic cell growth (Liu, W, Asa, SL, and Ezzat, S; α ,25-Dihydroxyvitamin D3 targets PTEN-dependent fibronectin expression to restore thyroid cancer cell adhesiveness, *Mol. Endocrinol.*, 2005, 19, 2349-2357).

[0056] The generation of tumour-associated FN isoforms allows the development of specific ligands (e.g., antibodies), which can be used for the selective delivery of therapeutic agents to the tumour environment. FN is used as a target for biomolecular intervention, both for the development of inhibitory molecules that block the interaction of FN with integrins and other receptors on the cell surface, and for the development of ligand-based targeted imaging and therapeutic strategies (Kaspar, M, Zardi, L, and Neri, D; Fibronectin as target for tumour therapy, *Int. J Cancer*, 2005, 118, 1331-1339). One study demonstrated that the treatment by in vivo expression of a recombinant CBD-HepII polypeptide of FN, designated as CH50, strongly inhibited the tumour growth, tumour invasion and angiogenesis. The gene therapy with CH50 not only prolonged the survival of mice bearing hepatocarcinoma in the liver, but also suppressed the growth and invasive ability of tumour in spleen and its metastasis to liver. Taken together, these findings suggest a prospective utility of CH50 in the gene therapy of liver cancer (Liu, Y, Huang, B, Yuan, Y, Gong, W, Xiao, H, Li, D, Yu, ZR, Wu, FH, Zhang, GM, and Feng, ZH; Inhibition of hepatocarcinoma and tumour metastasis to liver by gene therapy with recombinant CBD-HepII polypeptide of fibronectin, *Int. J Cancer*, 2007 121 (1) 184-92). Fibronectin (FN) has a cryptic functional site (YTIYVIAL sequence within the 14th type III repeat) opposing cell adhesion to extracellular matrix. A 22-mer FN peptide containing this site, termed FNIII14, inhibits β 1 integrin-mediated adhesion without binding to integrins. The study shows that FNIII14 has the potential to prevent lymphoma cell metastasis (Kato, R, Ishikawa, T, Kamiya, S, Oguma, F, Ueki, M, Goto, S, Nakamura, H, Katayama, T, and Fukai, F; A new type of antimetastatic peptide derived from fibronectin, *Clin Cancer Res.*, 2002, 8, 2455-2462).

Epidermal Growth Factor Receptor (EGFR)

[0057] EGFR plays an important role in the regulation of normal cell proliferation, differentiation and survival. For this reason EGFR status is often altered in a range of human tumour types and generally correlates with a poor prognosis. In neoplastic cells it contributes to their growth and survival through various divergent pathways (Maehama, T and Dixon, JE; The tumour suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate, *J Biol Chem.*, 1998, 273, 13375-13378). EGFR abnormalities are one of the most common molecular aberrations in glioblastoma (Zawrocki, A and Biernat, W; Epidermal growth factor receptor in glioblastoma, *Folia Neuropathol.*, 2005, 43, 123-132).

[0058] The EGFR amplification and mRNA overexpression are frequent in high grade gliomas of astrocytic origin, and are always strongly associated with an increased level of the EGFR protein (Wong, AJ, Bigner, SH, Bigner, DD, Kinzler, KW, Hamilton, SR, and Vogelstein, B; Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification, *Proc. Natl. Acad. Sci. U.S.A.*, 1987, 84, 6899-6903; Chaffanet, M, Chauvin, C, Laine, M, Berger, F, Chedin, M, Rost, N, Nissou, MF, and Benabid, AL; EGF receptor amplification and expression in human brain tumours, 1992, *Eur. J Cancer*, 28, 11-17). Protein overexpression without gene amplification has been reported in up to 27% of GBMs, but less malignant astrocytomas and oligodendrogliomas were also reported to demonstrate the EGFR overexpression without the underlying gene amplification (Reifenberger, J, Reifenberger, G, Ichimura, K, Schmidt, EE, Wechsler, W, and Collins, VP; Epidermal growth factor receptor expression in oligodendroglial tumours, *Am. J Pathol.*, 1996, 149, 29-35).

[0059] The prognostic implications of the EGFR amplification/overexpression in brain tumours are controversial. Some authors did not find any influence of the EGFR amplification/overexpression on survival of the patients (Olson, JJ, Barnett, D, Yang, J, Assietti, R, Cotsonis, G, and James, CD; Gene amplification as a prognostic factor in primary brain tumours, *Clin Cancer Res.*, 1998, 4, 215-222; Newcomb, EW, Cohen, H, Lee, SR, Bhalla, SK, Bloom, J, Hayes, RL, and Miller, DC; Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes, *Brain Pathol.*, 1998, 8, 655-667; Waha, A, Baumann, A, Wolf, HK, Fimmers, R, Neumann, J, Kindermann, D, Astrahantseff, K, Blumcke, I, von, DA, and Schlegel, U; Lack of prognostic relevance of alterations in the epidermal

growth factor receptor-transforming growth factor- α pathway in human astrocytic gliomas, *J Neurosurg.*, 1996, 85, 634-641) while the others concluded that these alterations were a negative prognostic factor (Etienne, MC, Formento, JL, Lebrun-Frenay, C, Gioanni, J, Chatel, M, Paquis, P, Bernard, C, Courdi, A, Bensadoun, RJ, Pignol, JP, Francoual, M, Grellier, P, Frenay, M, and Milano, G; Epidermal growth factor receptor and labelling index are independent prognostic factors in glial tumour outcome, *Clin Cancer Res.*, 1998, 4, 2383-2390; Jaros, E, Perry, RH, Adam, L, Kelly, PJ, Crawford, PJ, Kalbag, RM, Mendelow, AD, Sengupta, RP, and Pearson, AD; Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours, *Br. J Cancer*, 1992, 66, 373-385; Schlegel, J, Merdes, A, Stumm, G, Albert, FK, Forsting, M, Hynes, N, and Kiessling, M; Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma, *Int. J Cancer*, 1994, 56, 72-77; Zhu, A, Shaeffer, J, Leslie, S, Kolm, P, and El-Mahdi, AM; Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumours given definitive irradiation, *Int. J Radiat. Oncol. Biol Phys.*, 1996, 34, 809-815).

[0060] There exist a few treatment approaches to the EGFR molecule on the cancer cell. The most extensively studied include: specific antibody therapy by means of unarmed antibodies or antibodies conjugated with toxins, liposomes or nuclides, and the use of inhibitors of the receptor tyrosine kinase. There are several types of monoclonal antibodies directed against the EGFRwt. Their use results in blocking access to the receptor for its ligands (cetuximab) and/or rapid internalization of the receptor (ABX-EGF) (Sridhar, SS, Seymour, L, and Shepherd, FA; Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer, *Lancet Oncol.*, 2003, 4, 397-406). As the EGFRwt occurs also on the surface of normal cells, side effects may limit its use.

[0061] EGFR is overexpressed in head and neck squamous cell carcinoma (HNSCC) where expression levels correlate with decreased survival. Therapies that block EGFR have shown limited efficacy in clinical trials and primarily when combined with standard therapy. EGFRvIII is expressed in HNSCC where it contributes to enhanced growth and resistance to targeting wild-type EGFR. The antitumour efficacy of EGFR targeting strategies may be enhanced by the addition of EGFRvIII-specific blockade (Sok, JC, Coppelli, FM, Thomas, SM, Lango, MN, Xi, S, Hunt, JL, Freilino, ML, Graner, MW, Wikstrand, CJ, Bigner, DD, Gooding, WE, Furnari, FB, and Grandis, JR; Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting, *Clin Cancer Res.*, 2006, 12, 5064-5073).

[0062] Another strategy is to selectively induce the death of glioblastoma cells and other cancer cells that over-express the EGF receptor. Using a non-viral delivery vector that homes to the EGF receptor, synthetic anti-proliferative dsRNA (polyinosine-cytosine [poly IC]), a strong activator of apoptosis, was targeted selectively to cancer cells. EGFR-targeted poly IC induced rapid apoptosis in the target cells in vitro and in vivo. Tumoural delivery of the EGFR-targeted poly IC induced the complete regression of pre-established intracranial tumours in nude mice, with no obvious adverse toxic effects on normal brain tissue. A year after treatment completion the treated mice remain cancer-free and healthy (Shir, A, Ogris, M, Wagner, E, and Levitzki, A; EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumours in mice, *PLoS. Med.*, 2006 Jan; 3(1):e6. Epub 2005 Dec 6).

[0063] The application of small interfering RNAs (siRNAs) has become an effective and highly specific tool to modulate gene expression, and a wide range of oncogenes have been silenced successfully. siRNA-mediated down-regulation of EGFR was shown in two established glioma cell lines with different EGFR expression levels (U373 MG, LN18). The expression of EGFR mRNA and protein was down-regulated by 70-90%. However, siRNA treatment had no inhibitory effect on cell proliferation, migration and activation status of EGFR-coupled signalling cascades. In accordance with these results, gene expression analysis with microarrays revealed only small, albeit specific changes in expression patterns. In conclusion, these data indicate that the specific down-regulation of EGFR might not be sufficient for a single agent therapeutic approach in malignant glioma (Vollmann, A, Vornlocher, HP, Stempf, T, Brockhoff, G, Apfel, R, and Bogdahn, U; Effective silencing of EGFR with RNAi demonstrates non-EGFR dependent proliferation of glioma cells, *Int. J Oncol.*, 2006, 28, 1531-1542).

[0064] Several clinical studies have been conducted that show promising results. For example: h-R3 is a humanized monoclonal antibody that recognize the EGFR external domain with high affinity, inhibiting tyrosine kinase activation. To evaluate safety, immunogenicity and preliminary efficacy of h-R3 in newly diagnosed high-grade glioma patients, a Phase I/II trial was conducted (Ramos, TC, Figueredo, J, Catala, M, Gonzalez, S, Selva, JC, Cruz, TM, Toledo, C, Silva, S, Pestano, Y, Ramos, M, Leonard, I, Torres, O, Marinello, P, Perez, R, and Lage, A; Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial, *Cancer Biol Ther.*, 2006, 5, 375-379).

[0065] EKB-569 is a potent, low molecular weight, selective, and irreversible inhibitor of epidermal growth factor receptor (EGFR) that is being developed as an anticancer agent. A phase 1, dose-escalation study was conducted in Japanese patients. Based on RECIST criteria, they had stable disease but radiographic tumour regression was observed (Yoshimura, N, Kudoh, S, Kimura, T, Mitsuoka, S, Matsuura, K, Hirata, K, Matsui, K, Negoro, S, Nakagawa, K, and Fukuoka, M; EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib, *Lung Cancer*, 2006, 51, 363-368).

[0066] Gefitinib, a specific inhibitor of epidermal growth factor receptor (EGFR)-associated tyrosine kinase has dem-

onstrated efficacy in a subgroup of patients with non-small-cell lung carcinoma (NSCLC) who fail conventional chemotherapy. It is also reported to have an antitumour effect in brain metastases from NSCLC. Additionally, EGFR mutations have shown a strong association with gefitinib sensitivity for NSCLC. The efficacy of gefitinib in brain metastases from NSCLC was assessed and the association of this efficacy with EGFR mutations evaluated. Gefitinib appears to be effective in treating brain metastases in a subgroup of patients. The data suggested a possible association between the efficacy of gefitinib in the treatment of brain metastases and EGFR mutations (Shimato, S, Mitsudomi, T, Kosaka, T, Yatabe, Y, Wakabayashi, T, Mizuno, M, Nakahara, N, Hatano, H, Natsume, A, Ishii, D, and Yoshida, J; 2006, EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib, *Neuro. Oncol.*, 8, 137-144).

Chitinase 3-Like 2 (CHI3L2)

[0067] CHI3L2 was originally identified from chondrocytes. It has been frequently described as a target antigen in rheumatoid arthritis. No relevant association of CHI3L2 with cancer was identified. Chitinase 3-like proteins have been implied in stimulating proliferation of human connective tissue cells, e.g. fibroblasts, by activating extracellular signal-regulated kinase and PKB mediated signalling pathways (Recklies AD, White C, Ling H; The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39)- stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways; *Biochem J.* 2002; 365:119-126). In mice chitinase 3-like proteins have been found to be strongly upregulated in *Helicobacter*-induced gastric cancer models (Takaishi S, Wang TC; Gene expression profiling in a mouse model of *Helicobacter*-induced gastric cancer; *Cancer Sci.* 2007 (3): 284-293)

Doublecortin and CaM kinase-like 2 (DCAMKL2)

[0068] The microtubule (MT)-associated DCX protein plays an essential role in the development of the mammalian cerebral cortex. Identification of a protein kinase, doublecortin kinase-2 (DCAMKL2), with a domain (DC) highly homologous to DCX was reported. DCAMKL2 has MT binding activity associated with its DC domain and protein kinase activity mediated by a kinase domain, organized in a structure in which the two domains are functionally independent.

[0069] Overexpression of DCAMKL2 stabilizes the MT cytoskeleton against cold-induced depolymerization. Autophosphorylation of DCAMKL2 strongly reduces its affinity for MTs. DCAMKL2 and DCX mRNAs are nervous system-specific and are expressed during the period of cerebrocortical lamination. DCX is down-regulated postnatally, whereas DCAMKL2 persists in abundance into adulthood, suggesting that the DC sequence has previously unrecognized functions in the mature nervous system. In sympathetic neurons, DCAMKL2 is localized to the cell body and to the terminal segments of axons and dendrites.

[0070] DCAMKL2 may represent a phosphorylation-dependent switch for the reversible control of MT dynamics in the vicinity of neuronal growth cones. The patterns of expression, functional activities, regulation, and localization of DCAMKL2 suggest that it functions in parallel to, or in concert with, other members of the DC gene family (DC domain-encoding genes) in events important for neural development and, potentially, in those characteristic of mature nervous systems. DCAMKL2 is composed of two functional and independent domains, an MT-binding and -stabilizing domain (the DC sequence) and a kinase domain with protein phosphotransferase activity.

[0071] It was suggested that the DC sequence plays a critical role in transducing extracellular cues and their intracellular signals into changes in MT dynamics. In particular, based on an ability to interact with MTs in a fashion regulated by phosphorylation and to localize to terminal segments of axons and dendrites, regions in which MTs are dynamically unstable, DCAMKL2 should be considered a potential candidate mediator of the rapid cytoskeletal rearrangements that occur in response to neuronal signalling events (Edelman, AM, Kim, WY, Higgins, D, Goldstein, EG, Oberdoerster, M, and Sigurdson, W; Doublecortin kinase-2, a novel doublecortin-related protein kinase associated with terminal segments of axons and dendrites, *J Biol Chem.*, 2005, 280, 8531-8543).

ATP-sensitive inward rectifier potassium channel 10 (KCNJ10)

[0072] The major function of inwardly rectifying potassium channels (Kir) is in establishing the high potassium (K⁺) selectivity of the glial cell membrane and strongly negative resting membrane potential (RMP), which are characteristic physiological properties of glia. The classical property of Kir is that K⁺ flows inwards when the RMP is negative to the equilibrium potential for K⁺ (E(K)), but at more positive potentials outward currents are inhibited. A feature of CNS glia is their specific expression of the KCNJ10 subtype, which is a major K⁺ conductance in glial cell membranes and has a key role in setting the glial RMP. Hence, Kir, and in particular KCNJ10 are key regulators of glial functions, which in turn determine neuronal excitability and axonal conduction (Butt, AM and Kalsi, A; Inwardly rectifying potassium channels (Kir) in central nervous system glia: a special role for Kir4.1 in glial functions, *J Cell Mol. Med.* 2006, 10, 33-44).

[0073] Diminished potassium and glutamate buffering capabilities of astrocytes result in hyperexcitability of neurons and abnormal synaptic transmission. KCNJ10 channels are primarily responsible for significant hyperpolarization of cortical astrocytes and are likely to play a major role in potassium buffering. Significant inhibition of glutamate clearance in astrocytes with knock-down of KCNJ10 highlights the role of membrane hyperpolarization in this process (Kucheryavykh, YV, Kucheryavykh, LY, Nichols, CG, Maldonado, HM, Baksi, K, Reichenbach, A, Skatchkov, SN, and Eaton, MJ.; Downregulation of Kir4.1 inward rectifying potassium channel subunits by RNAi impairs potassium transfer and glutamate uptake by cultured cortical astrocytes, *Glia* 2006, 55 (3), 274 - 281).

[0074] KCNJ10 spatial buffering of extracellular K(+) in the central nervous system can only be performed due to the non-uniform distribution of KCNJ10 across the surface of the glial cell. A mislocalization of KCNJ10 in various human brain tumours (low- and high-grade astrocytomas and oligodendrogliomas) was observed, suggesting that buffering capacity of glial cells may be compromised, leading to water influx (cytotoxic edema) (Warth, A, Mittelbronn, M, and Wolburg, H; Redistribution of the water channel protein aquaporin-4 and the K⁺ channel protein Kir4.1 differs in low- and high-grade human brain tumours, *Acta Neuropathol. (Berl)*, 2005, 109, 418-426). KCNJ10 was also upregulated in astrocytes in damaged brain. The following hypothesis was proposed: in astrocytes, under normal conditions, AQP4 couples water transport with KCNJ10 mediated K⁺ siphoning, but in pathological states, AQP4 facilitates the flow of brain oedema fluid, and KCNJ10 buffers increased extracellular K⁺ (Saadoun, S, Papadopoulos, MC, and Krishna, S; Water transport becomes uncoupled from K⁺ siphoning in brain contusion, bacterial meningitis, and brain tumours: immunohistochemical case review, *J Clin Pathol.*, 2003, 56, 972-975).

[0075] It is furthermore known for MHC-class II presented peptides that these peptides are composed of a "core sequence" having a certain HLA-specific amino acid motif and, optionally, N-and/or C-terminal extensions which do not interfere with the function of the core sequence (i.e. are deemed as irrelevant for the interaction of the peptide and all or a subset of T-cell clones recognising the natural counterpart). The N- and/or C-terminal extensions can, for example, be between 1 to 10 amino acids in length, respectively. These peptides can be used either directly to load MHC class II molecules or the sequence can be cloned into the vectors according to the description herein below. As these peptides constitute the final product of the processing of larger peptides within the cell, longer peptides can be used as well.

[0076] Correspondingly, naturally occurring or artificial variants that induce T-cells cross-reacting with a peptide as described are often length variants. Examples for such naturally occurring length variants are given in Table 1 for SEQ ID NOs 11 and 12, and 21 and 24, respectively.

[0077] If a peptide is longer than around 12 amino acid residues is used directly to bind to a MHC class II molecule, it is preferred that the residues that flank the core HLA binding region do not substantially affect the ability of the peptide to bind specifically to the binding groove of the MHC class II molecule or to present the peptide to the CTL. However, as already indicated above, it will be appreciated that larger peptides may be used, e.g. when encoded by a polynucleotide, since these larger peptides may be fragmented by suitable antigen-presenting cells.

[0078] It is also possible, that MHC class I epitopes, although usually between 8-10 amino acids long, are generated by peptide processing from longer peptides or proteins that include the actual epitope. Similar to MHC class II epitopes, it is preferred that the residues that flank the binding region do not substantially affect the ability of the peptide to bind specifically to the binding groove of the MHC class I molecule or to present the peptide to the CTL nor mask the sites for proteolytic cleavage necessary to expose the actual epitope during processing.

[0079] Of course, the peptide according to the present invention will have the ability to bind to a molecule of the human major histocompatibility complex (MHC) class I. Binding of a peptide to a MHC complex may be tested by methods known in the art, for example those described in example 4 of the present invention or those described in the literature for different MHC class II alleles (e.g. Vogt AB, Kropshofer H, Kalbacher H, Kalbus M, Rammensee HG, Coligan JE, Martin R; Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides; *J Immunol.* 1994; 153(4):1665-1673; Malcherek G, Gnau V, Stevanovic S, Rammensee HG, Jung G, Melms A; Analysis of allele-specific contact sites of natural HLA-DR17 ligands; *J Immunol.* 1994; 153(3):1141-1149; Manici S, Sturniolo T, Imro MA, Hammer J, Sinigaglia F, Noppen C, Spagnoli G, Mazzi B, Bellone M, Dellabona P, Protti MP; Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11; *J Exp Med.* 1999; 189(5): 871-876; Hammer J, Gallazzi F, Bono E, Karr RW, Guenot J, Valsasnini P, Nagy ZA, Sinigaglia F; Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association; *J Exp Med.* 1995 181(5):1847-1855; Tompkins SM, Rota PA, Moore JC, Jensen PE; A europium fluoroimmunoassay for measuring binding of antigen to class II MHC glycoproteins; *J Immunol Methods.* 1993; 163(2): 209-216; Boyton RJ, Lohmann T, Londei M, Kalbacher H, Halder T, Frater AJ, Douek DC, Leslie DG, Flavell RA, Altmann DM; Glutamic acid decarboxylase T lymphocyte responses associated with susceptibility or resistance to type I diabetes: analysis in disease discordant human twins, non-obese diabetic mice and HLA-DQ transgenic mice; *Int Immunol.* 1998 (12):1765-1776).

[0080] Nevertheless, these stretches can be important to provide an efficient introduction of the peptide as disclosed into the cells. In one embodiment of the present invention, the peptide of the present invention is part of a fusion protein, comprising N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii) (p33, in the following "Ii") as derived from the NCBI, GenBank Accession-number X00497 (Strubin, M., Mach, B. and Long, E.O. The complete

sequence of the mRNA for the HLA-DR-associated invariant chain reveals a polypeptide with an unusual transmembrane polarity EMBO J. 1984, 3 (4), 869-872).

[0081] A non-peptide bond is, for example, $-\text{CH}_2\text{-NH}$, $-\text{CH}_2\text{S-}$, $-\text{CH}_2\text{CH}_2\text{-}$, $-\text{CH=CH-}$, $-\text{COCH}_2\text{-}$, $-\text{CH(OH)CH}_2\text{-}$, and $-\text{CH}_2\text{SO-}$. United States Patent 4,897,445 provides a method for the solid phase synthesis of non-peptide bonds ($-\text{CH}_2\text{-NH}$) in polypeptide chains that involves polypeptides synthesised by standard procedures and the non-peptide bond synthesised by reacting an amino aldehyde and an amino acid in the presence of NaCNBH_3 .

[0082] Peptides comprising the sequences described above may be synthesized with additional chemical groups present at their amino and/or carboxy termini, to enhance for example, the stability, bioavailability, and/or affinity of the peptides. For example, hydrophobic groups such as carbobenzoxy, dansyl, or t-butyloxycarbonyl groups may be added to the peptides' amino termini. Likewise, an acetyl group or a 9-fluorenylmethoxy-carbonyl group may be placed at the peptides' amino termini. Additionally, the hydrophobic group, t-butyloxycarbonyl, or an amido group may be added to the peptides' carboxyl termini.

[0083] Further, the peptides as described may be synthesized to alter their steric configuration. For example, the D-isomer of one or more of the amino acid residues of the peptide may be used, rather than the usual L-isomer. Still further, at least one of the amino acid residues of the peptides as described may be substituted by one of the well known non-naturally occurring amino acid residues. Alterations such as these may serve to increase the stability, bioavailability and/or binding action of the peptides as described.

[0084] Similarly, a peptide as described may be modified chemically by reacting specific amino acids either before or after synthesis of the peptide. Examples for such modifications are well known in the art and are summarised e.g. in R. Lundblad, Chemical Reagents for Protein Modification, 3rd ed. CRC Press, 2005. Chemical modification of amino acids includes but is not limited to, modification by acylation, amidination, pyridoxylation of lysine, reductive alkylation, trinitrobenzylation of amino groups with 2,4,6-trinitrobenzene sulphonic acid (TNBS), amide modification of carboxyl groups and sulphhydryl modification by performic acid oxidation of cysteine to cysteic acid, formation of mercurial derivatives, formation of mixed disulphides with other thiol compounds, reaction with maleimide, carboxymethylation with iodoacetic acid or iodoacetamide and carbamoylation with cyanate at alkaline pH, although without limitation thereto. In this regard, the skilled person is referred to Chapter 15 of Current Protocols In Protein Science, Eds. Coligan et al. (John Wiley & Sons NY 1995-2000) for more extensive methodology relating to chemical modification of proteins.

[0085] Briefly, modification of e.g. arginyl residues in proteins is often based on the reaction of vicinal dicarbonyl compounds such as phenylglyoxal, 2,3-butanedione, and 1,2-cyclohexanedione to form an adduct. Another example is the reaction of methylglyoxal with arginine residues. Cysteine can be modified without concomitant modification of other nucleophilic sites such as lysine and histidine. As a result, a large number of reagents are available for the modification of cysteine. The websites of Pierce Chemical Company and Sigma-Aldrich and others provide information on specific reagents.

[0086] Selective reduction of disulfide bonds in proteins is also common. Disulfide bonds can be formed and oxidized during the heat treatment of biopharmaceuticals. Woodward's Reagent K may be used to modify specific glutamic acid residues. N-(3-(dimethylamino)propyl)-N'-ethylcarbodiimide can be used to form intra-molecular crosslinks between a lysine residue and a glutamic acid residue. Diethylpyrocarbonate, for example, is a reagent for the modification of histidyl residues in proteins. Histidine can also be modified using 4-hydroxy-2-nonenal. The reaction of lysine residues and other α -amino groups is, for example, useful in binding of peptides to surfaces or the cross-linking of proteins/peptides. Lysine is the site of attachment of poly(ethylene)glycol and the major site of modification in the glycation of proteins. Methionine residues in proteins can be modified with e.g. iodoacetamide, bromoethylamine, chloramine T. Tetranitromethane and N-acetylimidazole can be used for the modification of tyrosyl residues. Cross-linking via the formation of dityrosine can be accomplished with hydrogen peroxide/copper ions.

[0087] Recent studies on the modification of tryptophan have used N-bromosuccinimide, 2-hydroxy-5-nitrobenzyl bromide or 3-bromo-3-methyl-2-(2-nitrophenylmercapto)-3H-indole (BPNS-skatole).

[0088] Successful modification of therapeutic proteins and peptides with PEG is often associated with an extension of circulatory half-life while cross-linking of proteins with glutaraldehyde, polyethyleneglycol diacrylate and formaldehyde is used for the preparation of hydrogels. Chemical modification of allergens for immunotherapy is often achieved by carbamylation with potassium cyanate.

[0089] Generally, peptides (at least those containing peptide linkages between amino acid residues) may be synthesised by the Fmoc-polyamide mode of solid-phase peptide synthesis as disclosed by Lu et al J. Org. Chem. 1981, 46, 3433 and references therein. Temporary N-amino group protection is afforded by the 9-fluorenylmethyloxycarbonyl (Fmoc) group. Repetitive cleavage of this highly base-labile protecting group is done using 20% piperidine in N, N-dimethylformamide. Side-chain functionalities may be protected as their butyl ethers (in the case of serine threonine and tyrosine), butyl esters (in the case of glutamic acid and aspartic acid), butyloxycarbonyl derivative (in the case of lysine and histidine), trityl derivative (in the case of cysteine) and 4-methoxy-2,3,6-trimethylbenzenesulphonyl derivative (in the case of arginine). Where glutamine or asparagine are C-terminal residues, use is made of the 4,4'-dimethoxybenzhydryl group for protection of the side chain amido functionalities. The solid-phase support is based on a polydimethyl-

acrylamide polymer constituted from the three monomers dimethylacrylamide (backbone-monomer), bisacryloylethylene diamine (cross linker) and acryloylsarcosine methyl ester (functionalising agent). The peptide-to-resin cleavable linked agent used is the acid-labile 4-hydroxymethyl-phenoxyacetic acid derivative. All amino acid derivatives are added as their preformed symmetrical anhydride derivatives with the exception of asparagine and glutamine, which are added using a reversed N, N-dicyclohexylcarbodiimide/lhydroxybenzotriazole mediated coupling procedure. All coupling and deprotection reactions are monitored using ninhydrin, trinitrobenzene sulphonic acid or isotin test procedures. Upon completion of synthesis, peptides are cleaved from the resin support with concomitant removal of side-chain protecting groups by treatment with 95% trifluoroacetic acid containing a 50 % scavenger mix. Scavengers commonly used are ethanedithiol, phenol, anisole and water, the exact choice depending on the constituent amino acids of the peptide being synthesized. In addition a combination of solid phase and solution phase methodologies for the synthesis of peptides is possible (see, for example, Bruckdorfer T, Marder O, Albericio F. From production of peptides in milligram amounts for research to multi-ton quantities for drugs of the future *Curr Pharm Biotechnol.* 2004 Feb; 5(1):29-43 and the references as cited therein).

[0090] Trifluoroacetic acid is removed by evaporation in vacuo, with subsequent trituration with diethyl ether affording the crude peptide. Any scavengers present are removed by a simple extraction procedure which on lyophilization of the aqueous phase affords the crude peptide free of scavengers. Reagents for peptide synthesis are generally available from e.g. Calbiochem-Novabiochem (UK) Ltd, Nottingham NG7 2QJ, UK.

[0091] Purification may be effected by any one, or a combination of, techniques such as recrystallization, size exclusion chromatography, ion-exchange chromatography, hydrophobic interaction chromatography and (usually) reverse-phase high performance liquid chromatography using e.g. acetonitril/water gradient separation.

[0092] Analysis of peptides may be carried out using thin layer chromatography, electrophoresis, in particular capillary electrophoresis, solid phase extraction (CSPE), reverse-phase high performance liquid chromatography, amino-acid analysis after acid hydrolysis and by fast atom bombardment (FAB) mass spectrometric analysis, as well as MALDI and ESI-Q-TOF mass spectrometric analysis.

[0093] A further aspect of the invention provides a nucleic acid (e.g. polynucleotide) encoding a peptide of the invention. The polynucleotide may be e.g. DNA, cDNA, RNA, mRNA, and siRNA or combinations thereof, either single- and/or double-stranded. Of course, only peptides containing naturally occurring amino acid residues joined by naturally occurring peptide bonds are encodable by a polynucleotide. A still further aspect of the invention provides an expression vector expressing a peptide according to the invention.

[0094] A variety of methods have been developed to operably link polynucleotides, especially DNA, to vectors for example via complementary cohesive termini. For instance, complementary homopolymer tracts can be added to the DNA segment to be inserted to the vector DNA. The vector and DNA segment are then joined by hydrogen bonding between the complementary homopolymeric tails to form recombinant DNA molecules.

[0095] Synthetic linkers containing one or more restriction sites provide an alternative method of joining the DNA segment to vectors. Synthetic linkers containing a variety of restriction endonuclease sites are commercially available from a number of sources including International Biotechnologies Inc, New Haven, CN, USA.

[0096] A desirable method of modifying the DNA encoding the polypeptide of the invention utilizes the polymerase chain reaction as disclosed by Saiki et al (1988) *Science* 239, 487-491. This method may be used for introducing the DNA into a suitable vector, for example by engineering in suitable restriction sites, or it may be used to modify the DNA in other useful ways as is known in the art.

[0097] If viral vectors are used, pox- or adenovirus vectors are preferred.

[0098] The DNA (or in the case of retroviral vectors, RNA) may then be expressed in a suitable host to produce a polypeptide comprising the peptide of the invention. Thus, the DNA encoding the peptide of the invention may be used in accordance with known techniques, appropriately modified in view of the teachings contained herein, to construct an expression vector, which is then used to transform an appropriate host cell for the expression and production of the polypeptide of the invention. Such techniques include those disclosed in US Patent Nos. 4,440,859 issued 3 April 1984 to Rutter et al, 4,530,901 issued 23 July 1985 to Weissman, 4,582,800 issued 15 April 1986 to Crowl, 4,677,063 issued 30 June 1987 to Mark et al, 4,678,751 issued 7 July 1987 to Goeddel, 4,704,362 issued 3 November 1987 to Itakura et al, 4,710,463 issued 1 December 1987 to Murray, 4,757,006 issued 12 July 1988 to Toole, Jr. et al, 4,766,075 issued 23 August 1988 to Goeddel et al and 4,810,648 issued 7 March 1989 to Stalker.

[0099] The DNA (or in the case of retroviral vectors, RNA) encoding the polypeptide constituting the compound of the invention may be joined to a wide variety of other DNA sequences for introduction into an appropriate host. The companion DNA will depend upon the nature of the host, the manner of the introduction of the DNA into the host, and whether episomal maintenance or integration is desired.

[0100] Generally, the DNA is inserted into an expression vector, such as a plasmid, in proper orientation and correct reading frame for expression. If necessary, the DNA may be linked to the appropriate transcriptional and translational regulatory control nucleotide sequences recognised by the desired host, although such controls are generally available in the expression vector. The vector is then introduced into the host through standard techniques. Generally, not all of

the hosts will be transformed by the vector. Therefore, it will be necessary to select for transformed host cells. One selection technique involves incorporating into the expression vector a DNA sequence, with any necessary control elements, that codes for a selectable trait in the transformed cell, such as antibiotic resistance.

[0101] Alternatively, the gene for such selectable trait can be on another vector, which is used to cotransform the desired host cell.

[0102] Host cells that have been transformed by the recombinant DNA of the invention are then cultured for a sufficient time and under appropriate conditions known to those skilled in the art in view of the teachings disclosed herein to permit the expression of the polypeptide, which can then be recovered.

[0103] Many expression systems are known, including bacteria (for example *E. coli* and *Bacillus subtilis*), yeasts (for example *Saccharomyces cerevisiae*), filamentous fungi (for example *Aspergillus*), plant cells, animal cells and insect cells. Preferably, the system can be mammalian cells such as colorectal cancer- or glioblastoma cells such as those available from the ATCC Cell Biology Collection.

[0104] A typical mammalian cell vector plasmid is pSVL available from Pharmacia, Piscataway, NJ, USA. An example of an inducible mammalian expression vector is pMSG, also available from Pharmacia. Useful yeast plasmid vectors are pRS403-406 and pRS413-416 and are generally available from Stratagene Cloning Systems, La Jolla, CA 92037, USA. Plasmids pRS403, pRS404, pRS405 and pRS406 are Yeast Integrating plasmids (YIps) and incorporate the yeast selectable markers HIS3, TRP1, LEU2 and URA3. Plasmids pRS413-416 are Yeast Centromere plasmids (Ycps). Other vectors and expression systems are well known in the art for use with a variety of host cells.

[0105] The present invention also relates to a host cell transformed with a polynucleotide vector construct of the present invention wherein said host cell is an antigen presenting cell.

[0106] Transformation of appropriate cell hosts with a DNA construct of the present invention is accomplished by well known methods that typically depend on the type of vector used. With regard to transformation of prokaryotic host cells, see, for example, Cohen et al, Proc. Natl. Acad. Sci. USA 1972, 69, 2110 and Sambrook et al (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. Transformation of yeast cells is described in Sherman et al (1986) Methods In Yeast Genetics, A Laboratory Manual, Cold Spring Harbor, NY. The method of Beggs, Nature 1978, 275,104-109 is also useful. With regard to vertebrate cells, reagents useful in transfecting such cells, for example calcium phosphate and DEAE-dextran or liposome formulations, are available from Stratagene Cloning Systems, or Life Technologies Inc., Gaithersburg, MD 20877, USA. Electroporation is also useful for transforming and/or transfecting cells and is well known in the art for transforming yeast cell, bacterial cells, insect cells and vertebrate cells.

[0107] Successfully transformed cells, i.e. cells that contain a DNA construct of the present invention, can be identified by well known techniques such as PCR. Alternatively, the presence of the protein in the supernatant can be detected using antibodies.

[0108] Antigen-presenting cells, such as dendritic cells, may be used to express the peptides of the invention so that they may be loaded into appropriate MHC molecules.

[0109] The host cell is an antigen presenting cell, in particular a dendritic cell or antigen presenting cell. APCs loaded with a recombinant fusion protein containing prostatic acid phosphatase (PAP) are currently under investigation for the treatment of prostate cancer (Sipuleucel-T) (Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM.; Placebo-controlled phase 3 trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer; J Clin Oncol. 2006; 24(19):3089-3094;

Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ; Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (Provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy; Cancer. 2006; 107(1):67-74)

[0110] A further aspect of the invention provides a method of producing a peptide. The method comprises culturing the host cell and isolating the peptide from the host cell or its culture medium.

[0111] In another embodiment the peptide, the nucleic acid or the expression vector of the invention are used in medicine. For example, the peptide may be prepared for intravenous (i.v.) injection, sub-cutaneous (s.c.) injection, intradermal (i.d.) injection, intraperitoneal (i.p.) injection, intramuscular (i.m.) injection. Preferred routes of peptide injection are s.c., i.d., i.p., i.m., and i.v. Preferred routes of DNA injection are i.d., i.m., s.c., i.p. and i.v. Doses of e.g. between 50 µg and 1.5 mg, preferably 125 µg to 500 µg, of peptide or DNA may be given and will depend from the respective peptide or DNA. Doses of this range were successfully used in previous trials (Brunsvig PF, Aamdal S, Gjertsen MK, Kvalheim G, Markowski-Grimsrud CJ, Sve I, Dyrhaug M, Trachsel S, Moller M, Eriksen JA, Gaudernack G; Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer; Cancer Immunol Immunother. 2006; 55(12): 1553-1564; M. Staehler, A. Stenzl, P. Y. Dietrich, T. Eisen, A. Haferkamp, J. Beck, A. Mayer, S. Walter, H. Singh, J. Frisch, C. G. Stief; An open label study to evaluate the safety and immunogenicity of the peptide based cancer vaccine IMA901, ASCO meeting 2007; Abstract No 3017).

[0112] An important aspect of the present invention is an in vitro method for producing activated CTL. The method comprising contacting in vitro CTL with antigen loaded human class I MHC molecules expressed on the surface of a

suitable antigen-presenting cell for a period of time sufficient to activate the CTL in an antigen specific manner. The antigen is a peptide according to the invention. Preferably a sufficient amount of the antigen is used with an antigen-presenting cell.

[0113] In case of a MHC class II epitope used as an antigen, the CTL are CD4-positive helper cells, preferably of T_{H1}-type. The MHC class II molecules may be expressed on the surface of any suitable cell and preferred the cell does not naturally express MHC class II molecules (in which case the cell is transfected to express such a molecule). Alternatively, if the cell naturally expresses MHC class II molecules, the cell is defective in the antigen-processing or antigen-presenting pathways. In this way, it is possible for the cell expressing the MHC class II molecule to be primed substantially completely with a chosen peptide antigen before activating the CTL.

[0114] The antigen-presenting cell (or stimulator cell) typically has MHC class II molecules on its surface and preferably is itself substantially incapable of loading said MHC class II molecule with the selected antigen. The MHC class II molecule may readily be loaded with the selected antigen in vitro.

[0115] Preferably the mammalian cell lacks or has a reduced level or has reduced function of the TAP peptide transporter. Suitable cells which lack the TAP peptide transporter include T2, RMA-S and Drosophila cells. TAP is the Transporter associated with Antigen Processing.

[0116] The human peptide loading deficient cell line T2 is available from the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852, USA under Catalogue No CRL 1992; the Drosophila cell line Schneider line 2 is available from the ATCC under Catalogue No CRL 19863; the mouse RMA-S cell line is described in Karre and Ljunggren (1985) J. Exp. Med. 162, 1745.

[0117] It is preferable that the host cell does not express MHC class I molecules before transfection. Preferably the stimulator cell expresses a molecule important for T-cell costimulation such as any of B7.1, B7.2, ICAM-1 and LFA 3.

[0118] The nucleic acid sequences of numerous MHC class II molecules, and of the costimulator molecules, are publicly available from the GenBank and EMBL databases.

[0119] Similarly, in the case of a MHC class I epitope used as an antigen, the CTL are CD8-positive helper cells. The MHC class I molecules may be expressed on the surface of any suitable cell and it is preferred that cell does not naturally express MHC class I molecules (in which case the cell is transfected to express such a molecule). Alternative, if the cell naturally expresses MHC class I molecules, is defective in the antigen-processing or antigen-presenting pathways.

[0120] In this way, it is possible for the cell expressing the MHC class I molecule to be primed substantially completely with a chosen peptide antigen before activating the CTL.

[0121] If an antigen-presenting cell is transfected to express such an epitope preferably the cell comprises an expression vector capable of expressing a peptide containing the sequence ALFVRLALA according to SEQ ID No. 8.

[0122] A number of other methods may be used for generating CTL in vitro. For example, the methods described in Peoples et al, Proc. Natl. Acad. Sci. USA 1995, 92, 432-436 and Kawakami et al (1992) J. Immunol. 148, 638-643 use autologous tumour-infiltrating lymphocytes in the generation of CTL. Plebanski et al (1995) Eur. J. Immunol. 25, 1783-1787 makes use of autologous peripheral blood lymphocytes (PLBs) in the preparation of CTL. Jochmus et al (1997) J. Gen. Virol. 78, 1689-1695 describes the production of autologous CTL by employing pulsing dendritic cells with peptide or polypeptide, or via infection with recombinant virus. Hill et al (1995) J. Exp. Med. 181, 2221-2228 and Jerome et al (1993) J. Immunol. 151, 1654-1662 make use of B cells in the production of autologous CTL. In addition, macrophages pulsed with peptide or polypeptide, or infected with recombinant virus, may be used in the preparation of autologous CTL. S. Walter et al. (Walter S, Herrgen L, Schoor O, Jung G, Wernet D, Buhning HJ, Rammensee HG, Stevanovic S. Cutting edge: predetermined avidity of human CD8 T-cells expanded on calibrated MHC/anti-CD28-coated microspheres. J Immunol. 2003 Nov 15; 171 (10):4974-8) describe the in vitro priming of T-cells by using artificial antigen presenting cells, which is also a suitable method for generating T-cells against the peptide of choice.

[0123] Allogeneic cells may also be used in the preparation of CTL and an exemplary method is described in detail in WO 97/26328. For example, in addition to Drosophila cells and T2 cells, other cells may be used to present antigens such as CHO cells, baculovirus-infected insect cells, bacteria, yeast, vaccinia-infected target cells. In addition plant viruses may be used (see, for example, Porta et al, Virology, 1994, 202, 449-955 which describes the development of cowpea mosaic virus as a high-yielding system for the presentation of foreign peptides.

[0124] The activated CTL that are directed against the peptides of the invention are useful in therapy. Thus, a further aspect of the invention provides activated CTL obtainable by the foregoing methods of the invention.

[0125] Activated CTLs, produced by the above method will selectively recognise a cell that aberrantly expresses a polypeptide comprising an amino acid sequence of SEQ ID NO 8.

[0126] Preferably, the CTL recognises the cell by interacting through its TCR with the HLA/peptide-complex (for example, binding). CTLs are useful in a method of killing target cells in a patient wherein the target cells aberrantly express a polypeptide comprising an amino acid sequence of the invention. The patient is administered an effective number of the activated CTLs. The CTLs administered to the patient may be derived from the patient and activated as described above (i.e. they are autologous CTLs). Alternatively, the CTLs are not from the patient but are from another individual. Of course, preferably the donor is a healthy individual. By "healthy individual" it is meant that the individual is generally

in good health, preferably has a competent immune system and, more preferably, is not suffering from any disease that can be readily tested for, and detected.

[0127] The target cells *in vivo* for the CD4-positive CTL according to the present invention can be cells of the tumour (which sometimes express MHC class II) and/or stromal cells surrounding the tumour (tumour cells) (which sometimes also express MHC class II; (Dengjel, J, Nastke, MD, Gouttefangeas, C, Gitsioudis, G, Schoor, O, Altenberend, F, Muller, M, Kramer, B, Missiou, A, Sauter, M, Hennenlotter, J, Wernet, D, Stenzl, A, Rammensee, HG, Klingel, K, and Stevanovic, S; Unexpected Abundance of HLA Class II Presented Peptides in Primary Renal Cell Carcinomas, Clin Cancer Res., 2006, 12, 4163-4170)).

[0128] The CTLs of the invention may be used as active ingredients in a therapeutic composition. Thus the invention also discloses a method of killing target cells in a patient where the target cells aberrantly express a polypeptide comprising an amino acid sequence of the invention. The method comprises administering to the patient an effective number of CTLs as defined above.

[0129] By "aberrantly expressed" we include the meaning that the polypeptide is over-expressed compared to normal levels of expression or that the gene is silent in the tissue from which the tumour is derived but in the tumour it is expressed. By "over-expressed" we mean that the polypeptide is present at a level at least 1.2 x that present in normal tissue; preferably at least 2 x and more preferably at least 5 x or 10 x the level present in normal tissue.

[0130] CTL may be obtained by methods known in the art, e.g. those described above.

[0131] Protocols for this so-called adoptive transfer of CTL are well known in the art and can be found, e.g. in (Rosenberg, SA, Lotze, MT, Muul, LM, Chang, AE, Avis, FP, Leitman, S, Linehan, WM, Robertson, CN, Lee, RE, Rubin, JT, et al., A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone, N. Engl. J. Med., 1987, 316, 889-897; Rosenberg, SA, Packard, BS, Aebersold, PM, Solomon, D, Topalian, SL, Toy, ST, Simon, P, Lotze, MT, Yang, JC, Seipp, CA, et al.; Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report, N.Engl.J Med, 1988, 319, 1676-1680; Dudley, ME, Wunderlich, JR, Robbins, PF, Yang, JC, Hwu, P, Schwartzentruber, DJ, Topalian, SL, Sherry, R, Restifo, NP, Hubicki, AM, Robinson, MR, Raffeld, M, Duray, P, Seipp, CA, Rogers-Freezer, L, Morton, KE, Mavroukakis, SA, White, DE, and Rosenberg, SA; Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes, Science, 2002, 298, 850-854; Yee, C, Thompson, JA, Byrd, D, Riddell, SR, Roche, P, Celis, E, and Greenberg, PD; Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: *in vivo* persistence, migration, and antitumor effect of transferred T cells, Proc. Natl. Acad. Sci. U.S.A, 2002, 99, 16168-16173; Dudley, ME, Wunderlich, JR, Yang, JC, Sherry, RM, Topalian, SL, Restifo, NP, Royal, RE, Kammula, U, White, DE, Mavroukakis, SA, Rogers, LJ, Gracia, GJ, Jones, SA, Mangiameli, DP, Pelletier, MM, Gea-Banacloche, J, Robinson, MR, Berman, DM, Filie, AC, Abati, A, and Rosenberg, SA; Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma, J. Clin. Oncol., 2005, 23, 2346-2357; reviewed in (Gattinoni, L, Powell, DJ, Jr., Rosenberg, SA, and Restifo, NP; Adoptive immunotherapy for cancer: building on success, Nat. Rev. Immunol., 2006, 6, 383-393) and (Morgan, RA, Dudley, ME, Wunderlich, JR, Hughes, MS, Yang, JC, Sherry, RM, Royal, RE, Topalian, SL, Kammula, US, Restifo, NP, Zheng, Z, Nahvi, A, de Vries, CR, Rogers-Freezer, LJ, Mavroukakis, SA, and Rosenberg, SA; Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes, Science, 2006, 314 (5796): 126-129).

[0132] Any molecule of the invention, i.e. the peptide, nucleic acid, expression vector, cell, activated CTL is useful for the treatment of disorders, characterised by cells escaping an immune response. Therefore any molecule of the present invention may be used as medicament or in the manufacture of a medicament. The molecule may be used by itself or combined with other molecule(s) of the invention or (a) known molecule(s).

[0133] Preferably the medicament is a vaccine. It may be administered directly into the patient, into the affected organ or systemically, or applied *ex vivo* to cells derived from the patient or a human cell line which are subsequently administered to the patient, or used *in vitro*, to select a subpopulation from immune cells derived from the patient, which are then re-administered to the patient. If the nucleic acid is administered to cells *in vitro*, it may be useful for the cells to be transfected so as to co-express immune-stimulating cytokines, such as interleukin-2. The peptide may be substantially pure, or combined with an immune-stimulating adjuvant (see below) or used in combination with immune-stimulatory cytokines, or be administered with a suitable delivery system, for example liposomes. The peptide may also be conjugated to a suitable carrier such as keyhole limpet haemocyanin (KLH) or mannan (see WO 95/18145 and Longenecker et al (1993) Ann. NY Acad. Sci. 690,276-291). The peptide may also be tagged, or be a fusion protein, or be a hybrid molecule. The peptides of the present invention are expected to stimulate CD4 or CD8 CTLs. However, stimulation is more efficient in the presence of help provided by T-cells positive for the opposite CD. Thus, for MHC Class II epitopes that stimulate CD4 CTLs the fusion partner or sections of a hybrid molecule suitably provide epitopes that stimulate CD8-positive T-cells. On the other hand, for MHC Class I epitopes that stimulate CD8 CTLs the fusion partner or sections of a hybrid molecule suitably provide epitopes that stimulate CD4-positive T-cells. CD4- and CD8-stimulating epitopes are well known in the art and include those identified in the present invention.

[0134] In one aspect of the invention, the vaccine comprises at least one peptide, preferably two to 50, more preferably two to 25, even more preferably two to 15 and most preferably two, three, four, five, six, seven, eight, nine, ten, eleven, twelve or thirteen peptides as disclosed or additional peptides. The peptide(s) may be derived from one or more specific TAAs and may bind to MHC class I and/or class II molecules.

[0135] Preferably, when the peptide of the invention is used in a vaccine or medicament of the invention, it is present as a salt, such as for example, but not limited to an acetate salt or a chloride salt. Example 7 provides studies of a vaccine IMA-910, which contains some of the peptides as disclosed and describes the preparation of the vaccine using peptides in their salt form and their particle size.

[0136] The polynucleotide may be substantially pure, or contained in a suitable vector or delivery system. The nucleic acid may be DNA, cDNA, RNA or a combination thereof. Methods for designing and introducing such a nucleic acid are well known in the art. An overview is provided by e.g. S. Pascolo: Vaccination with messenger RNA Methods Mol Med 2006, 127; 23-40; R. Stan, JD Wolchok and AD Cohen DNA vaccines against cancer Hematol Oncol Clin North Am 2006, 3; 613-636 or A Mahdavi and BJ Monk Recent advances in human papillomavirus vaccines Curr Oncol Rep 2006, 6, 465-472. Polynucleotide vaccines are easy to prepare, but the mode of action of these vectors in inducing an immune response is not fully understood. Suitable vectors and delivery systems include viral DNA and/or RNA, such as systems based on adenovirus, vaccinia virus, retroviruses, herpes virus, adeno-associated virus or hybrids containing elements of more than one virus. Non-viral delivery systems include cationic lipids and cationic polymers and are well known in the art of DNA delivery. Physical delivery, such as via a "gene-gun", may also be used. The peptide or peptide encoded by the nucleic acid may be a fusion protein, for example with an epitope that stimulates T-cells for the respective opposite CDR as noted above.

[0137] The medicament of the invention may also include one or more adjuvants. Adjuvants are substances that non-specifically enhance or potentiate the immune response (e.g., immune responses mediated by CTLs and helper-T (T_H) cells to an antigen, and would thus be considered useful in the medicament of the present invention. Suitable adjuvants include, but are not limited to 1018 ISS, aluminium salts, Amplivax, AS 15, BCG, CP-870,893, CpG7909, CyaA, dSLIM, GM-CSF, IC30, IC31, Imiquimod, ImuFact IMP321, IS Patch, ISS, ISCOMATRIX, JuvImmune, LipoVac, MF59, monophosphoryl lipid A, Montanide IMS 1312, Montanide ISA 206, Montanide ISA 50V, Montanide ISA-51, OK-432, OM-174, OM-197-MP-EC, ONTAK, PepTel® vector system, PLG microparticles, resiquimod, SRL172, Virosomes and other Virus-like particles, YF-17D, VEGF trap, R848, beta-glucan, Pam3Cys, Aquila's QS21 stimulon, which is derived from saponin, mycobacterial extracts and synthetic bacterial cell wall mimics, and other proprietary adjuvants such as Ribi's Detox, Quil, or Superfos. Adjuvants such as Freund's or GM-CSF are preferred. Several immunological adjuvants (e.g., MF59) specific for dendritic cells and their preparation have been described previously (Dupuis M, Murphy TJ, Higgins D, Ugozzoli M, van Nest G, Ott G, McDonald DM; Dendritic cells internalize vaccine adjuvant after intramuscular injection; Cell Immunol. 1998; 186(1):18-27; Allison AC; The mode of action of immunological adjuvants; Dev Biol Stand. 1998; 92:3-11). Also cytokines may be used. Several cytokines have been directly linked to influencing dendritic cell migration to lymphoid tissues (e.g., TNF- α), accelerating the maturation of dendritic cells into efficient antigen-presenting cells for T-lymphocytes (e.g., GM-CSF, IL-1 and IL-4) (U.S. Pat. No. 5,849,589) and acting as immunoadjuvants (e.g., IL-12) (Gabrilovich DI, Cunningham HT, Carbone DP; IL-12 and mutant P53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer; J Immunother Emphasis Tumor Immunol. 1996 (6):414-418).

[0138] CpG immunostimulatory oligonucleotides have also been reported to enhance the effects of adjuvants in a vaccine setting. Without being bound by theory, CpG oligonucleotides act by activating the innate (non-adaptive) immune system via Toll-like receptors (TLR), mainly TLR9. CpG triggered TLR9 activation enhances antigen-specific humoral and cellular responses to a wide variety of antigens, including peptide or protein antigens, live or killed viruses, dendritic cell vaccines, autologous cellular vaccines and polysaccharide conjugates in both prophylactic and therapeutic vaccines. More importantly it enhances dendritic cell maturation and differentiation, resulting in enhanced activation of T_{H1} cells and strong cytotoxic T-lymphocyte (CTL) generation, even in the absence of CD4 T-cell help. The T_{H1} bias induced by TLR9 stimulation is maintained even in the presence of vaccine adjuvants such as alum or incomplete Freund's adjuvant (IFA) that normally promote a T_{H2} bias. CpG oligonucleotides show even greater adjuvant activity when formulated or co-administered with other adjuvants or in formulations such as microparticles, nano particles, lipid emulsions or similar formulations, which are especially necessary for inducing a strong response when the antigen is relatively weak. They also accelerate the immune response and enabled the antigen doses to be reduced by approximately two orders of magnitude, with comparable antibody responses to the full-dose vaccine without CpG in some experiments (Arthur M. Krieg, Therapeutic potential of Toll-like receptor 9 activation, Nature Reviews, Drug Discovery, 5, JUNE 2006, 471-484). U. S. Pat. No. 6,406,705 B1 describes the combined use of CpG oligonucleotides, non-nucleic acid adjuvants and an antigen to induce an antigen-specific immune response. A commercially available CpG TLR9 antagonist is dSLIM (double Stem Loop Immunomodulator) by Mologen (Berlin, Germany) which is a preferred component of the pharmaceutical composition of the present invention. Other TLR binding molecules such as RNA binding TLR 7, TLR 8 and/or TLR 9 may also be used.

[0139] Other examples for useful adjuvants include, but are not limited to chemically modified CpGs (e.g. CpR, Id-

era), Poly(I:C), such as AmpliGen, non-CpG bacterial DNA or RNA as well as immunoactive small molecules and antibodies such as cyclophosphamide, sunitinib, Bavacizumab, celebrex, NCX-4016, sildenafil, tadalafil, vardenafil, sorafenib, XL-999, CP-547632, pazopanib, ZD2171, AZD2171, anti-CTLA4 and SC58175, which may act therapeutically and/or as an adjuvant. The amounts and concentrations of adjuvants and additives useful in the context of the present invention

can readily be determined by the skilled artisan without undue experimentation.

[0140] Preferred adjuvants are dSLIM, BCG, OK432, ALDARA, PeviT_{er}, and JuvImmune.

[0141] Preferably medicaments of the present invention are active against cancer. The cancer may be non-metastatic or metastatic in particular cancer of the buccal cavity and pharynx, cancer of the digestive tract, cancer of the colon, rectum, and anus, cancer of the respiratory tract, breast cancer, cancer of the cervix uteri, vagina, and vulva, cancer of the uterine corpus and ovary, cancer of the male genital tract, cancer of the urinary tract, cancer of the bone and soft tissue, and kaposi sarcoma, melanoma of the skin, eye melanoma, and non-melanoma eye cancer, cancer of the brain and central nervous system, cancer of the thyroid and other endocrine glands, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, and myeloma. Most preferably the neoplastic disorder treated by the method of the current invention is colorectal cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, gastric cancer, renal cancer, GIST or glioblastoma.

[0142] Since the peptide of the invention was isolated from glioblastoma, colorectal, pancreatic, lung, renal or gastric cancer, the medicament of the invention will be particularly useful if cancer to be treated is glioblastoma, colorectal, pancreatic, lung, renal or gastric cancer.

[0143] In addition to being useful for treating cancer, the peptides as disclosed are also useful as diagnostics. Since the peptides were generated from glioblastoma and since it was determined that these peptides are not present in normal tissues, these peptides can be used to diagnose the presence of a cancer.

[0144] The presence of the peptides as disclosed on tissue biopsies can assist a pathologist in diagnosis of cancer. Detection of certain peptides as disclosed by means of antibodies, mass spectrometry or other methods known in the art can tell the pathologist that the tissue is malignant or inflamed or generally diseased. Presence of groups of peptides as disclosed can enable classification or subclassification of diseased tissues.

[0145] The detection of the peptides as disclosed on diseased tissue specimen can enable the decision about the benefit of therapies involving the immune system, especially if T lymphocytes are known or expected to be involved in the mechanism of action. Loss of MHC expression is a well described mechanism by which infected or malignant cells escape immunosurveillance. Thus, presence of the peptides as disclosed shows that this mechanism is not exploited by the analyzed cells.

[0146] The peptides as disclosed might be used to analyze lymphocyte responses against those peptides as disclosed, such as T cell responses or antibody responses against the peptides as disclosed or the peptides as disclosed complexed to MHC molecules. These lymphocyte responses can be used as prognostic markers for decision on further therapy steps. These responses can also be used as surrogate markers in immunotherapy approaches aiming to induce lymphocyte responses by different means, e.g. vaccination of protein, nucleic acids, autologous materials, adoptive transfer of lymphocytes. In gene therapy settings, lymphocyte responses against the peptides as disclosed can be considered in the assessment of side effects. Monitoring of lymphocyte responses might also be a valuable tool for follow-up examinations of transplantation therapies, e.g. for the detection of graft versus host and host versus graft diseases.

[0147] The peptide of the present invention can be used to generate and develop specific antibodies against MHC/peptide complexes. These can be used for therapy, targeting toxins or radioactive substances to the diseased tissue. Another use of these antibodies can be targeting radionuclides to the diseased tissue for imaging purposes, such as PET. This use can help to detect small metastases or to determine the size and precise localization of diseased tissues. In addition, the peptides can be used to verify a pathologist's diagnosis of a cancer based on a biopsied sample.

[0148] Disclosed is a kit comprising (a) a container that contains a pharmaceutical composition as described above, in solution or in lyophilized form; (b) optionally, a second container containing a diluent or reconstituting solution for the lyophilized formulation; and (c) optionally, instructions for (i) use of the solution or (ii) reconstitution and/or use of the lyophilized formulation. Said kit may further comprise one or more of (iii) a buffer, (iv) a diluent, (v) a filter, (vi) a needle, or (v) a syringe. The container is preferably a bottle, a vial, a syringe or test tube; and it may be a multi-use container. The pharmaceutical composition is preferably lyophilized.

[0149] Kits as disclosed preferably comprise a lyophilized formulation of the present invention in a suitable container and instructions for its reconstitution and/or use. Suitable containers include, for example, bottles, vials (e.g. dual chamber vials), syringes (such as dual chamber syringes) and test tubes. The container may be formed from a variety of materials such as glass or plastic. Preferably the kit and/or container contains instructions on or associated with the container that indicates directions for reconstitution and/or use. For example, the label may indicate that the lyophilized formulation is to be reconstituted to peptide concentrations as described above. The label may further indicate that the formulation is useful or intended for subcutaneous administration.

[0150] The container holding the formulation may be a multi-use vial, which allows for repeat administrations (e.g., from 2-6 administrations) of the reconstituted formulation. The kit may further comprise a second container comprising

a suitable diluent (e.g., sodium bicarbonate solution).

[0151] Upon mixing of the diluent and the lyophilized formulation, the final peptide concentration in the reconstituted formulation is preferably at least 0.15 mg/mL/peptide (=75 μ g) and preferably not more than 3 mg/mL/peptide (=1500 μ g). The kit may further include other materials desirable from a commercial and user standpoint, including other buffers,

diluents, filters, needles, syringes, and package inserts with instructions for use.

[0152] Kits as disclosed may have a single container that contains the formulation of the pharmaceutical compositions according to the present invention with or without other components (e.g., other compounds or pharmaceutical compositions of these other compounds) or may have distinct container for each component.

[0153] Preferably, kits as disclosed include a formulation of the invention packaged for use in combination with the co-administration of a second compound (such as adjuvants (e.g. GM-CSF), a chemotherapeutic agent, a natural product, a hormone or antagonist, a anti-angiogenesis agent or inhibitor, a apoptosis-inducing agent or a chelator) or a pharmaceutical composition thereof. The components of the kit may be pre-complexed or each component may be in a separate distinct container prior to administration to a patient. The components of the kit may be provided in one or more liquid solutions, preferably, an aqueous solution, more preferably, a sterile aqueous solution. The components of the kit may also be provided as solids, which may be converted into liquids by addition of suitable solvents, which are preferably provided in another distinct container.

[0154] The container of a therapeutic kit may be a vial, test tube, flask, bottle, syringe, or any other means of enclosing a solid or liquid. Usually, when there is more than one component, the kit will contain a second vial or other container, which allows for separate dosing. The kit may also contain another container for a pharmaceutically acceptable liquid. Preferably, a therapeutic kit will contain an apparatus (e.g., one or more needles, syringes, eye droppers, pipette, etc.), which enables administration of the agents of the invention that are components of the present kit.

[0155] The pharmaceutical formulation of the present invention is one that is suitable for administration of the peptides by any acceptable route such as oral (enteral), nasal, ophthal, subcutaneous, intradermal, intramuscular, intravenous or transdermal. Preferably the administration is s.c., and most preferably, i.d. Administration may be by infusion pump.

EXAMPLES

1. Synthesis and structure

[0156] Peptides were synthesized by standard and well-established solid phase synthesis using Fmoc chemistry. After purification by preparative HPLC, ion-exchange procedure was performed to incorporate physiological compatible counter ions (acetate or chloride). Finally, white to off white solids were obtained after lyophilization. All TUMAPs are administered as acetate salts except IMA-CCN-001 which is supplied as chloride salt for technical reasons during the manufacturing procedure.

2. Identification of tumour associated peptides (TUMAPs) presented on cell surface

Tissue samples

[0157] Patients' tumour and healthy tissues were provided by several different clinical sites (see Table below). Written informed consents of all patients had been given before surgery. Tissues were shock-frozen in liquid nitrogen immediately after surgery and stored until isolation of TUMAPs at -80°C.

Isolation of HLA peptides from tissue samples

[0158] HLA peptide pools from shock-frozen tissue samples were obtained by immune precipitation from solid tissues according to a slightly modified protocol (Falk, K., Rotzschke, O., Stevanovic, S., Jung, G. and Rammensee, H.G. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. *Nature* 351, 290-296 (1991); Seeger, F.H. et al. The HLA-A*6601 peptide motif: prediction by pocket structure and verification by peptide analysis. *Immunogenetics* 49, 571-576 (1999)) using the HLA-A*02-specific antibody BB7.2 or the HLA-A, -B, -C-specific antibody W6/32, CNBr-activated sepharose, acid treatment and ultrafiltration.

Detection of TUMAPs by ESI-liquid chromatography mass spectrometry (ESI-LCMS)

[0159] The obtained HLA peptide pools were separated according to their hydrophobicity by reversed-phase chromatography (CapLC, Waters) and the eluting peptides were analyzed in a hybrid quadrupole orthogonal acceleration time of flight tandem mass spectrometer (Q-TOF Ultima, Waters) equipped with an ESI source. Peptide pools were loaded onto a C18 pre-column for concentration and desalting. After loading, the pre-column was placed in line for separation

by a fused-silica micro-capillary column (75 μm i.d. x 250 mm) packed with 5 μm C18 reversed-phase material (Dionex). Solvent A was 4 mM ammonium acetate/water. Solvent B was 2 mM ammonium acetate in 80% acetonitrile/water. Both solvents were adjusted to pH 3.0 with formic acid. A binary gradient of 15% to 60% B within 90 minutes was performed, applying a flow rate of 5 $\mu\text{l}/\text{min}$ reduced to approximately 200 nL/min by a split-system. A gold coated glass capillary (PicoTip, New Objective) was used for introduction into the micro-ESI source. The integration time for the TOF analyzer was 1.9 s with an interscan delay of 0.1 s. Subsequently, the peptide sequences were revealed by collisionally induced decay (CID) mass spectrometry (ESI-LCMS/MS). The identified TUMAP sequence was assured by comparison of the generated natural TUMAP fragmentation pattern with the fragmentation pattern of a synthetic sequence-identical reference peptide.

[0160] Fig 1 and Fig 2 show exemplary spectra obtained from tumour tissue for MHC class I associated TUMAPs (Fig. 1a-1h) and MHC class II associated TUMAPs (Fig. 2a-2f).

3. Expression profiling of genes encoding the peptides

[0161] The peptides identified as being presented on the surface of tumour cells by MHC molecules are likely able to induce T-cells with a high specificity of recognition for the tissue from which they were derived. To minimize the risk for autoimmunity induced by vaccination with such peptides the inventors focused on those peptides that are derived from proteins that are overexpressed on tumour cells compared to the majority of normal tissues.

[0162] The ideal peptide will be derived from a protein that is unique to the tumour and not present in any other tissue. To identify peptides that are derived from genes with an ideal expression the identified peptides were assigned to the proteins and genes, respectively, from which they were derived and expression profiles of the genes were generated.

RNA sources and preparation

[0163] Surgically removed tissue specimens were provided by several different clinical sites (see Table 2) after written informed consent had been obtained from each patient.

[0164] Tumour tissue specimens were snap-frozen in liquid nitrogen immediately after surgery and later homogenized with mortar and pestle under liquid nitrogen. Total RNA was prepared from these samples using TRIzol (Invitrogen, Karlsruhe, Germany) followed by a cleanup with RNeasy (QIAGEN, Hilden, Germany); both methods were performed according to the manufacturer's protocol.

[0165] Total RNA from healthy human tissues was obtained commercially (Ambion, Huntingdon, UK; Clontech, Heidelberg, Germany; Stratagene, Amsterdam, Netherlands; BioChain, Hayward, CA, USA). The RNA from several individuals (between 2 and 123 individuals) was mixed such that RNA from each individual was equally weighted. Leukocytes were isolated from blood samples of 4 healthy volunteers.

[0166] Quality and quantity of all RNA samples were assessed on an Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) using the RNA 6000 Pico LabChip Kit (Agilent).

Microarray experiments

[0167] Gene expression analysis of all tumour and normal tissue RNA samples was performed by Affymetrix Human Genome (HG) U133A or HG-U133 Plus 2.0 oligonucleotide microarrays (Affymetrix, Santa Clara, CA, USA). All steps were carried out according to the Affymetrix manual (http://www.affymetrix.com/support/technical/manual/expression_manual.affx). Briefly, double-stranded cDNA was synthesized from 5-8 μg of total RNA, using SuperScript RTII (Invitrogen) and the oligo-dT-T7 primer (MWG Biotech, Ebersberg, Germany) as described in the manual. In vitro transcription was performed with the BioArray High Yield RNA Transcript Labelling Kit (ENZO Diagnostics, Inc., Farmingdale, NY, USA) for the U133A arrays or with the GeneChip IVT Labelling Kit (Affymetrix) for the U133 Plus 2.0 arrays, followed by cRNA fragmentation, hybridization, and staining with streptavidin-phycoerythrin and biotinylated anti-streptavidin antibody (Molecular Probes, Leiden, Netherlands). Images were scanned with the Agilent 2500A GeneArray Scanner (U133A) or the Affymetrix Gene-Chip Scanner 3000 (U133 Plus 2.0), and data were analysed with the GCOS software (Affymetrix), using default settings for all parameters. For normalization, 100 housekeeping genes provided by Affymetrix were used (http://www.affymetrix.com/support/technical/mask_files.affx). Relative expression values were calculated from the signal log ratios given by the software and the normal sample was arbitrarily set to 1.0.

[0168] Expression profiles of all peptides as disclosed show a high expression of the respective gene in tumour tissue while being not or to a very low extend expressed in normal tissues.

[0169] Fig. 3 shows such profiles for the genes of glioblastoma specific peptides PTP-001 (gene: PTPRZ1, Fig. 3a), and CHI-001 (gene: CH3L2, Fig. 3b).

4. Re-detection of identified TUMAPs by ESI-liquid chromatography mass spectrometry (ESI-LCMS) in additional tumour samples

[0170] TUMAPs identified by the method of EXAMPLE 1 were systematically searched for on colorectal tumour samples by mass spectrometry.

[0171] The obtained HLA peptide pools were separated according to their hydrophobicity by reversed-phase chromatography (CapLC, Waters) and the eluting peptides were analyzed in a hybrid quadrupole orthogonal acceleration time of flight tandem mass spectrometer (Q-TOF Ultima, Waters) equipped with an ESI source. Peptide pools were loaded onto a C18 pre-column for concentration and desalting. After loading, the pre-column was placed in line for separation by a fused-silica micro-capillary column (75 μm i.d. x 250 mm) packed with 5 μm C18 reversed-phase material (Dionex). Solvent A was 4 mM ammonium acetate/water. Solvent B was 2 mM ammonium acetate in 80% acetonitrile/water. Both solvents were adjusted to pH 3.0 with formic acid. A binary gradient of 15% to 60% B within 90 minutes was performed, applying a flow rate of 5 $\mu\text{l}/\text{min}$ reduced to approximately 200 nL/min by a split-system. A gold coated glass capillary (PicoTip, New Objective) was used for introduction into the micro-ESI source. The integration time for the TOF analyzer was 1.9 s with an interscan delay of 0.1 s. For detection of defined peptides high sensitive screening was performed in this type of ESI-LCMS experiments on the basis of known molecular weights and retention times of the peptides in the chromatographic system. Therefore, a list containing the m/z values of the previously identified peptides (singly and/or doubly charged) was applied for precursor selection. Subsequently the sequence was revealed by collisionally induced decay (CID) mass spectrometry (ESI-LCMS/MS). The TUMAP sequence was confirmed by comparison of the generated natural TUMAP fragmentation pattern with the fragmentation pattern of a synthetic sequence-identical reference peptide. Evaluation of the HLA peptide purification yield and reproducibility of the analytical system, including retention time stability was carried out using the intensity and retention time of an abundant endogenous HLA-A*02 peptide (YLLPAIVHI derived from DDX5) as internal standard. Therefore, the CRC sample inclusion criterion for detection of previously identified TUMAP in these experiments was set to a minimal intensity of 650 counts per scan of the internal doubly charged standard signal (YLLPAIVHI) in the LCMS/MS experiment to assure a successful HLA peptide isolation and the correct performance of the analytical system.

[0172] Table 2 shows the results of an analysis of colon and rectum cancer samples of different stages as well as metastases originating from either primary tumour site. All HLA-A*02 TUMAPs were found on the majority of samples. Re-detection frequencies of HLA-DR TUMAPs are generally lower. This can be expected because for HLA class II peptides, several length variants for each core sequence may exist. ODC-001, a TUMAP identified previously (M Diehl, PhD thesis 1998, University of Tuebingen) and known to be presented on a large number of colon tumours served as positive control.

Table 2 Re-detection of TUMAPS in CRC samples

TUMAP re-detected (+) or not detected (-)										
				class I						class II
No	CRC sample	Tumor location	Tumor stage	C20-001	TGFBI-001	TOP-001	NOX-001	PCN-001	ODC-001	TGFBI-004
1	CCA062	colon	I	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	-
2	CCA740	colon	II	+	+	+	+	+	+	n.a.
3	CCA165	colon	II	+	+	+	+	+	+	-
4	CCA712	colon	III	+	+	+	-	-	+	n.a.
5	CCA707	colon	III	+	+	+	+	+	+	n.a.
6	CCA718	colon	III	+	+	+	+	+	+	n.a.
7	CCA739	colon	III	+	+	+	+	+	+	n.a.
8	CCA166	colon	III	+	+	+	+	+	+	-
9	CCA734	colon	III	+	+	+	+	+	+	n.a.
10	CCA719	colon	IV	+	+	+	+	-	+	n.a.
11	CCA725	colon	IV	+	+	+	-	+	+	n.a.
12	CCA164	colon	IV	+	+	-	-	+	+	-
13	CCA167	colon	IV	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	-
14	CCA056	colon	?	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	-
15	CCA305	colon	?	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	-
20	CCA708	colon metastasis	IV	+	+	+	+	+	+	+
16	CCA160	rectum	II	+	+	+	+	+	+	+
17	CCA754	rectum	II	+	+	+	-	+	+	n.a.
18	CCA170	rectum	III	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	+
19	CCA171	rectum	IV	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	-
21	CCA724	rectum metastasis	IV	+	+	-	-	-	+	+
Detected in % of analyzed samples				100%	100%	87%	67%	80%	100%	33%
n.a.: not analysed										

5. Binding of HLA class I-restricted peptides to HLA-A*0201

[0173] The HLA binding assay was performed using the ELISA Epl Kit (obtained from Soeren Buus, Institute of Medical Microbiology and Immunology at the University of Copenhagen, Denmark) according to Sylvester-Hvid (Sylvester-Hvid, C, Kristensen, N, Blicher, T, Ferre, H, Lauemoller, SL, Wolf, XA, Lamberth, K, Nissen, MH, Pedersen, LO, and Buus, S; Establishment of a quantitative ELISA capable of determining peptide - MHC class I interaction, Tissue Antigens, 2002, 59, 251-258) and the ELISA Epl Kit manual by the manufacturer.

Preparation of peptide solutions

[0174] Peptides were dissolved in DMSO + 0.5% TFA (Merck, Darmstadt, Germany) at a concentration of 10 mg/ml. The highest peptide working solution used in this assay was 200 μ M, therefore the stock solution was diluted 1:50 in a peptide-dilution buffer (PBS with 0.1 % Lutrol-F68 and 10 mg/l Phenol red) to a final volume of 100 μ l. A serial five-fold dilution was performed with peptide-dilution buffer.

*Refolding of HLA-A *0201/peptide complexes*

[0175] According to the manual, a 2-fold concentrated HLA-A*0201 solution was prepared by mixing 3x pH buffer (pH 6.6), Lutrol-F68, human β 2m, recombinant HLA-A*0201 (all included in the ELISA Epl Kit) with PBS.

[0176] For the refolding process, 15 μ l of peptide serial dilutions and 15 μ l of the 2-fold concentrated MHC mix were mixed in 96-well plates (Nunc, Rochester, NY, USA) and incubated at 18°C for 48 hours.

Quantification of the complexes by an ELISA

[0177] Maxisorp plates (Nunc, Rochester, NY) were coated with 5 μ g/ml w6/32 antibody in coating buffer (pH 9.6), incubated for 24 h at 4°C and blocked with 5% skim milk powder (Merck, Darmstadt, Germany) in PBS over night at 4°C.

[0178] MHC complex standard (ELISA Epl Kit) was diluted with 2% skim milk powder in PBS (SMP/PBS) to a concentration of 10 nM. A serial 3.16fold dilution was prepared and transferred to the coated and blocked Maxisorp plate. The peptide-MHC complexes were diluted 10-fold with 2% SMP/PBS, transferred to the same Maxisorp plate and incubated for 2 hours at 4°C. Rabbit anti-h β 2m antibody (ELISA Epl Kit) was added in a 1:2500 dilution in 2% SMP/PBS and incubated for 1 hour at 4°C. Amplification buffer (HRP-conjugated goat anti-rabbit polymer) and mouse serum (both supplied with the ELISA Epl Kit) was diluted in 2% SMP/PBS, added to the plates and incubated 30 minutes at room temperature. Development buffer (Tetramethylbenzidine, TMB; ELISA Epl Kit) was added, plates were incubated under light protection for 30 minutes at room temperature. The reaction was stopped by adding 0.2 M sulfuric acid (VWR, Darmstadt, Germany). Plates were read at OD450 nm using the VERSAmax ELISA-Reader (Molecular Devices, Sunnyvale, CA, USA).

[0179] Data were interpreted with Excel and Prism®, Graphpad 3.0.

[0180] Results are shown in Fig. 4. A lower KD value reflects higher affinity to HLA-A*0201. Binding affinities stretch over a range of approximately four decades but most peptides have similar binding affinities within one decade (C20-001, ODC-001, PCN-001, TOP-001). The affinity of MUC-001 is about one decade lower compared to the majority of the included ligands but MUC-001 was nevertheless able to induce a T-cell response when used in a vaccine for renal carcinoma (Wierecky, J, Muller, MR, Wirths, S, Halder-Oehler, E, Dorfel, D, Schmidt, SM, Hantschel, M, Brugger, W, Schroder, S, Horger, MS, Kanz, L, and Brossart, P; Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients, Cancer Res., 2006, 66, 5910-5918). On the other hand, NOX-001 has a slightly higher binding affinity and TGFBI-001 is the strongest binder with a 100-fold lower KD value compared with the majority of peptides.

[0181] In absolute terms, KD values between 0.01 and 0.1 nM as observed for the majority of peptides represent already a strong binding. Similar affinities had been also observed for peptides contained in the renal cell carcinoma vaccine IMA901 that was successfully tested (H. Singh-Jasuja, S. Walter, T. Weinschenk, A. Mayer, P. Y. Dietrich, M. Staehler, A. Stenzl, S. Stevanovic, H. Rammensee, J. Frisch; Correlation of T-cell response, clinical activity and regulatory T-cell levels in renal cell carcinoma patients treated with IMA901, a novel multi-peptide vaccine; ASCO Meeting 2007 Poster # 3017; M. Staehler, A. Stenzl, P. Y. Dietrich, T. Eisen, A. Haferkamp, J. Beck, A. Mayer, S. Walter, H. Singh, J. Frisch, C. G. Stief; An open label study to evaluate the safety and immunogenicity of the peptide based cancer vaccine IMA901, ASCO meeting 2007; Poster # 3017). Therefore, binding properties of peptides as disclosed are quite similar to those of peptides that have been *shown in vivo* to induce a T-cell response.

6. In vitro immunogenicity of MHC class I presented peptides

In vitro priming of CD8+ T cells

[0182] To perform *in vitro* stimulations by artificial antigen presenting cells (aAPC) loaded with peptide-MHC complex (pMHC) and anti-CD28 antibody, first PBMCs (peripheral blood mononuclear cells) were isolated from fresh HLA-A*02+ buffy coats by using standard density gradient separation medium (PAA, Cölbe, Germany). Buffy coats were either obtained from the Blood Bank Tübingen or from the Katharinenhospital Stuttgart. Isolated PBMCs were incubated overnight in T-cell medium (TCM) for human *in vitro* priming consisting of RPMI-Glutamax (Invitrogen, Karlsruhe, Germany) supplemented with 10% heat inactivated human AB serum (PAA, Cölbe, Germany), 100 U/ml Penicillin / 100 µg/ml Streptomycin (Cambrex, Verviers, Belgium), 1 mM sodium pyruvate (CC Pro, Neustadt, Germany) and 20 µg/ml Gentamycin (Cambrex). CD8+ lymphocytes were isolated using the CD8+ MACS positive selection kit (Miltenyi, Bergisch Gladbach, Germany) according to the manufacturer's instructions. Obtained CD8+ T-cells were incubated until use in TCM supplemented with 2.5 ng/ml IL-7 (PromoCell, Heidelberg, Germany) and 10 U/ml IL-2 (Chiron, Munich, Germany). Generation of pMHC/anti-CD28 coated beads, T-cell stimulations and readout was performed as described before (Walter, S, Herrgen, L, Schoor, O, Jung, G, Wernet, D, Buhning, HJ, Rammensee, HG, and Stevanovic, S; Cutting edge: predetermined avidity of human CD8 T cells expanded on calibrated MHC/anti-CD28-coated microspheres, J. Immunol., 2003, 171, 4974-4978) with minor modifications. Briefly, biotinylated recombinant HLA-A*0201 molecules lacking the transmembrane domain and being biotinylated at the carboxy terminus of the heavy chain were produced following a method described by Altman et al. (Altman, JD, Moss, PA, Goulder, PJ, Barouch, DH, Heyzer-Williams, MG, Bell, JI, McMichael, AJ, and Davis, MM; Phenotypic analysis of antigen-specific T lymphocytes, Science, 1996, 274, 94-96). The purified costimulatory mouse IgG2a anti human CD28 Ab 9.3 (Jung, G, Ledbetter, JA, and Muller-Eberhard, HJ; Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates, Proc Natl Acad Sci U S A, 1987, 84, 4611-4615) was chemically biotinylated using Sulfo-N-hydroxysuccinimidobiotin as recommended by the manufacturer (Perbio, Bonn, Germany). Beads used were 5.60 µm large streptavidin coated polystyrene particles (Bangs Laboratories, Illinois/USA). pMHC was used as positive control and negative controls were A*0201/MLA-001 (peptide ELAGIGILTV from modified Melan-A/MART-1) and A*0201/DDX5-001 (YLLPAIVHI from DDX5) or A*0201/HBV-001 (FLPSDFFPSV), respectively.

[0183] 800.000 beads / 200 µl were coated in 96-well plates in the presence of 600 ng biotin anti-CD28 plus 200 ng relevant biotin-pMHC (high density beads) or 2 ng relevant plus 200 ng irrelevant (pMHC library) MHC (low density beads). Stimulations were initiated in 96-well plates by coinocubating 1x10⁶ CD8+ T cells with 2x10⁵ washed coated beads in 200 µl TCM supplemented with 5 ng/ml IL-12 (PromoCell) for 3-4 days at 37°C. Half of the medium was then exchanged by fresh TCM supplemented with 80 U/ml IL-2 and incubation was continued for 3-4 days at 37°C. This stimulation cycle was performed for a total of three times. Finally, tetrameric analyses were performed with fluorescent MHC tetramers (produced as described by Altman, JD, Moss, PA, Goulder, PJ, Barouch, DH, Heyzer-Williams, MG, Bell, JI, McMichael, AJ, and Davis, MM; Phenotypic analysis of antigen-specific T lymphocytes, Science, 1996, 274, 94-96) plus antibody CD8-FITC clone SK1 (BD, Heidelberg, Germany) on a four-color FACSCalibur (BD). Peptide specific cells were calculated as percentage of total CD8+ T cells. Evaluation of tetrameric analysis was performed using the software FCS Express (De Novo Software). *In vitro* priming of specific tetramer+ CD8+ lymphocytes was detected by appropriate gating and by comparison to negative control stimulations. Immunogenicity for a given antigen was detected if at least one evaluable *in vitro* stimulated well of one healthy donor was found to contain a specific CD8+ T-cell line after *in vitro* stimulation (i.e. this well contained at least 1% of specific tetramer+ among CD8+ T-cells and the percentage of specific tetramer+ cells was at least 10x the median of the negative control stimulations).

[0184] Peptides as disclosed were tested together with peptides of known *in vivo* immunogenicity for comparison. A representative staining showing generation of T-cell lines specific for NOX-001 and ODC-001 is shown in Figure 5. The results are summarized in table 3 below.

Table 3: In vitro immunogenicity of peptides compared with those of vaccine peptides

Antigen	Immunogenicity detected
TGFBI-001	yes
NOX-001	yes
PCN-001	yes
TOP-001	yes
C20-001	yes

(continued)

Antigen	Immunogenicity detected
ODC-001	yes
CCN-001	yes
PTP-001	yes
CHI-001	yes
JAK-001	yes

Table 3a: *In vitro* immunogenicity of peptides

Antigen	Positive donors / donors tested	Positive wells / wells tested
IMA-HBV-001	7/16 (44%)	10/107 (9%)
IMA-TGFBI-001	3/4 (75%)	4/22 (18%)
IMA-NOX-001	3/5 (60%)	9/60 (15%)
IMA-PCN-001	3/4 (75%)	4/42 (10%)
IMA-TOP-001	2/5 (40%)	7/72 (10%)
IMA-C20-001	1/5 (20%)	1/60 (2%)
IMA-ODC-001	1/5 (20%)	1/60 (2%)
IMA-HBV-001	2/5 (40%)	10/54 (19%)
IMA-CEA-004	4/4 (100%)	50/60 (83%)
IMA-CCN-001	5/5 (100%)	42/54 (78%)
IMA-MET-001	4/6 (67%)	30/72 (42%)

[0185] Results of *in vitro* immunogenicity experiments conducted by the inventors are summarized here. Results shown have been obtained by stimulation of CD8+ cells with high density beads. As different human serum lots may highly affect the immunogenicity results, only assays in that one and the same serum lot was used, were evaluated together.

7. *In vitro* immunogenicity for MHC class II presented peptides

[0186] T helper cells play an important role in supporting CTLs to activate and sustain immune responses against tumour cells. Therefore, MHC class II peptides were included in IMA910. TGFBI-004, one of the three class II peptides contained in IMA910, was tested for its immunogenic potential *in vitro* and proved to be an inducer of both specific CD4+ and CD8+ T cells. The generation of CD4+ and functional CD8+ T lymphocytes was shown in experiments using stimulations performed in an autologous system.

Principle of test

[0187] Priming and expansion of specific human CD4+ and CD8+ cells were assayed *in vitro* by priming of monocyte-depleted PBMCs with autologous DCs and restimulation with autologous PBMCs. Briefly, to generate antigen-specific CD4+ T cells, monocyte-depleted PBMCs of one healthy donor (HLA genotype class I: A1/A25/B8/B18 and class II: DQB1*02/DQB1*06/DRB1*03/DRB1*15/DRB3/DRB5) were stimulated using peptide-pulsed autologous DCs and restimulated with autologous PBMCs plus peptide. As a read-out system, IFN γ production upon short term restimulation was assessed by ELISPOT and flow cytometry. T cells were analyzed after eight stimulations by ELISPOT and intracellular IFN γ staining plus CD4-FITC and CD8-PerCP to determine the percentage of IFN γ -producing cells in specific T-cell subpopulations. In this experiment, cells stimulated with TGFBI-004 peptide from different wells were pooled, incubated with irrelevant peptide for the read-out and performed as negative controls.

Generation of dendritic cells (DCs)

[0188] Human DCs were obtained from monocytes cultured in DC medium consisting of RPMI 1640-Glutamax/25mM Hepes (Invitrogen, Germany) supplemented with 10% autologous plasma // 100 U/ml penicillin and 100 µg/ml streptomycin. First, buffy coat and plasma was obtained by centrifugation of the blood from a healthy donor (Bloodbank Tübingen). PBMCs were then isolated from the buffy coat by standard density gradient separation (Lymphocyte Separation Medium, PAA, Austria) and resuspended in DC medium to determine total cell number. 100-120 million of PBMCs were washed, resuspended in 15 ml X-Vivo 20 medium (BioWhittaker, Belgium) and transferred to a cell culture flask. After 2 hours at 37°C, media containing peripheral blood leukocytes (PBL) was removed, adherent monocytes were washed twice with 10 ml PBS and cultured for 6 days in 10 ml DC medium with 100 ng/ml GM-CSF and 30 ng/ml IL-4 (ImmunoTools, Germany) or 20 ng/ml (R&D systems, Germany). On day 3 and 5 100 ng/ml GM-CSF and 30 ng/ml IL-4 (ImmunoTools) or 20 ng/ml IL-4 (R&D Systems, Germany) was added. On day 7 immature DCs were activated with 10 ng/ml TNF-α (R&D Systems, Germany) and 20 µg/ml poly(IC) (Sigma Aldrich, Germany) or 100 ng/ml LPS for 24 hours. Remaining PBMCs and obtained PBLs were aliquoted and frozen.

In vitro priming of specific T cells

[0189] To generate CD4+ T cells, 3 million PBMCs/PBLs were stimulated with 2 x 10⁵ autologous DCs. DCs were harvested on day 8 (see chapter 3.1, Generation of DCs). PBS with 5 mM EDTA was used for this purpose to gain as many cells as possible (including adherent cells). After being washed with DC medium, cell number was determined. For loading with peptide, DCs were resuspended in 1 ml DC medium and incubated with 25 µg/ml peptide for 2 hours at 37° C. Peptides used for pulsing of DCs were TGFBI-004, Posmix (mix of EBV and CMV related peptides), Padre and CMV. Autologous PBMCs/PBLs were thawed, washed with DC medium (at least twice) and plated in a 24 well plate at a density of 3 Mio cells/ml in 1 ml. DCs loaded with peptide were then added (as 1 ml suspension containing the peptide) to the plated PBMCs/PBLs and incubated for 7 days at 37° C. After priming, obtained CTLs were first restimulated with cryopreserved autologous peptide-loaded PBMCs that have been irradiated (30 Gy; Gammacell 1000 Elite, Nordion International, Canada). 5 x 10⁵ CTLs and 2,5 x 10⁶ PBMCs were added per well for this purpose. Pulsing of PBMCs with peptide was performed as aforementioned (for DCs). On day 1 after the first restimulation, IL-2 (R&D Systems, Germany) and IL-7 was added to a final concentration of 2 ng/ml and 5 ng/ml, respectively. Afterwards, every 2nd day and every 7th day IL-2 and IL-7 were added to the media. Second restimulation was performed 7 days later, but this time peptide was added alone (without PBMCs) to the cultured CTLs. Restimulations were performed in a 7 day cycle, with peptide-loaded PBMCs and peptide alone being added alternatively. Analyses were performed after the eight stimulation by intracellular IFNγ staining and IFNγ ELISPOT.

Results

[0190] It was possible to prime CD4+ T cell lines specifically reacting to the peptide of interest (Figure 6 and Figure 3). T-cell responses could be detected via ELISPOT in 2 out of 4 T-cell lines, whereas in 3 out of 4 T-cell lines TGFBI-004 specific IFNγ producing CD4+ and/or CD8+ cells were shown via ICS. Thus, TGFBI-004 was able to elicit CD4+ and CD8+ T cell responses in one donor tested with the above described experimental system. According to this promising result, it is likely that this peptide is immunogenic and has the capacity to induce T-cell responses.

8. Functional validation exemplified by NOX-001 and TGFBI-001

[0191] Immunogenicity of peptides included in the IMA910 vaccine was demonstrated in vitro by using immatics' TUMAP validation platform (immatics biotechnologies GmbH, Tübingen, Germany). The induction of specific T cells is an indication for the ability of peptides to successfully activate the immune system. Since efficient anti-tumour immune response is only possible when activated T cells are of high avidity and functional, the TUMAPs' ability to prime high avidity, functional T lymphocytes was investigated by testing their ability to produce IFNγ or to kill tumour cell lines. Two peptides, NOX-001 and TGFBI-001, were chosen for deeper validation due to their capacity to induce high avidity CTLs in vitro. The results proved that high avidity precursor T cells exist against both peptides in humans and that functional CD8+ T cell lines could be generated by NOX-001.

Principle of test

[0192] To get additional insight on the immunogenicity of IMA910 peptides and the properties of specific T cells, two peptides, NOX-00 and TGFBI-001, were selected for further evaluation. The experiments performed for this purpose were conducted at immatics biotechnologies GmbH, Tübingen, Germany (cell sorting was performed at the University

of Tübingen, laboratory of Dr. Bühring).

[0193] Dependent on their ability to be activated by high- or low-density antigen, T cell lines can be divided into high- or low-avidity. As it has been shown before (Walter, S, Herrgen, L, Schoor, O, Jung, G, Wernet, D, Bühring, HJ, Ram-mensee, HG, and Stevanovic, S; Cutting edge: predetermined avidity of human CD8 T cells expanded on calibrated MHC/anti-CD28-coated microspheres, J. Immunol., 2003, 171, 4974-4978), human high-avidity CTLs can be raised successfully by using less peptide for activation compared to low-avidity CD8+ T cells. It has also been demonstrated that cells expanded this way are more efficient in recognizing antigenexpressing tumour cell lines, hereby constituting a possible major tool in the development of therapy strategies.

[0194] To determine the ability of peptides to generate high-avidity CTL lines, isolated human CD8+ cells were primed and expanded by repeated in vitro stimulations with beads coated with low-density pMHC (peptide-MHC-complex) and anti-CD28 antibody in the presence of IL-12 and IL-2. After three stimulations, a fraction of in vitro primed T cells were pMHC-tetramer stained and detected by cytometric analysis. Tetramer-positive cells of each donor were pooled afterwards according to the antigen specificity, stained with pMHC-tetramer and human anti-CD8-FITC antibody and finally subjected to FACS sorting on a FACS Aria. Sorted cells were cultured and expanded in the presence of irradiated feeder cells, cytokines and mitogen. As a read-out for the generation of primed high avidity antigen specific cells, pMHC-tetramer staining was performed. To determine their functionality, IFN γ production was assayed by ELISPOT and killing of tumour cell lines was examined using a cytotoxicity assay based on live/dead staining after restimulation of the cells with the corresponding peptide and tumour cell lines.

Generation of specific CD8+ T-cell lines

[0195] In vitro stimulations using artificial antigen presenting cells (aAPC) loaded with peptide-MHC complex (pMHC) and anti-CD28 antibody were conducted as described above. The only difference to the method described above was the fact that stimulations were performed with beads loaded with 2 ng relevant plus 200 ng irrelevant library (pMHC)MHC (low density beads) instead of 200 ng relevant MHC (high density beads). Thus, predominantly high avidity T cells were generated for deeper validation of peptides. After three stimulations, a fraction of in vitro primed T cells was pMHC-tetramer stained and detected by cytometric analysis. Immunogenicity for a given antigen was detected if at least one evaluable in vitro stimulated well of one healthy donor was found to contain a specific CD8+ T-cell line after in vitro stimulation (i.e. this well contained at least 1% of specific tetramer+ among CD8+ T-cells and the percentage of specific tetramer+ cells was at least 10x the median of the negative control stimulations). Tetramer-positive cells of each donor were pooled afterwards according to the antigen specificity, stained with the corresponding pMHC-tetramer and human anti-CD8-FITC antibody clone SK1 and finally subjected to FACS sorting on a FACS Aria (BD Biosciences, Germany). Sorted cells were cultured in T cell medium (RPMI-Glutamax supplemented with 10% heat inactivated human AB serum, 100 U/ml penicillin, 100 μ g/ml streptomycin, 1 mM sodium pyruvate and 20 μ g/ml Gentamycin) in the presence of 5 x 10⁵ cells/ml irradiated fresh allogeneic PBMCs, 5 x 10⁴ cells/ml irradiated LG2-EBV cells, 150 U/ml IL-2 (Chiron, Munich, Germany) and 0,5 μ g/ml PHA-L (Roche Diagnostics, Mannheim, Germany). Expansion of these cells occurred in T cell medium containing 150 U/ml IL-2. As a read-out for the generation of primed high avidity antigen specific cells, pMHC-tetramer staining was performed as above and analyzed on a four-color FACSCalibur (BD Biosciences, Germany).

Functionality tests

[0196] To determine their functionality, IFN γ production was assessed by ELISPOT (IFN γ ELISPOT Set, BD, Germany) after restimulation of the cells with the corresponding peptide. Additionally, cell-mediated cytotoxicity of specific CTLs was investigated by killing of tumour cell lines using the LIVE/DEAD cell-mediated cytotoxicity Kit (L7010, Invitrogen, Germany). Both assays were performed according to manufacturer's instructions, except noted otherwise.

Results

[0197] Both peptides, NOX-001 and TGFBI-001, were immunogenic *in vitro* as shown by successful priming with low pMHC density aAPCs. For NOX-001 as well as for TGFBI-001 specific T-cell lines could be established by FACS, thus demonstrating that high-avidity CD8+ T cell precursors exist in healthy donors.

[0198] Additionally, for NOX-001, one T-cell line could be established that also proved to be functional by ELISPOT since it was specifically expressing IFN γ after restimulation with this peptide (Fig. 8).

9. Binding of HLA class I-restricted peptides to HLA-A*0201

[0199] The objective of this analysis was to evaluate the affinity of the HLA class I peptides CHI-001, DCA-001, JAK-001 and PTP-001 to the MHC molecule coded by the HLA-A*0201 allele. Affinities for all peptides to HLA-A*0201 were

comparable to the well-known control peptide HBV-001, dissociations constants (K_D) being in the range from 0.05 to 1.6 nM.

Principle of test

[0200] Stable HLA/peptide complexes consist of three molecules: HLA heavy chain, beta-2 microglobulin (b2m) and the peptidic ligand. The activity of denatured recombinant HLA-A*0201 heavy chain molecules alone can be preserved making them functional equivalents of "empty HLA-A*0201 molecules". When diluted into aqueous buffer containing b2m and an appropriate peptide, these molecules fold rapidly and efficiently in an entirely peptide-dependent manner. The availability of these molecules is used in an ELISA-based assay to measure the affinity of interaction between peptide and HLA class I molecule (Sylvester-Hvid C, Kristensen N, Blicher T, Ferre H, Lauemoller SL, Wolf XA, Lamberth K, Nissen MH, Pedersen LO, Buus S. Establishment of a quantitative ELISA capable of determining peptide - MHC class I interaction. Tissue Antigens 2002, 59, 251-258).

[0201] Purified recombinant HLA-A*0201 molecules were incubated together with b2m and graded doses of the peptide of interest. The amount of de novo-folded HLA/peptide complexes was determined by a quantitative ELISA. Dissociation constants (K_D values) were calculated using a standard curve recorded from dilutions of a calibrant HLA/peptide complex.

Results

[0202] Results are shown in Figure 9. A lower K_D value reflects higher affinity to HLA-A*0201. Affinities for all peptides to HLA-A*0201 were comparable to the well-known control peptide HBV-001, dissociations constants (K_D) being in the range from 0.05 to 1.6 nM.

SEQUENCE LISTING

[0203]

<110> immatics biotechnologies GmbH

<120> Novel immunogenic epitopes for immunotherapy

<130> FB22517/D

<160> 29

<170> PatentIn version 3.4

<210> 1

<211> 9

<212> PRT

<213> homo sapiens

<400> 1

Ala Leu Ser Asn Leu Glu Val Thr Leu
1 5

<210> 2

<211> 9

<212> PRT

<213> homo sapiens

<400> 2

Ile Leu Ala Pro Val Ile Leu Tyr Ile
1 5

<210> 3

EP 2 562 184 B1

<211> 10
 <212> PRT
 <213> homo sapiens
 5 <400> 3
 Lys Leu Met Asp Leu Asp Val Glu Gln Leu
 1 5 10
 10 <210> 4
 <211> 9
 <212> PRT
 <213> homo sapiens
 15 <400> 4
 Ser Met Ser Ala Asp Val Pro Leu Val
 1 5
 20 <210> 5
 <211> 10
 <212> PRT
 <213> homo sapiens
 25 <400> 5
 Lys Ile Phe Asp Glu Ile Leu Val Asn Ala
 1 5 10
 30 <210> 6
 <211> 10
 <212> PRT
 <213> homo sapiens
 35 <400> 6
 Ala Ala Phe Val Glu Glu Leu Asp Lys Val
 1 5 10
 40 <210> 7
 <211> 14
 <212> PRT
 <213> homo sapiens
 45 <400> 7
 Val Leu Leu Leu Val His Asn Leu Pro Gln His Leu Phe Gly
 1 5 10
 50 <210> 8
 <211> 10
 <212> PRT
 <213> homo sapiens
 55 <400> 8
 Ala Leu Phe Val Arg Leu Leu Ala Leu Ala
 1 5 10

EP 2 562 184 B1

<210> 9
 <211> 14
 <212> PRT
 <213> homo sapiens
 5
 <400> 9

 Gly Asp Lys Leu Glu Val Ser Leu Lys Asn Asn Val Val Ser
 1 5 10
 10
 <210> 10
 <211> 18
 <212> PRT
 <213> homo sapiens
 15
 <400> 10

 Gly Lys Lys Leu Arg Val Phe Val Tyr Arg Asn Ser Leu Cys Ile Glu
 1 5 10 15
 20
 Asn Ser

 <210> 11
 <211> 17
 <212> PRT
 <213> homo sapiens
 25
 <400> 11
 30
 Leu Lys Asn Asn Val Val Ser Val Asn Lys Glu Pro Val Ala Glu Pro
 1 5 10 15
 35
 Asp

 <210> 12
 <211> 15
 <212> PRT
 <213> homo sapiens
 40
 <400> 12

 Asn Gly Val Ile His Tyr Ile Asp Glu Leu Leu Ile Pro Asp Ser
 1 5 10 15
 45
 <210> 13
 <211> 14
 <212> PRT
 <213> homo sapiens
 50
 <400> 13

 Leu Asn Arg Ile Leu Gly Asp Pro Glu Ala Leu Arg Asp Leu
 1 5 10
 55
 <210> 14
 <211> 15

EP 2 562 184 B1

<212> PRT

<213> homo sapiens

<400> 14

5

Thr Pro Pro Ile Asp Ala His Thr Arg Asn Leu Leu Arg Asn His
1 5 10 15

<210> 15

10

<211> 9

<212> PRT

<213> homo sapiens

<400> 15

15

Ala Leu Thr Thr Leu Met His Gln Leu
1 5

<210> 16

20

<211> 9

<212> PRT

<213> homo sapiens

<400> 16

25

Ser Leu Asp Pro Ser Ser Pro Gln Val
1 5

<210> 17

30

<211> 9

<212> PRT

<213> homo sapiens

<400> 17

35

Ser Leu Trp Ala Gly Val Val Val Leu
1 5

<210> 18

40

<211> 9

<212> PRT

<213> homo sapiens

<400> 18

45

Lys Leu Thr Asp Ile Gln Ile Glu Leu
1 5

<210> 19

50

<211> 9

<212> PRT

<213> homo sapiens

<400> 19

55

Tyr Leu Ile His Phe Pro Val Ser Val
1 5

EP 2 562 184 B1

<210> 20
 <211> 9
 <212> PRT
 <213> homo sapiens
 5
 <400> 20

 Ile Val Asp Asp Ile Thr Tyr Asn Val
 1 5
 10
 <210> 21
 <211> 16
 <212> PRT
 <213> homo sapiens
 15
 <400> 21

 Gly Ala Val Arg Phe Ser Asn Asn Pro Ala Leu Cys Asn Val Glu Ser
 1 5 10 15
 20
 <210> 22
 <211> 16
 <212> PRT
 <213> homo sapiens
 25
 <400> 22

 Asn Pro Thr Thr Tyr Gln Met Asp Val Asn Pro Glu Gly Lys Tyr Ser
 1 5 10 15
 30
 <210> 23
 <211> 13
 <212> PRT
 <213> homo sapiens
 35
 <400> 23

 Phe Lys Lys Ile Lys Val Leu Gly Ser Gly Ala Phe Gly
 1 5 10
 40
 <210> 24
 <211> 18
 <212> PRT
 <213> homo sapiens
 45
 <400> 24

 Thr Thr Leu Ile Lys Glu Met Lys Ala Glu Phe Ile Lys Glu Ala Gln
 1 5 10 15
 50
 Pro Gly

 <210> 25
 <211> 15
 <212> PRT
 <213> homo sapiens

<400> 25

Val Lys Ser Lys Val Gln Tyr Leu Lys Asp Arg Gln Leu Ala Gly
1 5 10 15

<210> 26

<211> 15

<212> PRT

<213> homo sapiens

<400> 26

Ser Arg Arg Thr Phe Ile Lys Ser Val Pro Pro Phe Leu Arg Thr
1 5 10 15

<210> 27

<211> 11

<212> PRT

<213> homo sapiens

<400> 27

Lys Leu Gly Asp Phe Gly Leu Ala Thr Val Val
1 5 10

<210> 28

<211> 9

<212> PRT

<213> homo sapiens

<400> 28

Ser Leu Phe Asp Gln Val Val Lys Val
1 5

<210> 29

<211> 9

<212> PRT

<213> homo sapiens

<400> 29

Ala Leu Leu Ser Glu Val Ile Gln Leu
1 5

Claims

1. A peptide consisting of the sequence ALFVRLALA according to SEQ ID No. 8 which induces T cells cross-reacting with said peptide.
2. The peptide according to claim 1, wherein the peptide is part of a fusion protein, comprising N-terminal amino acids of the HLA-DR antigen-associated invariant chain (li).
3. A nucleic acid, encoding for a peptide according to claim 1 or 2, which is DNA, cDNA, RNA or combinations thereof, or an expression vector, wherein the vector is operably linked to said nucleic acid.
4. A peptide according to claim 1 or 2, or a nucleic acid or an expression vector according to claim 3 for use in medicine.

5. A host cell comprising a nucleic acid or an expression vector according to claim 3, wherein said host cell is an antigen presenting cell.
6. A method of producing a peptide according to claim 1 or 2, the method comprising culturing the host cell according to claim 5, and isolating the peptide from the host cell or its culture medium.
7. An *in vitro* method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting *in vitro* CTL with antigen loaded human class I MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is a peptide according to claim 1, and wherein said antigen-presenting cell preferably comprises an expression vector according to claim 3.
8. Activated cytotoxic T lymphocyte (CTL), produced by the method according to claim 7, which selectively recognizes a cell which aberrantly expresses a polypeptide comprising an amino acid sequence given in claim 1 by interacting through its TCR with the HLA/peptide-complex of the cell.
9. An effective number of cytotoxic T lymphocytes (CTL) as defined in claim 8 for use in killing target cells in a patient which target cells aberrantly express a polypeptide comprising an amino acid sequence given in claim 1.
10. An antibody or a fragment thereof, specific against an MHC/peptide complex comprising the peptide according to claim 1.
11. A peptide according to claim 1 or 2, a nucleic acid or an expression vector according to claim 3, a host cell according to claim 5, an activated cytotoxic T lymphocyte according to claim 8, or an antibody according to claim 10 for use in the treatment of cancer.
12. The peptide, the activated cytotoxic T lymphocyte or the antibody for use according to claim 11, wherein said cancer is selected from glioblastoma, colorectal cancer, pancreatic cancer, lung cancer, renal cancer and gastric cancer.
13. The peptide, the activated cytotoxic T lymphocyte or the antibody for use according to claim 11 or 12, wherein said treatment is as a vaccine.

Patentansprüche

1. Peptid, bestehend aus der Sequenz ALFVRLALA nach SEQ ID No. 8 und das T Zellen induziert, die mit dem Peptid kreuzreagieren.
2. Peptid nach Anspruch 1, wobei das Peptid Teil eines Fusionsproteins ist, umfassend die N-terminalen Aminosäuren der HLA-DR Antigen-assoziierten invarianten Kette (li).
3. Nukleinsäure, die für ein Peptid nach Anspruch 1 oder 2 kodiert, die DNA, cDNA, RNA oder Kombinationen davon ist, oder ein Expressionsvektor, wobei der Vektor operativ mit der Nukleinsäure verbunden ist.
4. Peptid nach einem der Ansprüche 1 bis 2, oder eine Nukleinsäure oder ein Expressionsvektor nach Anspruch 3 zur Verwendung in der Medizin.
5. Wirtszelle, umfassend eine Nukleinsäure oder einen Expressionsvektor nach Anspruch 3, wobei die Wirtszelle eine Antigen-präsentierende Zelle ist.
6. Verfahren zur Herstellung eines Peptids nach Anspruch 1 oder 2, wobei das Verfahren ein Kultivieren der Wirtszelle nach Anspruch 5 und Isolieren des Peptids aus der Wirtszelle oder ihres Kulturmediums umfasst.
7. *In vitro* Verfahren zur Herstellung von aktivierten zytotoxischen T Lymphozyten (CTL), wobei das Verfahren ein Kontaktieren *in vitro* von CTL mit Antigen-beladenen menschlichen Klasse I MHC Molekülen umfasst, die auf der Oberfläche einer geeigneten Antigen-präsentierenden Zelle exprimiert werden, für eine Zeitdauer, die ausreichend ist, um die CTL auf eine Antigen-spezifische Weise zu aktivieren, wobei das Antigen ein Peptid nach Anspruch 1 ist, und wobei die Antigen-präsentierende Zelle bevorzugt einen Expressionsvektor nach Anspruch 3 umfasst.

8. Aktivierter zytotoxischer T Lymphozyt (CTL), hergestellt durch das Verfahren nach Anspruch 7, der über eine Interaktion mittels seines TCT mit dem HLA/Peptidkomplex der Zelle selektiv eine Zelle erkennt, die aberrant ein Polypeptid umfassend eine Aminosäuresequenz wie in Anspruch 1 angegeben exprimiert.
9. Eine effektive Zahl von zytotoxischen T Lymphozyten (CTL) wie definiert in Anspruch 8 zur Verwendung zur Abtötung von Zielzellen in einem Patienten wobei die Zielzellen aberrant ein Polypeptid umfassend eine Aminosäuresequenz wie in Anspruch 1 angegeben exprimieren.
10. Antikörper oder Fragment davon, spezifisch gegen einen MHC/Peptidkomplex umfassend das Peptid nach Anspruch 1.
11. Peptid nach Anspruch 1 oder 2, eine Nukleinsäure oder ein Expressionsvektor nach Anspruch 3, eine Wirtszelle nach Anspruch 5, ein aktivierter zytotoxischer T Lymphozyt nach Anspruch 8 oder ein Antikörper nach Anspruch 10 zur Verwendung in der Behandlung von Krebs.
12. Peptid, der aktivierte zytotoxische T Lymphozyt oder der Antikörper zur Verwendung nach Anspruch 11, wobei der Krebs ausgewählt ist aus Glioblastom, colorectalem Krebs, Pancreaskrebs, Lungenkrebs, Nierenkrebs und Magenkrebs.
13. Peptid, der aktivierte zytotoxische T Lymphozyt oder der Antikörper zur Verwendung nach Anspruch 11 oder 12, wobei die Behandlung als ein Vakzin vorliegt.

Revendications

1. Peptide consistant en la séquence ALFVRLLALA correspondant à la séquence SEQ ID n° 8 qui induit des cellules T réagissant de façon croisée avec ledit peptide.
2. Peptide conforme à la revendication 1, où le peptide fait partie d'une protéine de fusion, comprenant des acides aminés N-terminaux de la chaîne invariante (II) associée aux antigènes du système HLA-DR.
3. Acide nucléique, codant pour un peptide conforme à la revendication 1 ou 2, qui est un ou des combinaisons d'ADN, ADNc, ARN, ou vecteur d'expression, où le vecteur est opérablement lié audit acide nucléique.
4. Peptide conforme à la revendication 1 ou 2, ou acide nucléique ou vecteur d'expression conforme à la revendication 3 pour usage médical.
5. Cellule hôte comprenant un acide nucléique ou un vecteur d'expression conforme à la revendication 3, où ladite cellule hôte est une cellule présentatrice d'antigènes.
6. Méthode de production d'un peptide conforme à la revendication 1 ou 2, cette méthode comprenant la mise en culture de la cellule hôte conforme à la revendication 5 et l'isolement du peptide de la cellule hôte ou de son milieu de culture.
7. Méthode *in vitro* de production de lymphocytes T cytotoxiques (CTL) activés, cette méthode comprenant la mise en contact *in vitro* des CTL avec des molécules du CMH de classe I humain chargées d'antigènes exprimées à la surface d'une cellule présentatrice d'antigènes appropriée pendant un temps suffisant pour activer, de manière antigène-spécifique, lesdits CTL, où ledit antigène est un peptide conforme à la revendication 1, et où ladite cellule présentatrice d'antigènes comprend de préférence un vecteur d'expression conforme à la revendication 3.
8. Lymphocyte T cytotoxique (CTL) activé, produit par la méthode conforme à la revendication 7, qui reconnaît de façon sélective une cellule exprimant anormalement un polypeptide comprenant une séquence d'acides aminés telle que décrite dans la revendication 1 en interagissant par l'intermédiaire de son TCR avec le complexe HLA/peptide de la cellule.
9. Nombre effectif de lymphocytes T cytotoxiques (CTL) tels que définis dans la revendication 8 destinés à tuer les cellules cibles chez un patient dont les cellules cibles expriment anormalement un polypeptide comprenant une séquence d'acides aminés telle que décrite dans la revendication 1.

EP 2 562 184 B1

10. Anticorps ou fragment dudit anticorps, spécifiquement dirigé contre un complexe CMH/peptide comprenant le peptide conforme à la revendication 1.

5 **11.** Peptide conforme à la revendication 1 ou 2, acide nucléique ou vecteur d'expression conforme à la revendication 3, cellule hôte conforme à la revendication 5, lymphocyte T cytotoxique activé conforme à la revendication 8, ou anticorps conforme à la revendication 10 pour utilisation dans le traitement du cancer.

10 **12.** Peptide, lymphocyte T cytotoxique activé ou anticorps pour utilisation conformément à la revendication 11, où ledit cancer est sélectionné parmi glioblastome, cancer colorectal, cancer du pancréas, cancer du poumon, cancer rénal et cancer gastrique.

13. Peptide, lymphocyte T cytotoxique activé ou anticorps pour utilisation conformément à la revendication 11 ou 12, où ledit traitement est un vaccin.

15

20

25

30

35

40

45

50

55

Figure 1a: PCN-002 (CCA707)




Figure 1b: TOP-002 (GB1006)




Figure 1c: PTP-001 (GB1006)




Figure 1d: GAL-001 (RCC190)




Figure 1e: CHI-001 (GB1002)




Figure 1f: JAK-001 (GB1002)




Figure 1g: AKR-001 (NSCLC-Pool2)




Figure 1h: FNI-001 (PC330)




Figure 2a: CEA-009 (GC-Pool2)





Figure 2b: TGFBI-006 (GC-Pool1)



30



Figure 2d: TGFBI-008 (GB1004)




Figure 2c: TGFBI-009 (NSCLC-Pool 1)




Figure 2f: TGFBI-010 (GB6002)





Figure 3a: Expression profile of PTP

Figure 3b: Expression profile of CHI




Figure 4: MHC class I molecule binding affinities




Figure 5




Figure 6




Figure 7




Figure 8





Figure 9



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- EP 04023546 A [0008]
- EP 05019254 A [0008]
- WO 2005116051 A [0019]
- US 4897445 A [0081]
- US 4440859 A, Rutter [0098]
- US 4530901 A, Weissman [0098]
- US 4582800 A, Crowl [0098]
- US 4677063 A, Mark [0098]
- US 4678751 A, Goeddel [0098]
- US 4704362 A, Itakura [0098]
- US 4710463 A, Murray [0098]
- US 4757006 A, Toole, Jr. [0098]
- US 4766075 A, Goeddel [0098]
- US 4810648 A, Stalker [0098]
- WO 9726328 A [0123]
- WO 9518145 A [0133]
- US 5849589 A [0137]
- US 6406705 B1 [0138]

Non-patent literature cited in the description

- CHEEVER et al. *Annals N.Y. Acad. Sci.* 1993, vol. 690, 101-112 [0003]
- ZEH HJ ; PERRY-LALLEY D ; DUDLEY ME ; ROSENBERG SA ; YANG JC. *J Immunol.*, 1999, vol. 162 (2), 989-94 [0003]
- SCHUBERT U ; ANT6N LC ; GIBBS J ; NORBURY CC ; YEWDELL JW ; BENNINK JR. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. *Nature*, 2000, vol. 404 (6779), 770-774 [0003]
- CRESSWELL P. *Annu. Rev. Immunol.*, 1994, vol. 12, 259-93 [0004]
- KOBAYASHI, H. ; R. OMIYA ; M. RUIZ ; E. HUARTE ; P. SAROBE ; J. J. LASARTE ; M. HERRAIZ ; B. SANGRO ; J. PRIETO ; F. BORRAS-CUESTA. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. *Clin. Cancer Res.*, 2002, vol. 8, 3219-3225 [0005]
- GNJATIC, S. ; D. ATANACKOVIC ; E. JÄGER ; M. MATSUO ; A. SELVAKUMAR ; N.K. ALTORKI ; R.G. MAKI ; B. DUPONT ; G. RITTER ; Y.T. CHEN. Survey of naturally occurring CD4+ T-cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses. *Proc. Natl. Acad. Sci. U.S.A.*, 2003, vol. 100 (15), 8862-7 [0005]
- QIN Z ; SCHWARTZKOPFF J ; PRADERAF ; KAM-MERTOENS T ; SELIGER B ; PIRCHER H ; BLANKENSTEIN T. A critical requirement of interferon gamma-mediated angiostasis for tumour rejection by CD8+ T cells. *Cancer Res.*, 2003, vol. 63 (14), 4095-4100 [0005]
- DENGJEL J ; NASTKE MD ; GOUTTEFANGEAS C ; GITSIODIS G ; SCHOOR O ; ALTENBEREND F ; MÜLLER M ; KRÄMER B ; MISSIOU A ; SAUTER M. Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. *Clin Cancer Res.*, 2006, vol. 12, 4163-4170 [0006] [0008]
- QIN, Z. ; T. BLANKENSTEIN. CD4+ T-cell-mediated tumour rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. *Immunity*, 2000, vol. 12, 677-686 [0007]
- KENNEDY, R.C. ; M.H. SHEARER ; A.M. WATTS ; R.K. BRIGHT. CD4+ T lymphocytes play a critical role in antibody production and tumour immunity against simian virus 40 large tumour antigen. *Cancer Res.*, 2003, vol. 63, 1040-1045 [0007]
- MACH, B. ; V. STEIMLE ; E. MARTINEZ-SORIA ; W. REITH. Regulation of MHC class II genes: lessons from a disease. *Annu. Rev. Immunol.*, 1996, vol. 14, 301-331 [0008]
- RAMMENSEE H. G. ; BACHMANN J. ; STEVANOVIC, S. MHC Ligands and Peptide Motifs. Chapman & Hall, 1998 [0009]
- VIGNERON N ; STROOBANT V ; CHAPIRO J ; OOMS A ; DEGIOVANNI G ; MOREL S ; VAN DER BRUGGEN P ; BOON T ; VAN DEN EYNDE BJ. An antigenic peptide produced by peptide splicing in the proteasome. *Science*, 23 April 2004, vol. 304 (5670), 587-90 [0011]
- LINEHAN WM ; WALTHER MM ; ZBAR B. The genetic basis of cancer of the kidney. *J Urol.*, December 2003, vol. 170, 2163-72 [0012]
- MCCARTEY et al. *Cancer Research*, 1998, vol. 15 (58), 2601-5 [0012]
- DISIS et al. *Ciba Found. Symp.*, 1994, vol. 187, 198-211 [0012]

- SINGH-JASUJA H. ; EMMERICH N. P. ; RAMMEN-SEE H. G. *Cancer Immunol. Immunother.*, March 2004, vol. 453 (3), 187-95 [0013]
- LEMMEL C. ; WEIKS. ; EBERLE U. ; DENGJEL J. ; KRATT T. ; BECKER H. D. ; RAMMENSEE H. G. ; STEVANOVIC S. *Nat. Biotechnol.*, April 2004, vol. 22 (4), 450-4 [0015]
- T. WEINSCHENK ; C. GOUTTEFANGEAS ; M. SCHIRLE ; F. OBERMAYR ; S. WALTER ; O. SCHOOR ; R. KUREK ; W. LOESER ; K. H. BICHLER ; D. WERNET. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. *Cancer Res.*, 2002, vol. 62 (20), 5818-5827 [0015]
- SYLVESTER-HVID, C ; KRISTENSEN, N ; BLICHER, T ; FERRE, H ; LAUEMOLLER, SL ; WOLF, XA ; LAMBERTH, K ; NISSEN, MH ; PEDERSEN, LO ; BUUS, S. Establishment of a quantitative ELISA capable of determining peptide - MHC class I interaction. *Tissue Antigens*, 2002, vol. 59, 251-258 [0020] [0173]
- *Nucleic Acid Res.*, 1994, vol. 22 (22), 4673-4680 [0022]
- FONG, L ; HOU, Y ; RIVAS, A ; BENIKE, C ; YUEN, A ; FISHER, GA ; DAVIS, MM ; ENGLEMAN, EG. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. *Proc. Natl. Acad. Sci. U.S.A.*, 2001, vol. 98, 8809-8814 [0023]
- ZAREMBA, S ; BARZAGA, E ; ZHU, M ; SOARES, N ; TSANG, KY ; SCHLOM, J. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. *Cancer Res.*, 1997, vol. 57, 4570-4577 [0023]
- COLOMBETTI, S ; FAGERBERG, T ; BAUMGARTNER, P ; CHAPATTE, L ; SPEISER, DE ; RUFER, N ; MICHIELIN, O ; LEVY, F. Impact of orthologous melan-A peptide immunizations on the anti-self melan-A/HLA-A2 T cell cross-reactivity. *J Immunol.*, 2006, vol. 176, 6560-6567 [0023]
- APPAY, V ; SPEISER, DE ; RUFER, N ; REYNARD, S ; BARBEY, C ; CEROTTINI, JC ; LEYVRAZ, S ; PINILLA, C ; ROMERO, P. Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide. *Eur. J Immunol.*, 2006, vol. 36, 1805-1814 [0023]
- HERZ, C ; AUMAILLEY, M ; SCHULTE, C ; SCHLOTZER-SCHREHARDT, U ; BRUCKNER-TUDERMAN, L ; HAS, C. Kindlin-1 is a phosphoprotein involved in regulation of polarity, proliferation, and motility of epidermal keratinocytes. *J Biol Chem.*, 2006, vol. 281, 36082-36090 [0025]
- SADLER, E ; KLAUSEGGER, A ; MUSS, W ; DEINSBERGER, U ; POHLA-GUBO, G ; LAIMER, M ; LANSCHUETZER, C ; BAUER, JW ; HINTNER, H. Novel KIND1 gene mutation in Kindler syndrome with severe gastrointestinal tract involvement. *Arch. Dermatol.*, 2006, vol. 142, 1619-1624 [0025]
- WEINSTEIN, EJ ; BOURNER, M ; HEAD, R ; ZAKERI, H ; BAUER, C ; MAZZARELLA, R. URP1: a member of a novel family of PH and FERM domain-containing membrane-associated proteins is significantly over-expressed in lung and colon carcinomas. *Biochim. Biophys. Acta*, 2003, vol. 1637, 207-216 [0026]
- KLOEKER, S ; MAJOR, MB ; CALDERWOOD, DA ; GINSBERG, MH ; JONES, DA ; BECKERLE, MC. The Kindler syndrome protein is regulated by transforming growth factor-beta and involved in integrin-mediated adhesion. *J. Biol. Chem.*, 2004, vol. 279, 6824-6833 [0026]
- SUH, Y. A. et al. Cell transformation by the superoxide-generating oxidase Mox1. *Nature*, 1999, vol. 401, 79-82 [0027]
- HARPER, R. W. ; XU, C. ; SOUCEK, K. ; SETIADI, H. ; EISERICH, J. P. A reappraisal of the genomic organization of human Nox1 and its splice variants. *Arch. Biochem. Biophys.*, 2005, vol. 435, 323-330 [0027]
- SZANTO, I. et al. Expression of NOX1, a superoxide-generating NADPH oxidase, in colon cancer and inflammatory bowel disease. *J. Pathol.*, 2005, vol. 207, 164-176 [0028]
- FUKUYAMA, M. et al. Overexpression of a novel superoxide-producing enzyme, NADPH oxidase 1, in adenoma and well differentiated adenocarcinoma of the human colon. *Cancer Lett.*, 2005, vol. 221, 97-104 [0030]
- PETROPOULOS, H. ; SKERJANC, I. S. Beta-catenin is essential and sufficient for skeletal myogenesis in P19 cells. *J Biol Chem.*, 2002, vol. 277, 15393-15399 [0031]
- TEN, KM ; VAN DER WAL, JB ; SLUITER, W ; HOFLAND, LJ ; JEEKEL, J ; SONNEVELD, P ; VAN EIJCK, CH. The role of superoxide anions in the development of distant tumour recurrence. *Br. J Cancer*, 2006, vol. 95, 1497-1503 [0032]
- JARVINEN, TA ; LIU, ET. Topoisomerase II alpha gene (TOP2A) amplification and deletion in cancer-more common than anticipated. *Cytopathology*, 2003, vol. 14, 309-313 [0035]
- KELLNER, U ; SEHESTED, M ; JENSEN, PB ; GIESELER, F ; RUDOLPH, P. Culprit and victim -DNA topoisomerase II. *Lancet Oncol.*, 2002, vol. 3, 235-243 [0036]
- SAKAGUCHI, A ; KIKUCHI, A. Functional compatibility between isoform alpha and beta of type II DNA topoisomerase. *J Cell Sci.*, 2004, vol. 117, 1047-1054 [0037]
- HEGDE, P ; QI, R ; GASPARD, R ; ABERNATHY, K ; DHARAP, S ; EARLE-HUGHES, J ; GAY, C ; NWOKEKEH, NU ; CHEN, T ; SAEED, AI. Identification of tumour markers in models of human colorectal cancer using a 19,200-element complementary DNA microarray. *Cancer Res.*, 2001, vol. 61, 7792-7797 [0038]

- **THOMPSON, JA ; GRUNERT, F ; ZIMMERMANN, W.** Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. *J Clin Lab Anal.*, 2005, vol. 5, 344-366 [0039]
- **SIKORSKA, H ; SHUSTER, J ; GOLD, P.** Clinical applications of carcinoembryonic antigen. *Cancer Detect. Prev.*, 1988, vol. 12, 321-355 [0039]
- **LOCKER, GY ; HAMILTON, S ; HARRIS, J ; JESSUP, JM ; KEMENY, N ; MACDONALD, JS ; SOMERFIELD, MR ; HAYES, DF ; BAST, RC, JR.** ASCO 2006 update of recommendations for the use of tumour markers in gastrointestinal cancer. *J Clin Oncol.*, 2006, vol. 24, 5313-5327 [0039]
- **OREFICE, S ; FOSSATI, G ; PIETROJUSTI, E ; BONFANTI, G.** Delayed cutaneous hypersensitivity reaction to carcinoembryonic antigen in cancer patients. *Tumouri*, 1982, vol. 68, 473-475 [0040]
- **SAROBÉ, P ; HUARTE, E ; LASARTE, JJ ; BORRAS-CUESTA, F.** Carcinoembryonic antigen as a target to induce anti-tumour immune responses. *Curr. Cancer Drug Targets*, 2004, vol. 4, 443-454 [0040]
- **MOSOLITS, S ; ULLENHAG, G ; MELLSTEDT, H.** Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. *Ann. Oncol.*, 2005, vol. 16, 847-862 [0040]
- **VON MEHREN, M.** Colorectal cancer vaccines: what we know and what we don't yet know. *Semin. Oncol.*, 2005, vol. 32, 76-84 [0040] [0041]
- **CROSTI, M ; LONGHI, R ; CONSOGNO, G ; MELONI, G ; ZANNINI, P ; PROTTI, MP.** Identification of novel subdominant epitopes on the carcinoembryonic antigen recognized by CD4+ T-cells of lung cancer patients. *J Immunol.*, 2006, vol. 176, 5093-5099 [0041]
- **NOVELLINO, L ; CASTELLI, C ; PARMIANI, G.** A listing of human tumour antigens recognized by T-cells. *Cancer Immunol. Immunother.*, March 2004, vol. 54, 187-207 [0041]
- **RUIZ, M ; KOBAYASHI, H ; LASARTE, JJ ; PRIETO, J ; BORRAS-CUESTA, F ; CELIS, E ; SAROBÉ, P.** Identification and characterization of a T-helper peptide from carcinoembryonic antigen. *Clin Cancer Res.*, 2004, vol. 10, 2860-2867 [0041]
- **BABATZ, J ; ROLLIG, C ; LOBEL, B ; FOLPRECHT, G ; HAACK, M ; GUNTHER, H ; KOHNE, CH ; EHNINGER, G ; SCHMITZ, M ; BOMHAUSER, M.** Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumours after vaccination with altered peptide ligand-loaded dendritic cells. *Cancer Immunol. Immunother.*, 2006, vol. 55, 268-276 [0041]
- **FONG, L ; HOU, Y ; RIVAS, A ; BENIKE, C ; YUEN, A ; FISHER, GA ; DAVIS, MM ; ENGLEMAN, EG.** Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumour immunotherapy. *Proc. Natl. Acad. Sci. U.S.A.*, 2001, vol. 98, 8809-8814 [0041]
- **LIU, KJ ; WANG, CC ; CHEN, LT ; CHENG, AL ; LIN, DT ; WU, YC ; YU, WL ; HUNG, YM ; YANG, HY ; JUANG, SH.** Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. *Clin Cancer Res.*, 2004, vol. 10, 2645-2651 [0041]
- **MATSUDA, K ; TSUNODA, T ; TANAKA, H ; UMANO, Y ; TANIMURA, H ; NUKAYA, I ; TAKESAKO, K ; YAMAUE, H.** Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide-pulsed dendritic cells. *Cancer Immunol. Immunother.*, 2004, vol. 53, 609-616 [0041]
- **UEDA, Y ; ITOH, T ; NUKAYA, I ; KAWASHIMA, I ; OKUGAWA, K ; YANO, Y ; YAMAMOTO, Y ; NAITOH, K ; SHIMIZU, K ; IMURA, K.** Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas. *Int. J. Oncol.*, 2004, vol. 24, 909-917 [0041]
- **WEIHRAUCH, MR ; ANSEN, S ; JURKIEWICZ, E ; GEISEN, C ; XIA, Z ; ANDERSON, KS ; GRACIEN, E ; SCHMIDT, M ; WITTIG, B ; DIEHL, V.** Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. *Clin Cancer Res.*, 2005, vol. 11, 5993-6001 [0041]
- **BUCKHAULTS, P ; RAGO, C, ST, CB ; ROMANS, KE ; SAHA, S ; ZHANG, L ; VOGELSTEIN, B ; KINZLER, KW.** Secreted and cell surface genes expressed in benign and malignant colorectal tumours. *Cancer Res.*, 2001, vol. 61, 6996-7001 [0043]
- **SHIH, W ; CHETTY, R ; TSAO, MS.** Expression profiling by microarrays in colorectal cancer. *Oncol. Rep.*, 2005, vol. 13, 517-524 [0044]
- **SCHNEIDER, D ; KLEEFF, J ; BERBERAT, PO ; ZHU, Z ; KORC, M ; FRIESS, H ; BUCHLER, MW.** Induction and expression of betaig-h3 in pancreatic cancer cells. *Biochim. Biophys. Acta*, 2002, vol. 1588, 1-6 [0045]
- **AITKENHEAD, M ; WANG, SJ ; NAKATSU, MN ; MESTAS, J ; HEARD, C ; HUGHES, CC.** Identification of endothelial cell genes expressed in an in vitro model of angiogenesis: induction of ESM-1, (beta)ig-h3, and NrCAM. *Microvasc. Res.*, 2002, vol. 63, 159-171 [0046]

- **WU, CW ; LI, AF ; CHI, CW ; LIN, WC.** Protein tyrosine-phosphatase expression profiling in gastric cancer tissues. *Cancer Lett.*, 2006, vol. 242, 95-103 [0047]
- **HARROCH, S ; FURTADO, GC ; BRUECK, W ; ROSENBLUTH, J ; LAFAILLE, J ; CHAO, M ; BUXBAUM, JD ; SCHLESSINGER, J.** A critical role for the protein tyrosine phosphatase receptor type Z in functional recovery from demyelinating lesions. *Nat. Genet.*, 2002, vol. 32, 411-414 [0047]
- **WANG, V ; DAVIS, DA ; HAQUE, M ; HUANG, LE ; YARCHOAN, R.** Differential gene up-regulation by hypoxia-inducible factor-1 alpha and hypoxia-inducible factor-2 alpha in HEK293T-cells. *Cancer Res.*, 2005, vol. 65, 3299-3306 [0047]
- **LU, KV ; JONG, KA ; KIM, GY ; SINGH, J ; DIA, EQ ; YOSHIMOTO, K ; WANG, MY ; CLOUGHESY, TF ; NELSON, SF ; MISCHER, PS.** Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. *J Biol Chem.*, 2005, vol. 280, 26953-26964 [0048]
- **MULHOLLAND, PJ ; FIEGLER, H ; MAZZANTI, C ; GORMAN, P ; SASIENI, P ; ADAMS, J ; JONES, TA ; BABBAGE, JW ; VATCHEVA, R ; ICHIMURA, K.** Genomic profiling identifies discrete deletions associated with translocations in glioblastoma multiforme. *Cell Cycle*, 2006, vol. 5, 783-791 [0049]
- **LAE, M ; AHN, E ; MERCADO, G ; CHUAI, S ; EDGAR, M ; PAWEL, B ; OLSHEN, A ; BARR, F ; LADANYI, M.** Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas. *J Pathol.*, 2007, vol. 212, 143-151 [0050]
- **HYNES, RO.** Fibronectins. *Sci. Am.*, 1987, vol. 254, 42-51 [0051]
- **YI, M ; RUOSLAHTI, E.** A fibronectin fragment inhibits tumour growth, angiogenesis, and metastasis. *Proc. Natl. Acad. Sci. U.S.A.*, 2001, vol. 98, 620-624 [0052]
- **AKERMAN, ME ; PILCH, J ; PETERS, D ; RUOSLAHTI, E.** Angiostatic peptides use plasma fibronectin to home to angiogenic vasculature. *Proc. Natl. Acad. Sci. U.S.A.*, 2005, vol. 102, 2040-2045 [0052]
- **QIU, Z ; KWON, AH ; TSUJI, K ; KAMIYAMA, Y ; OKUMURA, T ; HIRAO, Y.** Fibronectin prevents D-galactosamine/lipopolysaccharide-induced lethal hepatic failure in mice. *Shock*, 2006, vol. 25, 80-87 [0052]
- **HAN, S ; SIDELL, N ; ROSER-PAGE, S ; ROMAN, J.** Fibronectin stimulates human lung carcinoma cell growth by inducing cyclooxygenase-2 (COX-2) expression. *Int. J. Cancer*, 2004, vol. 111, 322-331 [0052]
- **KHAN, ZA ; CAURTERO, J ; BARBIN, YP ; CHAN, BM ; UNIYAL, S ; CHAKRABARTI, S.** ED-B fibronectin in non-small cell lung carcinoma. *Exp. Lung Res.*, 2005, vol. 31, 701-711 [0053]
- **MHAWECH, P ; DULGUEROV, P ; ASSALY, M ; ARES, C ; ALLAL, AS.** EB-D fibronectin expression in squamous cell carcinoma of the head and neck. *Oral Oncol.*, 2005, vol. 41, 82-88 [0053]
- **COMI, AM ; HUNT, P ; VAWTER, MP ; PARDO, CA ; BECKER, KG ; PEVSNER, J.** Increased fibronectin expression in sturge-weber syndrome fibroblasts and brain tissue. *Pediatr. Res.*, 2003, vol. 53, 762-769 [0054]
- **DEMETER, A ; SZIRMAI, K ; OLAH, J ; PAPP, Z ; JENEY, A.** Elevated expression of matrix metalloproteinase-9, and fibronectin concentration in recurrent epithelial ovarian cancer. *Orv. Hetil.*, 2004, vol. 145, 1617-1624 [0054]
- **URTREGER, AJ ; WERBAJH, SE ; VERRECCHIA, F ; MAUVIEL, A ; PURICELLI, LI ; KORNBLIHT, AR ; BAL DE KIER JOFFE ED.** Fibronectin is distinctly downregulated in murine mammary adenocarcinoma cells with high metastatic potential. *Oncol. Rep.*, 2006, vol. 16, 1403-1410 [0054]
- **HADDEN, HL ; HENKE, CA.** Induction of lung fibroblast apoptosis by soluble fibronectin peptides. *Am. J. Respir. Crit. Care Med.*, 2000, vol. 162, 1553-1560 [0055]
- **HAN, S ; RITZENTHALER, JD ; SITARAMAN, SV ; ROMAN, J.** Fibronectin increases matrix metalloproteinase 9 expression through activation of c-Fos via extracellular-regulated kinase and phosphatidylinositol 3-kinase pathways in human lung carcinoma cells. *J Biol Chem.*, 2006, vol. 281, 29614-29624 [0055]
- **LIU, W ; ASA, SL ; EZZAT, S.** 1alpha,25-Dihydroxyvitamin D3 targets PTEN-dependent fibronectin expression to restore thyroid cancer cell adhesiveness. *Mol. Endocrinol.*, 2005, vol. 19, 2349-2357 [0055]
- **KASPAR, M ; ZARDI, L ; NERI, D.** Fibronectin as target for tumour therapy. *Int. J. Cancer*, 2005, vol. 118, 1331-1339 [0056]
- **LIU, Y ; HUANG, B ; YUAN, Y ; GONG, W ; XIAO, H ; LI, D ; YU, ZR ; WU, FH ; ZHANG, GM ; FENG, ZH.** Inhibition of hepatocarcinoma and tumour metastasis to liver by gene therapy with recombinant CBD-HepII polypeptide of fibronectin. *Int. J. Cancer*, 2007, vol. 121 (1), 184-92 [0056]
- **KATO, R ; ISHIKAWA, T ; KAMIYA, S ; OGUMA, F ; UEKI, M ; GOTO, S ; NAKAMURA, H ; KATAYAMA, T ; FUKAI, F.** A new type of antimetastatic peptide derived from fibronectin. *Clin Cancer Res.*, 2002, vol. 8, 2455-2462 [0056]
- **MAEHAMA, T ; DIXON, JE.** The tumour suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. *J Biol Chem.*, 1998, vol. 273, 13375-13378 [0057]
- **ZAWROCKI, A ; BIERNAT, W.** Epidermal growth factor receptor in glioblastoma. *Folia Neuropathol.*, 2005, vol. 43, 123-132 [0057]

- **WONG, AJ ; BIGNER, SH ; BIGNER, DD ; KINZLER, KW ; HAMILTON, SR ; VOGELSTEIN, B.** Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. *Proc. Natl. Acad. Sci. U.S.A.*, 1987, vol. 84, 6899-6903 [0058]
- **CHAFFANET, M ; CHAUVIN, C ; LAINE, M ; BERGER, F ; CHEDIN, M ; ROST, N ; NISSOU, MF ; BEN-ABID, AL.** EGF receptor amplification and expression in human brain tumours. *Eur. J Cancer*, 1992, vol. 28, 11-17 [0058]
- **REIFENBERGER, J ; REIFENBERGER, G ; ICHIMURA, K ; SCHMIDT, EE ; WECHSLER, W ; COLLINS, VP.** Epidermal growth factor receptor expression in oligodendroglial tumours. *Am. J Pathol.*, 1996, vol. 149, 29-35 [0058]
- **OLSON, JJ ; BARNETT, D ; YANG, J ; ASSIETTI, R ; COTSONIS, G ; JAMES, CD.** Gene amplification as a prognostic factor in primary brain tumours. *Clin Cancer Res.*, 1998, vol. 4, 215-222 [0059]
- **NEWCOMB, EW ; COHEN, H ; LEE, SR ; BHALLA, SK ; BLOOM, J ; HAYES, RL ; MILLER, DC.** Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. *Brain Pathol.*, 1998, vol. 8, 655-667 [0059]
- **WAHA, A ; BAUMANN, A ; WOLF, HK ; FIMMERS, R ; NEUMANN, J ; KINDERMANN, D ; ASTRAHANTSEFF, K ; BLUMCKE, I ; VON, DA ; SCHLEGEL, U.** Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor- α pathway in human astrocytic gliomas. *J Neurosurg.*, 1996, vol. 85, 634-641 [0059]
- **ETIENNE, MC ; FORMENTO, JL ; LEBRUN-FRENNAY, C ; GIOANNI, J ; CHATEL, M ; PAQUIS, P ; BERNARD, C ; COURDI, A ; BENSADOUN, RJ ; PIGNOL, JP.** Epidermal growth factor receptor and labelling index are independent prognostic factors in glial tumour outcome. *Clin Cancer Res.*, 1998, vol. 4, 2383-2390 [0059]
- **JAROS, E ; PERRY, RH ; ADAM, L ; KELLY, PJ ; CRAWFORD, PJ ; KALBAG, RM ; MENDELOW, AD ; SENGUPTA, RP ; PEARSON, AD.** Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. *Br. J Cancer*, 1992, vol. 66, 373-385 [0059]
- **SCHLEGEL, J ; MERDES, A ; STUMM, G ; ALBERT, FK ; FORSTING, M ; HYNES, N ; KIESSLING, M.** Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma. *Int. J Cancer*, 1994, vol. 56, 72-77 [0059]
- **ZHU, A ; SHAEFFER, J ; LESLIE, S ; KOLM, P ; EL-MAHDI, AM.** Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumours given definitive irradiation. *Int. J Radiat. Oncol. Biol Phys.*, 1996, vol. 34, 809-815 [0059]
- **SRIDHAR, SS ; SEYMOUR, L ; SHEPHERD, FA.** Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. *Lancet Oncol.*, 2003, vol. 4, 397-406 [0060]
- **SOK, JC ; COPPELLI, FM ; THOMAS, SM ; LANGO, MN ; XI, S ; HUNT, JL ; FREILINO, ML ; GRANGER, MW ; WIKSTRAND, CJ ; BIGNER, DD.** Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. *Clin Cancer Res.*, 2006, vol. 12, 5064-5073 [0061]
- **SHIR, A ; OGRIS, M ; WAGNER, E ; LEVITZKI, A.** EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumours in mice. *PLoS. Med.*, 06 December 2005, vol. 3 (1), e6 [0062]
- **VOLLMANN, A ; VORNLOCHER, HP ; STEMPEL, T ; BROCKHOFF, G ; APFEL, R ; BOGDHANN, U.** Effective silencing of EGFR with RNAi demonstrates non-EGFR dependent proliferation of glioma cells. *Int. J Oncol.*, 2006, vol. 28, 1531-1542 [0063]
- **RAMOS, TC ; FIGUEREDO, J ; CATALA, M ; GONZALEZ, S ; SELVA, JC ; CRUZ, TM ; TOLEDO, C ; SILVA, S ; PESTANO, Y ; RAMOS, M.** Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. *Cancer Biol Ther.*, 2006, vol. 5, 375-379 [0064]
- **YOSHIMURA, N ; KUDOH, S ; KIMURA, T ; MITSUOKA, S ; MATSUURA, K ; HIRATA, K ; MATSUI, K ; NEGORO, S ; NAKAGAWA, K ; FUKUOKA, M.** EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. *Lung Cancer*, 2006, vol. 51, 363-368 [0065]
- **SHIMATO, S ; MITSUDOMI, T ; KOSAKA, T ; YATABE, Y ; WAKABAYASHI, T ; MIZUNO, M ; NAKAHARA, N ; HATANO, H ; NATSUME, A ; ISHII, D.** EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. *Neuro. Oncol.*, 2006, vol. 8, 137-144 [0066]
- **RECKLIES AD ; WHITE C ; LING H.** The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39)- stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. *Biochem J.*, 2002, vol. 365, 119-126 [0067]
- **TAKAISHI S ; WANG TC.** Gene expression profiling in a mouse model of Helicobacter-induced gastric cancer. *Cancer Sci.*, 2007, 284-293 [0067]

- **EDELMAN, AM ; KIM, WY ; HIGGINS, D ; GOLDSTEIN, EG ; OBERDOERSTER, M ; SIGURDSON, W.** Doublecortin kinase-2, a novel doublecortin-related protein kinase associated with terminal segments of axons and dendrites. *J Biol Chem.*, 2005, vol. 280, 8531-8543 [0071]
- **BUTT, AM ; KALSI, A.** Inwardly rectifying potassium channels (Kir) in central nervous system glia: a special role for Kir4.1 in glial functions. *J Cell Mol. Med.*, 2006, vol. 10, 33-44 [0072]
- **KUCHERYAVYKH, YV ; KUCHERYAVYKH, LY ; NICHOLS, CG ; MALDONADO, HM ; BAKSI, K ; REICHENBACH, A ; SKATCHKOV, SN ; EATON, MJ.** Downregulation of Kir4.1 inward rectifying potassium channel subunits by RNAi impairs potassium transfer and glutamate uptake by cultured cortical astrocytes. *Glia*, 2006, vol. 55 (3), 274-281 [0073]
- **WARTH, A ; MITTELBRONN, M ; WOLBURG, H.** Redistribution of the water channel protein aquaporin-4 and the K⁺ channel protein Kir4.1 differs in low- and high-grade human brain tumours. *Acta Neuropathol.*, 2005, vol. 109, 418-426 [0074]
- **SAADOUN, S ; PAPADOPOULOS, MC ; KRISHNA, S.** Water transport becomes uncoupled from K⁺ siphoning in brain contusion, bacterial meningitis, and brain tumours: immunohistochemical case review. *J Clin Pathol.*, 2003, vol. 56, 972-975 [0074]
- **VOGT AB ; KROPSHOFER H ; KALBACHER H ; KALBUS M ; RAMMENSEE HG ; COLIGAN JE ; MARTIN R.** Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides. *J Immunol.*, 1994, vol. 153 (4), 1665-1673 [0079]
- **MALCHEREK G ; GNAU V ; STEVANOVIC S ; RAMMENSEE HG ; JUNG G ; MELMS A.** Analysis of allele-specific contact sites of natural HLA-DR17 ligands. *J Immunol.*, 1994, vol. 153 (3), 1141-1149 [0079]
- **MANICI S ; STURNIOLO T ; IMRO MA ; HAMMER J ; SINIGAGLIA F ; NIPPEN C ; SPAGNOLI G ; MAZZI B ; BELLONE M ; DELLABONA P.** Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. *J Exp Med.*, 1999, vol. 189 (5), 871-876 [0079]
- **HAMMER J ; GALLAZZI F ; BONO E ; KARR RW ; GUENOT J ; VALSASNINI P ; NAGY ZA ; SINIGAGLIA F.** Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. *J Exp Med.*, 1995, vol. 181 (5), 1847-1855 [0079]
- **TOMPKINS SM ; ROTA PA ; MOORE JC ; JENSEN PE.** A europium fluoroimmunoassay for measuring binding of antigen to class II MHC glycoproteins. *J Immunol Methods*, 1993, vol. 163 (2), 209-216 [0079]
- **BOYTON RJ ; LOHMANN T ; LONDEI M ; KALBACHER H ; HALDER T ; FRATER AJ ; DOUEK DC ; LESLIE DG ; FLAVELL RA ; ALTMANN DM.** Glutamic acid decarboxylase T lymphocyte responses associated with susceptibility or resistance to type I diabetes: analysis in disease discordant human twins, non-obese diabetic mice and HLA-DQ transgenic mice. *Int Immunol.*, 1998, 1765-1776 [0079]
- **STRUBIN, M. ; MACH, B. ; LONG, E.O.** The complete sequence of the mRNA for the HLA-DR-associated invariant chain reveals a polypeptide with an unusual transmembrane polarity. *EMBO J.*, 1984, vol. 3 (4), 869-872 [0080]
- **R. LUNDBLAD.** Chemical Reagents for Protein Modification. CRC Press, 2005 [0084]
- Current Protocols In Protein Science. John Wiley & Sons, 1995 [0084]
- **LU et al.** *J. Org. Chem.*, 1981, vol. 46, 3433 [0089]
- **BRUCKDORFER T ; MARDER O ; ALBERICIO F.** From production of peptides in milligram amounts for research to multi-ton quantities for drugs of the future. *Curr Pharm Biotechnol.*, February 2004, vol. 5 (1), 29-43 [0089]
- **SAIKI et al.** *Science*, 1988, vol. 239, 487-491 [0096]
- **COHEN et al.** *Proc. Natl. Acad. Sci. USA*, 1972, vol. 69, 2110 [0106]
- **SAMBROOK et al.** Molecular Cloning, A Laboratory Manual. Cold Spring Harbor Laboratory, 1989 [0106]
- **SHERMAN et al.** Methods In Yeast Genetics, A Laboratory Manual. 1986 [0106]
- **BEGGS.** *Nature*, 1978, vol. 275, 104-109 [0106]
- **SMALL EJ ; SCHELLHAMMER PF ; HIGANO CS ; REDFERN CH ; NEMUNAITIS JJ ; VALONE FH ; VERJEE SS ; JONES LA ; HERSHBERG RM.** Placebo-controlled phase 3 trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. *J Clin Oncol.*, 2006, vol. 24 (19), 3089-3094 [0109]
- **RINIBI ; WEINBERG V ; FONG L ; CONRYS ; HERSHBERG RM ; SMALL EJ.** Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (Provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. *Cancer*, 2006, vol. 107 (1), 67-74 [0109]
- **BRUNSVIG PF ; AAMDAL S ; GJERTSEN MK ; KVALHEIM G ; MARKOWSKI-GRIMSRUD CJ ; SVEI ; DYRHAUG M ; TRACHSEL S ; MOLLER M ; ERIKSEN JA.** Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. *Cancer Immunol Immunother.*, 2006, vol. 55 (12), 1553-1564 [0111]

- **M. STAEHLER ; A. STENZL ; P. Y. DIETRICH ; T. EISEN ; A. HAFERKAMP ; J. BECK ; A. MAYER ; S. WALTER ; H. SINGH ; J. FRISCH.** An open label study to evaluate the safety and immunogenicity of the peptide based cancer vaccine IMA901. *ASCO meeting*, 2007 [0111] [0181]
- **KARRE ; LJUNGGREN.** *J. Exp. Med.*, 1985, vol. 162, 1745 [0116]
- **PEOPLES et al.** *Proc. Natl. Acad. Sci. USA*, 1995, vol. 92, 432-436 [0122]
- **KAWAKAMI et al.** *J. Immunol.*, 1992, vol. 148, 638-643 [0122]
- **PLEBANSKI et al.** *Eur. J. Immunol.*, 1995, vol. 25, 1783-1787 [0122]
- **JOCHMUS et al.** *J. Gen. Virol.*, 1997, vol. 78, 1689-1695 [0122]
- **HILL et al.** *J. Exp. Med.*, 1995, vol. 181, 2221-2228 [0122]
- **JEROME et al.** *J. Immunol.*, 1993, vol. 151, 1654-1662 [0122]
- **WALTER S ; HERRGEN L ; SCHOOR O ; JUNG G ; WERNET D ; BUHRING HJ ; RAMMENSEE HG ; STEVANOVIC S.** Cutting edge: predetermined avidity of human CD8 T-cells expanded on calibrated MHC/anti-CD28-coated microspheres. *J Immunol.*, 15 November 2003, vol. 171 (10), 4974-8 [0122]
- **PORTA et al.** *Virology*, 1994, vol. 202, 449-955 [0123]
- **DENGJEL, J ; NASTKE, MD ; GOUTTEFANGEAS, C ; GITSIODIS, G ; SCHOOR, O ; ALTENBEREND, F ; MULLER, M ; KRAMER, B ; MISSIOU, A ; SAUTER, M.** Unexpected Abundance of HLA Class II Presented Peptides in Primary Renal Cell Carcinomas. *Clin Cancer Res.*, 2006, vol. 12, 4163-4170 [0127]
- **ROSENBERG, SA ; LOTZE, MT ; MUUL, LM ; CHANG, AE ; AVIS, FP ; LEITMAN, S ; LINEHAN, WM ; ROBERTSON, CN ; LEE, RE ; RUBIN, JT et al.** A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. *N. Engl. J. Med.*, 1987, vol. 316, 889-897 [0131]
- **ROSENBERG, SA ; PACKARD, BS ; AEBERSOLD, PM ; SOLOMON, D ; TOPALIAN, SL ; TOY, ST ; SIMON, P ; LOTZE, MT ; YANG, JC ; SEIPP, CA et al.** Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. *N.Engl.J Med*, 1988, vol. 319, 1676-1680 [0131]
- **DUDLEY, ME ; WUNDERLICH, JR ; ROBBINS, PF ; YANG, JC ; HWU, P ; SCHWARTZENTRUBER, DJ ; TOPALIAN, SL ; SHERRY, R ; RESTIFO, NP ; HUBICKI, AM.** Cancer regression and autoimmunity in patients after clonal repopulation with anti-tumor lymphocytes. *Science*, 2002, vol. 298, 850-854 [0131]
- **YEE, C ; THOMPSON, JA ; BYRD, D ; RIDDELL, SR ; ROCHE, P ; CELIS, E ; GREENBERG, PD.** Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. *Proc. Natl. Acad. Sci. U.S.A.*, 2002, vol. 99, 16168-16173 [0131]
- **DUDLEY, ME ; WUNDERLICH, JR ; YANG, JC ; SHERRY, RM ; TOPALIAN, SL ; RESTIFO, NP ; ROYAL, RE ; KAMMULA, U ; WHITE, DE ; MAVROUKAKIS, SA.** Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. *J. Clin. Oncol.*, 2005, vol. 23, 2346-2357 [0131]
- **GATTINONI, L ; POWELL, DJ, JR. ; ROSENBERG, SA ; RESTIFO, NP.** Adoptive immunotherapy for cancer: building on success. *Nat. Rev. Immunol.*, 2006, vol. 6, 383-393 [0131]
- **MORGAN, RA ; DUDLEY, ME ; WUNDERLICH, JR ; HUGHES, MS ; YANG, JC ; SHERRY, RM ; ROYAL, RE ; TOPALIAN, SL ; KAMMULA, US ; RESTIFO, NP.** Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes. *Science*, 2006, vol. 314 (5796), 126-129 [0131]
- **LONGENECKER et al.** *Ann. NY Acad. Sci.*, 1993, vol. 690, 276-291 [0133]
- **S. PASCOLO.** Vaccination with messenger RNA. *Methods Mol Med*, 2006, vol. 127, 23-40 [0136]
- **R. STAN ; JD WOLCHOK ; AD COHEN.** DNA vaccines against cancer. *Hematol Oncol Clin North Am*, 2006, vol. 3, 613-636 [0136]
- **A MAHDAVI ; BJ MONK.** Recent advances in human papillomavirus vaccines. *Curr Oncol Rep*, 2006, vol. 6, 465-472 [0136]
- **DUPUIS M ; MURPHY TJ ; HIGGINS D ; UGOZZOLI M ; VAN NEST G ; OTT G ; MCDONALD DM.** Dendritic cells internalize vaccine adjuvant after intramuscular injection. *Cell Immunol.*, 1998, vol. 186 (1), 18-27 [0137]
- **ALLISON AC.** The mode of action of immunological adjuvants. *Dev Biol Stand.*, 1998, vol. 92, 3-11 [0137]
- **GABRILOVICH DI ; CUNNINGHAM HT ; CARBONE DP.** IL-12 and mutant P53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer. *J Immunother Emphasis Tumor Immunol.*, 1996, 414-418 [0137]
- **ARTHUR M. KRIEG.** Therapeutic potential of Toll-like receptor 9 activation. *Nature Reviews, Drug Discovery*, June 2006, vol. 5, 471-484 [0138]
- **FALK, K. ; ROTZSCHKE, O. ; STEVANOVIC, S. ; JUNG, G. ; RAMMENSEE, H.G.** Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. *Nature*, 1991, vol. 351, 290-296 [0158]

- **SEEGER, F.H. et al.** The HLA-A*6601 peptide motif: prediction by pocket structure and verification by peptide analysis. *Immunogenetics*, 1999, vol. 49, 571-576 [0158]
- **M DIEHL.** *PhD thesis*, 1998 [0172]
- **WIERECKY, J ; MULLER, MR ; WIRTHS, S ; HALDER-OEHLER, E ; DORFEL, D ; SCHMIDT, SM ; HANTSCHHEL, M ; BRUGGER, W ; SCHRODER, S ; HORGER, MS.** Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. *Cancer Res.*, 2006, vol. 66, 5910-5918 [0180]
- **H. SINGH-JASUJA ; S. WALTER ; T. WEINSCHENK ; A. MAYER ; P. Y. DIETRICH ; M. STAEHLER ; A. STENZL ; S. STEVANOVIC ; H. RAMMENSEE ; J. FRISCH.** Correlation of T-cell response, clinical activity and regulatory T-cell levels in renal cell carcinoma patients treated with IMA901, a novel multi-peptide vaccine. *ASCO Meeting*, 2007 [0181]
- **WALTER, S ; HERRGEN, L ; SCHOOR, O ; JUNG, G ; WERNET, D ; BUHRING, HJ ; RAMMENSEE, HG ; STEVANOVIC, S.** Cutting edge: predetermined avidity of human CD8 T cells expanded on calibrated MHC/anti-CD28-coated microspheres. *J. Immunol.*, 2003, vol. 171, 4974-4978 [0182] [0193]
- **ALTMAN, JD ; MOSS, PA ; GOULDER, PJ ; BAROUCH, DH ; HEYZER-WILLIAMS, MG ; BELL, JI ; MCMICHAEL, AJ ; DAVIS, MM.** Phenotypic analysis of antigen-specific T lymphocytes. *Science*, 1996, vol. 274, 94-96 [0182] [0183]
- **JUNG, G ; LEDBETTER, JA ; MULLER-EBERHARD, HJ.** Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates. *Proc Natl Acad Sci U S A*, 1987, vol. 84, 4611-4615 [0182]
- **SYLVESTER-HVID C ; KRISTENSEN N ; BLICHER T ; FERRE H ; LAUEMOLLER SL ; WOLF XA ; LAMBERTH K ; NISSEN MH ; PEDERSEN LO ; BUUS S.** Establishment of a quantitative ELISA capable of determining peptide - MHC class I interaction. *Tissue Antigens*, 2002, vol. 59, 251-258 [0200]

SZABADALMI IGÉNYPONTOK

1. A SEQ ID No. 8 szerinti ALFVRLALA szekvenciából álló peptid, amely indukálja az említett peptiddel keresztreakcióba lépő T-sejteket.
2. Az 1. igénypont szerinti peptid, amelyben a peptid a HLA-DR antigén asszociált invariáns lánc (Ii) N-terminális aminosavait tartalmazó fúziós protein részét képezi.
3. Az 1. vagy a 2. igénypont szerinti peptidet kódoló nukleinsav, amely DNS, cDNS, PNS, RNS vagy ezek kombinációja, vagy egy expressziós vektor, melyben a vektor operábilisan van kapcsolva az említett nukleinsavhoz.
4. Az 1. vagy a 2. igénypont szerinti peptid, vagy az 3. igénypont szerinti nukleinsav vagy expressziós vektor, gyógyászatban történő alkalmazásra.
5. A 3. igénypont szerinti nukleinsavat vagy expressziós vektort tartalmazó gazdasejt, melyben az említett gazdasejt egy antigénprezentáló sejt.
6. Az 1. vagy a 2. igénypont szerinti peptid előállítására szolgáló módszer, amely az 5. igénypont szerinti gazdasejt tenyésztéséből, és a peptidnek a gazdasejtből vagy a gazdasejt tenyészközegéből történő izolálásából áll.
7. Egy in vitro módszer aktivált citotoxikus T-limfociták (CTL) előállítására, melynek során a CTL-t in vitro egy alkalmas antigénprezentáló sejt felületén expresszált humán I. osztályú, antigénnel feltöltött MHC molekulákkal hoznak érintkezésbe annyi ideig, amennyi elegendő az említett CTL antigén-specifikus aktivációjához, ahol az említett antigén az 1. igénypont szerinti peptid, és ahol az említett antigénprezentáló sejt előnyösen a 3. igénypont szerinti peptidet expresszáló expressziós vektort tartalmazza.
8. A 7. igénypont szerinti módszerrel előállított aktivált citotoxikus T-limfocita (CTL), amely a limfocita T-sejt receptora (TCR) és a sejt HLA/peptid komplexének kölcsönhatása útján szelektíven felismeri az 1. igénypontban megadott aminosav-szekvenciát tartalmazó polipeptidet abnormális módon expresszáló sejtet.
9. A hatásos számú, 8. igénypont szerinti citotoxikus T-limfocita (CTL) a betegben lévő célsejtek elpusztítására, ahol a célsejtek abnormális módon expresszálják az 1. igénypontban megadott aminosav-szekvenciát tartalmazó polipeptidet.
10. Az 1. igénypont szerinti peptidet tartalmazó MHC/peptid komplex elleni specifikus antitest vagy annak fragmentuma.
11. Az 1. vagy a 2. igénypont szerinti peptid, az 3. igénypont szerinti nukleinsav vagy expressziós vektor, az 5. igénypont szerinti gazdasejt vagy a 8. igénypont szerinti aktivált citotoxikus T-limfocita vagy a 10. igénypont szerinti antitest, amely a rákbetegség kezelésére szolgál.
12. A 11. igénypont szerinti peptid, aktivált citotoxikus T-limfocita vagy antitest, ahol az említett rákbetegség a következő csoportból választható: glioblastoma, colorectalis rák, hasnyálmirigyrák, tüdőrák, veserák és gyomorrák.
13. A 11. vagy a 12. igénypont szerinti használatra szolgáló peptid, aktivált citotoxikus T-limfocita vagy antitest, ahol az említett kezelés módja egy védőoltás.